Akorn (AKRX) 10-K 14 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 03, 2014	Jun. 30, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'AKORN INC	'	'
Entity Central Index Key	'0000003116	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Large Accelerated Filer	'	'
Entity Public Float	'	'	$742,940,000
Entity Common Stock, Shares Outstanding	'	96,652,900	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
CURRENT ASSETS	'	'
Cash and cash equivalents	$34,178	$40,781
Trade accounts receivable, net	64,998	51,017
Inventories, net	55,982	52,495
Deferred taxes, current	7,945	9,190
Prepaid expenses and other current assets	5,753	5,224
TOTAL CURRENT ASSETS	168,856	158,707
PROPERTY, PLANT AND EQUIPMENT, NET	82,108	80,679
OTHER LONG-TERM ASSETS	'	'
Goodwill	29,831	32,159
Product licensing rights, net	115,900	63,654
Other intangibles, net	14,605	16,731
Deferred financing costs, net	5,676	3,078
Long-term investments	10,006	10,299
Deferred taxes, non current	1,643	930
Other	3,180	3,328
TOTAL OTHER LONG-TERM ASSETS	180,841	130,179
TOTAL ASSETS	431,805	369,565
CURRENT LIABILITIES	'	'
Trade accounts payable	22,999	21,784
Purchase consideration payable, current	14,728	0
Accrued compensation	7,692	7,533
Accrued royalties	6,004	5,768
Accrued administration fees	2,544	2,204
Accrued expenses and other liabilities	7,278	6,002
TOTAL CURRENT LIABILITIES	61,245	43,291
LONG-TERM LIABILITIES	'	'
Long-term debt	108,750	104,637
Purchase consideration payable, non-current	0	16,113
Deferred taxes - non-current	0	1,991
Product warranty liability	0	1,299
Lease incentive obligation and other long-term liabilities	1,630	1,153
TOTAL LONG-TERM LIABILITIES	110,380	125,193
TOTAL LIABILITIES	171,625	168,484
SHAREHOLDERS' EQUITY	'	'
Common stock, no par value, 150,000,000 shares authorized; 96,569,186 and 95,844,012 shares issued and outstanding at December 31, 2013 and 2012	239,235	226,035
Warrants to acquire common stock	17,946	17,946
Retained earnings (accumulated deficit)	15,366	-36,996
Accumulated other comprehensive loss	-12,367	-5,904
TOTAL SHAREHOLDERS' EQUITY	260,180	201,081
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$431,805	$369,565

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
SHAREHOLDERS' EQUITY	'	'
Common stock, par value (in dollars per share)	$0	$0
Common stock, authorized (in shares)	150,000,000	150,000,000
Common stock, issued (in shares)	96,569,186	95,844,012
Common stock, outstanding (in shares)	96,569,186	95,844,012

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME [Abstract]	'	'	'
REVENUES	$317,711	$256,158	$136,920
Cost of sales (exclusive of amortization of intangibles, included within operating expenses below)	145,807	107,466	57,231
GROSS PROFIT	171,904	148,692	79,689
Selling, general and administrative expenses	53,508	48,053	32,392
Research and development expenses	19,858	15,858	11,555
Amortization of intangibles	7,422	6,870	1,733
Acquisition-related costs	2,912	9,155	743
TOTAL OPERATING EXPENSES	83,700	79,936	46,423
OPERATING INCOME	88,204	68,756	33,266
Amortization of deferred financing costs	-842	-782	-1,948
Interest expense, net	-8,649	-10,474	-4,392
Equity in earnings of unconsolidated joint venture	80	0	14,550
Bargain purchase gain	3,707	0	0
Other non-operating income (expense), net	395	0	-170
INCOME BEFORE INCOME TAXES	82,895	57,500	41,306
Income tax provision (benefit)	30,533	22,122	-1,707
CONSOLIDATED NET INCOME	52,362	35,378	43,013
CONSOLIDATED NET INCOME PER COMMON SHARE:	'	'	'
BASIC (in dollars per share)	$0.54	$0.37	$0.45
DILUTED (in dollars per share)	$0.46	$0.32	$0.41
SHARES USED IN COMPUTING CONSOLIDATED NET INCOME PER COMMON SHARE:	'	'	'
BASIC (in shares)	96,181	95,189	94,549
DILUTED (in shares)	113,898	110,510	103,912
COMPREHENSIVE INCOME:	'	'	'
Consolidated net income	52,362	35,378	43,013
Foreign currency translation loss	-6,463	-5,904	0
COMPREHENSIVE INCOME	$45,899	$29,474	$43,013

CONSOLIDATED_STATEMENTS_OF_SHA

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (USD $)	Common Stock [Member]	Warrants to acquire Common Stock [Member]	Retained Earnings (Accumulated Deficit) [Member]	Other Comprehensive Loss [Member]	Total
In Thousands, except Share data, unless otherwise specified
BALANCES at Dec. 31, 2010	$182,466	$19,673	($115,387)	$0	$86,752
BALANCES (in shares) at Dec. 31, 2010	93,975,000	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'
Consolidated net income	0	0	43,013	0	43,013
Exercise of stock warrants	3,454	-1,727	0	0	1,727
Exercise of stock warrants (in shares)	365,000	'	'	'	'
Exercise of stock options	867	0	0	0	867
Exercise of stock options (in shares)	454,000	'	'	'	'
Employee stock purchase plan issuances	220	0	0	0	220
Employee stock purchase plan issuances (in shares)	129,000	'	'	'	'
Restricted stock awards	17	0	0	0	17
Restricted stock awards (in shares)	15,000	'	'	'	'
Equity portion of convertible notes offering	20,470	0	0	0	20,470
Stock-based compensation expense	5,142	0	0	0	5,142
BALANCES at Dec. 31, 2011	212,636	17,946	-72,374	0	158,202
BALANCES (in shares) at Dec. 31, 2011	94,938,000	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'
Consolidated net income	0	0	35,378	0	35,378
Exercise of stock options	1,511	0	0	0	1,511
Exercise of stock options (in shares)	806,000	'	'	'	'
Employee stock purchase plan issuances	368	0	0	0	368
Employee stock purchase plan issuances (in shares)	71,000	'	'	'	'
Restricted stock awards	351	0	0	0	351
Restricted stock awards (in shares)	29,000	'	'	'	'
Stock-based compensation expense	6,681	0	0	0	6,681
Foreign currency translation loss	0	0	0	-5,904	-5,904
Excess tax benefit - stock compensation	4,488	0	0	0	4,488
BALANCES at Dec. 31, 2012	226,035	17,946	-36,996	-5,904	201,081
BALANCES (in shares) at Dec. 31, 2012	95,844,000	'	'	'	95,844,012
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'
Consolidated net income	0	0	52,362	0	52,362
Exercise of stock options	2,634	0	0	0	2,634
Exercise of stock options (in shares)	630,000	'	'	'	'
Employee stock purchase plan issuances	588	0	0	0	588
Employee stock purchase plan issuances (in shares)	61,000	'	'	'	'
Restricted stock awards	579	0	0	0	579
Restricted stock awards (in shares)	34,000	'	'	'	'
Stock-based compensation expense	6,471	0	0	0	6,471
Foreign currency translation loss	0	0	0	-6,463	-6,463
Excess tax benefit - stock compensation	2,928	0	0	0	2,928
BALANCES at Dec. 31, 2013	$239,235	$17,946	$15,366	($12,367)	$260,180
BALANCES (in shares) at Dec. 31, 2013	96,569,000	'	'	'	96,569,186

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
OPERATING ACTIVITIES:	'	'	'
Consolidated net income	$52,362	$35,378	$43,013
Adjustments to reconcile consolidated net income to net cash provided by operating activities:	'	'	'
Depreciation and amortization	14,476	11,455	5,246
Amortization of deferred financing fees	842	782	1,948
Amortization of unfavorable contract liability	-1,905	-635	0
Non-cash stock compensation expense	7,050	7,032	5,159
Non-cash interest expense	4,634	6,436	2,109
Non-cash gain on bargain purchase	-3,707	0	0
Non-cash settlement of product warranty liability	-1,299	0	0
Deferred tax assets, net	2,091	67	-4,411
Excess tax benefit from stock compensation	-2,928	-4,488	0
Equity in earnings of unconsolidated joint venture	-80	0	-14,550
Changes in operating assets and liabilities:	'	'	'
Trade accounts receivable	-14,277	-23,856	-13,581
Inventories	-3,797	-15,447	-9,307
Prepaid expenses and other current assets	-648	-5,689	-183
Trade accounts payable	1,975	4,489	2,546
Accrued expenses and other liabilities	2,537	10,720	1,668
NET CASH PROVIDED BY OPERATING ACTIVITIES	57,326	26,244	19,657
INVESTING ACTIVITIES:	'	'	'
Payments for acquisitions and equity investments	-55,482	-55,047	-87,412
Purchases of property, plant and equipment	-11,642	-20,454	-11,503
Distributions from unconsolidated joint venture	250	0	3,881
NET CASH USED IN INVESTING ACTIVITIES	-66,874	-75,501	-95,034
FINANCING ACTIVITIES:	'	'	'
Proceeds from issuance of convertible notes	0	0	120,000
Debt financing costs	-3,032	0	-5,098
Net proceeds from common stock offering and warrant exercises	0	0	1,727
Excess tax benefit from stock compensation	2,928	4,488	0
Proceeds under stock option and stock purchase plans	3,222	1,878	1,087
NET CASH PROVIDED BY FINANCING ACTIVITIES	3,118	6,366	117,716
Effect of changes in exchange rates on cash and cash equivalents	-173	-290	0
(DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	-6,603	-43,181	42,339
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	40,781	83,962	41,623
CASH AND CASH EQUIVALENTS AT END OF YEAR	$34,178	$40,781	$83,962

Business_and_Basis_of_Presenta

Business and Basis of Presentation	12 Months Ended
	Dec. 31, 2013
Business and Basis of Presentation [Abstract]	'
Business and Basis of Presentation	'
	Note 1 — Business and Basis of Presentation
	Business: Akorn, Inc. and its wholly-owned subsidiaries (collectively, the “Company”) manufacture and market a full line of diagnostic and therapeutic ophthalmic pharmaceuticals as well as niche hospital drugs and injectable pharmaceuticals.  In addition, through its subsidiary Advanced Vision Research, Inc. (“AVR”), the Company manufactures and markets a line of over-the-counter (“OTC”) ophthalmic products for the treatment of dry eye, eyelid hygiene and macular degeneration primarily under the TheraTears® brand name, as well as marketing various private-labeled OTC eye care products to various major drug chains.  The Company is a manufacturer and/or marketer of diagnostic and therapeutic pharmaceutical products in various specialty areas, including ophthalmology, antidotes, anti-infectives, vaccines, and controlled substances for pain management and anesthesia, among others.  The Company operates pharmaceutical manufacturing plants in the U.S. at Decatur, Illinois and Somerset, New Jersey, and internationally at Paonta Sahib, Himachal Pradesh, India, as well as a central distribution warehouse in Gurnee, Illinois, an R&D center Vernon Hills, Illinois and corporate offices in Lake Forest, Illinois.  Customers of the Company’s products include physicians, optometrists, wholesalers, chain drug stores, group purchasing organizations and their member hospitals, alternate site providers, wholesalers, distributors, and other pharmaceutical companies.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Summary of Significant Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	Note 2 — Summary of Significant Accounting Policies
	Consolidation: The accompanying consolidated financial statements include the accounts of Akorn, Inc. and its wholly owned domestic and foreign subsidiaries.  All inter-company transactions and balances have been eliminated in consolidation, and the financial statements of AIPL have been translated from Indian rupees to U.S. dollars based on the currency translation rates in effect during the period or as of the date of consolidation, as applicable.  The Company has no involvement with variable interest entities.
	The Company is a 50% owner of a dormant joint venture, Akorn-Strides, LLC (the “Joint Venture Company”) (See Note 17.).  The Company and its strategic partner each have equal voting rights and shared operational control.  Accordingly, the Company accounts for its investment in the Joint Venture Company using the equity method of accounting.  The Company’s proportionate share of the Joint Venture Company’s income has been recorded under the caption “Equity in earnings of unconsolidated joint venture” in the Company’s consolidated statements of operations.  The Joint Venture Company sold all of its abbreviated new drug application (“ANDA”) rights to Pfizer, Inc. in December 2010 and ceased operations during 2011.
	Use of Estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. Significant estimates and assumptions for the Company relate to the allowances for doubtful accounts, chargebacks, rebates, product returns and coupons and promotions, and the reserve for slow-moving and obsolete inventories, the carrying value and lives of intangible assets, the useful lives of fixed assets, the carrying value of deferred income tax assets, the assumptions underlying share-based compensation and accrued but unreported employee benefit costs.
	Revenue Recognition: Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the sales price is fixed or determinable, and collectability is reasonably assured.  Revenue from product sales is recognized when title and risk of loss have passed to the customer.
	Provision for estimated doubtful accounts, chargebacks, coupon redemption, rebates, discounts and product returns is made at the time of sale and is analyzed and adjusted, if necessary, at each balance sheet date.
	Freight:  The Company records amounts billed to customers for shipping and handling as revenue, and records shipping and handling expense related to product sales as cost of sales.
	Cash and Cash Equivalents: The Company considers all unrestricted, highly liquid investments with maturity of three months or less when purchased to be cash and cash equivalents.  At December 31, 2013 and 2012, approximately $2.7 million and $3.2 million of cash held by our India operations as of those respective dates was restricted, and was reported within other long term assets.
	Accounts Receivable: Trade accounts receivable are stated at their net realizable value.  The nature of the Company’s business involves, in the ordinary course, significant judgments and estimates relating to chargebacks, coupon redemption, product returns, rebates, discounts given to customers and allowances for doubtful accounts.  Depending on the products, the end-user customers, the specific terms of national supply contracts and the particular arrangements with the Company’s wholesaler customers, certain rebates, chargebacks and other credits are recorded as deductions to the Company’s trade accounts receivable.
	Unless otherwise noted, the provisions and allowances for the following customer deductions are reflected in the accompanying consolidated financial statements as reductions of revenues and trade accounts receivable, respectively.
	Chargebacks and Rebates: The Company enters into contractual agreements with third parties such as hospitals and group-purchasing organizations to sell certain products at predetermined prices. The parties have elected to have these contracts administered through wholesalers that buy the product from the Company and subsequently sell it to these third parties. When a wholesaler sells products to one of these third parties that are subject to a contractual price agreement, the difference between the price paid to the Company by the wholesaler and the price under the specific contract is charged back to the Company by the wholesaler. The Company tracks sales and submitted chargebacks by product number and contract for each wholesaler. Utilizing this information, the Company estimates a chargeback percentage for each product and records an allowance as a reduction of gross sales when the Company records its sale of the products. The Company reduces the chargeback allowance when a chargeback request from a wholesaler is processed. Actual chargebacks processed by the Company can vary materially from period to period based upon actual sales volume through the wholesalers. However, the Company’s provision for chargebacks is fully reserved for at the time when sales revenues are recognized.
	Management obtains certain wholesaler inventory reports to aid in analyzing the reasonableness of the chargeback allowance. The Company assesses the reasonableness of its chargeback allowance by applying the product chargeback percentage based on historical activity to the quantities of inventory on hand per the wholesaler inventory reports. In accordance with its accounting policy, the Company estimates the percentage amount of wholesaler inventory that will ultimately be sold to third parties that are subject to contractual price agreements based on a six-quarter trend of such sales through wholesalers. The Company uses this percentage estimate until historical trends indicate that a revision should be made. On an ongoing basis, the Company evaluates its actual chargeback rate experience, and new trends are factored into its estimates each quarter as market conditions change.
	Set forth below are the Company’s historical estimates of the percentage of sales that are subject to chargebacks that were used during each quarterly period in the three years ended December 31, 2013:
	Year			Q1			Q2			Q3				Q4
	2013			90.00%			90.00%			90.00%				90.00%
	2012			98.50%			98.50%			95.00%				90.00%
	2011			98.50%			98.50%			98.50%				98.50%
	Similarly, the Company maintains an allowance for rebates related to contract and other programs with certain customers. Rebate percentages vary by product and by volume purchased by each eligible customer. The Company tracks sales by product number for each eligible customer and then applies the applicable rebate percentage, using both historical trends and actual experience to estimate its rebate allowance. The Company reduces gross sales and increases the rebate allowance by the estimated rebate amount when the Company sells its products to its rebate-eligible customers. The Company reduces the rebate allowance when it processes a customer request for a rebate. At each balance sheet date, the Company analyzes the allowance for rebates against actual rebates processed and makes necessary adjustments as appropriate. Actual rebates processed can vary materially from period to period.
	The recorded allowances reflect the Company’s current estimate of the future chargeback and rebate liabilities to be paid or credited to its wholesaler and other customers under the applicable contracts and programs. For the years ended December 31, 2013, 2012 and 2011, the Company recorded chargeback and rebate expense of $183.4 million, $112.2 million, and $68.1 million, respectively. The allowance for chargebacks and rebates was $12.9 million and $13.5 million as of December 31, 2013 and 2012, respectively.
	Sales Returns: Certain of the Company’s products are sold with the customer having the right to return the product within specified periods and guidelines for a variety of reasons, including but not limited to, pending expiration dates. Provisions are made at the time of sale based upon tracked historical experience, by customer in some cases.  Historical factors such as one-time events as well as pending new developments that would impact the expected level of returns are taken into account to determine the appropriate reserve estimate at each balance sheet date. As part of the evaluation of the balance required, the Company considers actual returns to date that are in process, the expected impact of any product recalls and the wholesaler’s inventory information to assess the magnitude of unconsumed product that may result in a sales returns to the Company in the future. The sales returns level can be impacted by factors such as overall market demand and market competition and availability for substitute products which can increase or decrease the end-user pull through for sales of the Company’s products and ultimately impact the level of sales returns. Actual returns experience and trends are factored into the Company’s estimates each quarter as market conditions change. Actual returns processed can vary materially from period to period.
	For the years ended December 31, 2013, 2012 and 2011, the Company recorded a net expense for product returns of $5.0 million, $3.8 million and $2.7 million, respectively.  The Company’s allowance for potential product returns was $8.2 million and $8.4 million at December 31, 2013 and 2012, respectively.
	Allowance for Coupons and Promotions: The Company issues coupons from time to time redeemable against our TheraTears® eye care products.  Upon release of coupons into the market, the Company records an estimate of the dollar value of coupons expected to be redeemed.  This estimate is based on historical experience and is adjusted as needed based on actual redemptions.   In addition to couponing, from time to time the Company authorizes various retailers to run in-store promotional sales of our products. Upon confirmation that a promotion was run, the Company accrues an estimate of the dollar amount expected to be owed back to the retailer.  This estimate is trued up upon receipt of invoice from the retailer.
	For the years ended December, 31, 2013, 2012 and 2011, the Company recorded provisions for coupons and promotions totaling $4.5 million, $3.0 million and $1.9 million, respectively.  As of December 31, 2013 and 2012, the balances in the Company’s reserve for coupons and promotions were $0.7 million and $0.8 million, respectively.
	Doubtful Accounts: Provisions for doubtful accounts, which reflect trade receivable balances owed to the Company that are believed to be uncollectible, are recorded as a component of SG&A expenses. In estimating the allowance for doubtful accounts, the Company considers its historical experience with collections and write-offs, the credit quality of its customers and any recent or anticipated changes thereto, and the outstanding balances and past due amounts from its customers.  Accounts are considered past due when they remain uncollected beyond the due date specified in the applicable contract or on the applicable invoice, whichever is deemed to take precedence.
	For the years ended December 31, 2013, 2012 and 2011, the Company recorded net provisions for doubtful accounts that were insignificant in amount, at less than $0.1 million in each year.
	As of December 31, 2013, the Company had a total of $6.1 million of past due gross accounts receivable, of which $0.8 million was more than 60 days past due. The Company performs monthly a detailed analysis of the receivables due from its wholesaler customers and provides a specific reserve against known uncollectible items. The Company also includes in the allowance for doubtful accounts an amount that it estimates to be uncollectible for all other customers, based on a percentage of the past due receivables. The percentage reserved increases as the age of the receivables increases.  Accounts are written off once all reasonable collections efforts have been exhausted and/or when facts or circumstances regarding the customer (i.e. bankruptcy filing) indicate that the chance of collection is remote.
	Advertising and Promotional Allowances to Customers: The Company routinely sells its non-prescription ophthalmic and other drug products to major retail drug chains.  From time to time, the Company may arrange for these retailers to run in-store promotional sales of the Company’s products.  The Company reserves an estimate of the dollar amount owed back to the retailer, recording this amount as a reduction to revenue at the later of the date on which the revenue is recognized or the date the sales incentive is offered. When the actual invoice for the sales promotion is received from the retailer, the Company adjusts its estimate accordingly.
	For the Company’s treatment of advertising and promotional expenses paid to customers, costs are expensed as incurred in accordance with ASC 605-50, Customer Payments and Incentives.
	Inventories: Inventories are stated at the lower of cost (average cost method) or market (see Note 4 — “Inventories”). The Company maintains an allowance for slow-moving and obsolete inventory as well as inventory with a carrying value in excess of its net realizable value (“NRV”). For finished goods inventory, the Company estimates the amount of inventory that may not be sold prior to its expiration or is slow moving based upon recent sales activity by unit and wholesaler inventory information. The Company also analyzes its raw material and component inventory for slow moving items. For the years ended December 31, 2013, 2012 and 2011, the Company recorded a provision for inventory obsolescence/NRV of $2.1 million, $2.4 million, and $0.6 million, respectively. The allowances for inventory obsolescence were $2.9 million and $2.2 million as of December 31, 2013 and 2012, respectively.
	The Company capitalizes inventory costs associated with its products prior to regulatory approval when, based on management judgment, future commercialization is considered probable and the future economic benefit is expected to be realized.  The Company assesses the regulatory approval process and where the product stands in relation to that approval process including any known constraints or impediments to approval.  The Company considers the shelf life of the product in relation to the product timeline for approval.
	At December 31, 2013, the Company established a reserve of $1.0 million related to R&D raw materials that are not expected to be utilized prior to expiration.  At December 31, 2012, the Company had approximately $0.8 million in inventory for generic drugs under development which have not yet received FDA approval, the entire balance of which had been reserved, as the Company deemed it unlikely that the products would receive FDA approval far enough in advance of expiration to be sellable.
	Intangible Assets: Intangible assets consist primarily of goodwill, which is carried at its initial value, subject to evaluation for impairment, and product licensing costs, trademarks and other such costs, which are capitalized and amortized on a straight-line basis over their useful lives, ranging from four (4) years to thirty (30) years.  Accumulated amortization was $39.1 million and $31.9 million at December 31, 2013 and 2012, respectively.  Amortization expense was $7.4 million, $6.9 million and $1.7 million for the years ended December 31, 2013, 2012 and 2011, respectively. The Company regularly assesses its intangible assets for impairment based on several factors, including estimated fair value and anticipated cash flows.  If the Company incurs additional costs to renew or extend the life of an intangible asset, such costs are added to the remaining unamortized cost of the asset, if any, and the sum is amortized over the extended remaining life of the asset.
	Goodwill is tested for impairment annually or more frequently if changes in circumstances or the occurrence of events suggest that impairment may exist. The Company uses widely accepted valuation techniques to determine the fair value of its reporting units used in its annual goodwill impairment analysis. The Company’s valuation is primarily based on qualitative and quantitative assessments regarding the fair value of goodwill relative to its carrying value. The Company modeled the fair value of the reporting unit based on actual projected earnings and cash flows of the reporting unit. The Company performed its annual impairment test on October 1, 2013 and determined that the fair value of its reporting unit exceeded its carrying value and, therefore, no impairment charge was necessary.
	Changes in goodwill during the two years ended December 31, 2013 were as follows (in thousands):
			Goodwill
	31-Dec-11		$	11,863
	Acquisitions			22,613
	Impairments		-
	Foreign currency translation			(2,317	)
	31-Dec-12		$	32,159
	Acquisitions		-
	Impairments		-
	Foreign currency translation			(2,328	)
	31-Dec-13		$	29,831
	The following table sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of December 31, 2013 for those assets that are not already fully amortized (dollar amounts in thousands):
			Gross			Accumulated			Net			Weighted Average
			Carrying			Amortization			Carrying			Remaining
			Amount						Amount			Amortization Period
	Product licensing rights		$	151,504		$	(35,604	)	$	115,900		9.8 years
	Trademarks			9,500			(844	)		8,656		27.4 years
	Customer relationships			6,166			(1,528	)		4,638		9.8 years
	Non-Compete			2,428			(1,117	)		1,311		2.2 years
			$	169,598		$	(39,093	)	$	130,505
	Changes in intangible assets during the two years ended December 31, 2013 were as follows (in thousands):
			Product			Trademarks			Customer				Non-Compete
			licensing rights						Relationships				Agreements
	31-Dec-11		$	67,822			$9,289		$	3,727			$	-
	Acquisitions			1,100			-			2,560				2,743
	Amortization			(5,268	)		(317	)		(705	)			(580	)
	Foreign currency translation		-			-				6				8
	31-Dec-12		$	63,654		$	8,972		$	5,588			$	2,171
	Acquisitions			57,969		-			-				-
	Amortization			(5,723	)		(316	)		(740	)			(643	)
Foreign currency translation		-			-				(210	)			(217	)
31-Dec-13		$	115,900		$	8,656		$	4,638			$	1,311
The amortization expense of acquired intangible assets for each of the following five years will be as follows (in thousands):
Year ending		Amortization Expense
December 31,
2014		$	15,996
2015			15,388
2016			14,862
2017			14,345
2018			14,262
Property, Plant and Equipment: Property, plant and equipment is stated at cost, less accumulated depreciation. Depreciation is provided using the straight-line method in amounts considered sufficient to amortize the cost of the assets to operations over their estimated useful lives or lease terms. Depreciation expense was $7.1 million, $4.6 million and $3.5 million for the years ended December 31, 2013, 2012 and 2011, respectively.  The amortization of assets under capital leases is included within depreciation expense. The following table sets forth the average estimated useful lives of the Company’s property, plant and equipment, by asset category:
Asset category		Depreciable Life
Buildings		30 years
Leasehold improvements		18 years
Furniture and equipment		10 years
Automobiles		5 years
Computer hardware and software		5 years
Net Income Per Common Share: Basic net income per common share is based upon weighted average common shares outstanding. Diluted net income per common share is based upon the weighted average number of common shares outstanding, including the dilutive effect, if any, of stock options, warrants and convertible securities using the treasury stock and if converted methods.  Anti-dilutive shares excluded from the computation of diluted net income per share for 2013, 2012 and 2011 include 975,000, 581,000 and 1,560,000 shares, respectively, related to options, warrants and convertible securities.
Income Taxes: Income taxes are accounted for under the asset and liability method.  Deferred income tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and net operating loss and other tax credit carry-forwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company records a valuation allowance to reduce the deferred income tax assets to the amount that is more likely than not to be realized.
Fair Value of Financial Instruments: The Company applies ASC Topic 820, which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC Topic 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company’s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC Topic 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity’s own assumptions based on market data and the entity’s judgments about the assumptions that market participants would use in pricing the asset or liability, and are to be developed based on the best information available in the circumstances.
The valuation hierarchy is composed of three categories.  The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement.  The categories within the valuation hierarchy are described below:
	-	Level 1—Assets and liabilities with unadjusted, quoted prices listed on active market exchanges.  Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.  The carrying value of the Company‘s cash and cash equivalents are considered Level 1 assets.
	-	Level 2—Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as directly or indirectly observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.  The market value of the Company’s forward contracts to hedge against changes in currency translation rates between U.S. dollars and Indian rupees is a Level 2 asset.
	-	Level 3—Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.  The purchase consideration payable related to the Company’s acquisition on December 22, 2011 of three branded, injectable drug products from the U.S. subsidiary of H. Lundbeck A/S (the “Lundbeck Acquisition”) is a Level 3 liability.
The following table summarizes the basis used to measure the fair values of the company’s financial instruments (amounts in thousands):
					Fair Value Measurements at Reporting Date, Using:
					Quoted Prices			Significant
					in Active			Other				Significant
					Markets for			Observable				Unobservable
		December 31,			Identical Items			Inputs				Inputs
Description		2013			(Level 1)			(Level 2)				(Level 3)
Cash and cash equivalents		$	34,178		$	34,178		$	-			$	-
Foreign currency forward contracts			208			-			208				-
Total assets		$	34,386		$	34,178		$	208			$	-
Purchase consideration payable		$	14,728		$	-		$	-			$	14,728
Total liabilities		$	14,728		$	-		$	-			$	14,728
					Quoted Prices			Significant
					in Active			Other				Significant
					Markets for			Observable				Unobservable
		December 31,			Identical Items			Inputs				Inputs
Description		2012			(Level 1)			(Level 2)				(Level 3)
Cash and cash equivalents		$	40,781		$	40,781		$	-			$	-
Total assets		$	40,781		$	40,781		$	-			$	-
Purchase consideration payable		$	14,208		$	-		$	-			$	14,208
Total liabilities		$	14,208		$	-		$	-			$	14,208
The carrying amount of the purchase consideration payable was initially determined based on the terms of the underlying contracts and the Company’s subjective evaluation of the likelihood of the additional purchase consideration becoming payable.  The purchase consideration payable is related to the Company’s obligation to pay additional consideration related to the acquisition of selected assets from H. Lundbeck A/S (“Lundbeck”) on December 22, 2011.  The underlying obligation was long-term in nature, and therefore was discounted to present value based on an assumed discount rate.  The additional consideration of $15.0 million, contingently payable to Lundbeck on December 22, 2014, was initially discounted to $11.3 million based on a discount rate of 10.0%, and subsequently adjusted in final acquisition accounting to $11.6 million based on applying a 9.0% discount rate.  At December 31, 2012, the Company performed an evaluation of the fair value of this liability based on utilizing significant unobservable inputs to derive a discount rate of 2.75%, and determined that the appropriate discounted value was $14.2 million.  Accordingly, the Company recorded non-cash interest expense of $2.6 million during 2012 to accrue the carrying value of the contingent payment liability to $14.2 million as of December 31, 2012.  At December 31, 2013, the Company once again evaluated the fair value based on utilizing significant unobservable inputs and derived a discount rate of 1.85%, determining that the appropriate discounted value was $14.7 million.  The fair value of the liability is based upon the likelihood of achieving the underlying revenue targets and a derived cost of debt based on the remaining term.
The Company initially determined that there was a 100% likelihood of the purchase consideration ultimately becoming payable, and reaffirmed this determination as of December 31, 2012 and December 31, 2013.  Should subjective and objective evidence lead the Company to change this assessment, an adjustment to the carrying value of the liability would be recorded as “other income” in the Company’s condensed consolidated statements of comprehensive income.
The purchase consideration payable to Lundbeck was classified as a long-term liability on the Company’s consolidated balance sheet as of December 31, 2012.  This liability was reclassified as a current liability on the Company’s a consolidated balance sheet as of December 31, 2013, since the $15.0 million payment will be due in less than a year from that date.
The Company entered into three non-deliverable forward contracts in October 2013 to hedge planned capital expenditures at AIPL against unfavorable trends with regard to currency translation rates between U.S. dollars (“USD”) and Indian rupees (“INR”).  The three forward contracts were based on future anticipated investments of USD $3.3 million on each of April 2, 2014, July 3, 2014 and September 30, 2014 in the Company’s subsidiary in India, Akorn India Private Limited (“AIPL”).  These forward contracts include projected currency translation rates between INR and USD.  Any difference between the actual and projected foreign currency translations rates on the respective settlement dates will result in payment from the bank to the Company, or vice versa, as the case may be.  As of December 31, 2013, the bank provided the Company with a report of the fair market value of the forward contracts.  Due to strengthening of the Indian rupee against the U.S. dollar, the contracts had a positive fair value to the Company of $0.2 million as of December 31, 2013.  The Company recorded this gain in fair value as “other income” in its consolidated statements of comprehensive income and has included the asset value within “prepaid expenses and other current assets” in its consolidated balance sheet.
As of December 31, 2013 and 2012, the Company was carrying long-term investments valued at $10.0 million and $10.3 million, respectively.  The underlying assets are cost-basis investments for which fair value is not readily determinable.
Warrants: The Company issued various warrants during 2009 to entities controlled by John N. Kapoor, Ph.D., the Chairman of the Company’s Board of Directors (the “Kapoor Warrants”).  The Company had classified the fair value of these warrants as a current liability in accordance with ASC 815-40-15-3, Derivatives and Hedging, (formerly EITF 00-19, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock). This classification was made as a result of the requirement that the shares to be issued upon exercise of the Kapoor Warrants be registered shares, which could not be absolutely assured.  The Kapoor Warrants were adjusted to fair value at the end of each quarter through Black-Scholes calculations which considered changes in the market price of the Company’s common stock, the remaining contractual life of the Kapoor Warrants, and other factors.  Any change in the fair value of the Kapoor Warrants was recorded as income or expense on the Company’s consolidated statements of operations for the applicable period.
On June 28, 2010, the Company and Dr. Kapoor entered into an Amended and Restated Registration Rights Agreement (the “Amended Agreement”) which modified certain terms related to the Company’s obligation to obtain and maintain registration of any shares issued pursuant to exercise of the Kapoor Warrants.  The Amended Agreement still requires the Company to use “commercially reasonable efforts” to file a registration statement pursuant to Rule 415 of the Securities Act of 1933 (“Registration Statement”) for any shares of common stock that may be issued under the applicable warrant agreements, and to maintain the continuous effectiveness of such Registration Statement until the earliest of: (i) the date no shares of the Company’s common stock qualify as registrable securities, (ii) the date on which all of the registrable securities may be sold in a single transaction by the holder to the public pursuant to Rule 144 or a similar rule, or (iii) the date upon which the John N. Kapoor Trust Dated September 20, 1989 (the “Kapoor Trust”) and EJ Funds, LP (“EJ Funds”) have transferred all of the registrable securities.  However, the Registration Rights Agreement has been amended to explicitly state that in the event the Company, after using its good faith commercially reasonable efforts, is not able to obtain or maintain registration of the common stock, delivery of unregistered shares upon exercise of the Kapoor Warrants will be deemed acceptable and a net cash settlement will not be required. The Amended Agreement further provides that the term “commercially reasonable efforts” in such instance shall not mean an absolute obligation of the Company to obtain and maintain registration.
As a result of the changes effected through the Amended Agreement, on June 28, 2010 the Company changed its accounting treatment of the Kapoor Warrants, no longer classifying them as a current liability with periodic adjustments to fair value but instead classifying them as a component of shareholders’ equity in accordance with ASC 815-40.   Accordingly, the fair value of the Kapoor Warrants, which was $17.9 million on June 28, 2010, was reclassified from a current liability to a component of shareholders’ equity on that date.  Following this change in classification, no future fair value adjustments are required.
The liability at June 28, 2010 for the Kapoor Warrants was estimated using a Black-Scholes valuation model with the fair value per warrant ranging from $2.49 to $2.50.  The expected volatility of the Kapoor Warrants was based on the historical volatility of the Company’s common stock. The expected life assumption was based on the remaining life of the Kapoor Warrants. The risk-free interest rate for the expected term of the Kapoor Warrants was based on the average market rate on U.S. treasury securities in effect during the applicable quarter. The dividend yield reflected historical experience as well as future expectations over the expected term of the Kapoor Warrants.
The assumptions used in estimating the fair value of the warrants at June 28, 2010 were as follows:
Expected Volatility	79.70%
Expected Life (in years)	3.8 – 4.1
Risk-free interest rate	1.80%
Dividend yield	-
The following table provides summarized information about the Kapoor Warrants as of December 31, 2013:
			Warrants			Exercise			Book Value
Granted To:	Grant Date		Granted			Price			($000s)
EJ Funds	Apr.13, 2009			1,939,639		$	1.11		$	4,829
Kapoor Trust	Apr.13, 2009			1,501,933		$	1.11			3,740
EJ Funds	Aug.17, 2009			1,650,806		$	1.16			4,127
Kapoor Trust	Aug.17, 2009			2,099,935		$	1.16			5,250
				7,192,313					$	17,946
Stock-Based Compensation: Stock-based compensation cost is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period. The Company uses the Black-Scholes model for estimating the fair value of stock options. Determining the assumptions that enter into the model is highly subjective and requires judgment. The Company uses an expected volatility that is based on the historical volatility of its stock. The expected life assumption is based on historical employee exercise patterns and employee post-vesting termination behavior. The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. treasury securities in effect during the quarter in which the options were granted. The dividend yield reflects historical experience as well as future expectations over the expected term of the option. The Company estimates forfeitures at the time of grant and revises in subsequent periods, if necessary, if actual forfeitures differ from those estimates.
Warranty Liability: The product warranty liability relates to a ten year expiration guarantee on DTPA Products sold to the United States Department of Health and Human Services (“HHS”) in 2006. The Company had been performing yearly stability studies for the DTPA Products and, if the annual stability did not support the ten-year product life, it would replace the product at no charge. The Company’s supplier, Hameln Pharmaceuticals (“Hameln”), was to share one-half of this cost if the product did not meet the stability requirement.  During 2013, the Company and Hameln agreed to settle the remaining obligations under this arrangement.  Pursuant to the settlement, the Company was released from its remaining obligations with regard to product stability testing.  Once this occurred, the Company reversed its product warranty reserve balance against cost of sales.

Allowance_for_Customer_Deducti

Allowance for Customer Deductions	12 Months Ended
	Dec. 31, 2013
Allowance for Customer Deductions [Abstract]	'
Allowance for Customer Deductions	'
	Note 3 — Allowance for Customer Deductions
	The annual activity in the Company’s allowance for customer deductions accounts for the three years ended December 31, 2013 is as follows (in thousands):
		Returns			Chargebacks			Discounts			Doubtful			Advert. &			TOTAL
					& Rebates						Accounts			Promotions
	Balance at December 31, 2010	$	3,463		$	2,522		$	345		$	3		$	-		$	6,333
	Provision		2,687			68,067			3,431			25			1,135			75,345
	Additions from business combinations		1,845			-			50			187			132			2,214
	Charges processed		(1,149	)		(64,640	)		(3,083	)		(116	)		(881	)		(69,869	)
	Balance at December 31, 2011		6,846			5,949			743			99			386			14,023
	Provision		3,783			112,243			6,074			(82	)		2,063			124,081
	Charges processed		(2,220	)		(104,740	)		(5,455	)		13			(1,864	)		(114,266	)
	Balance at December 31, 2012		8,409			13,452			1,362			30			585			23,838
	Provision		5,001			183,403			8,464			(5	)		4,524			201,387
	Charges processed		(5,246	)		(183,973	)		(8,182	)		—			(4,657	)		(202,058	)
	Balance at December 31, 2013	$	8,164		$	12,882		$	1,644		$	25		$	452		$	23,167

Inventories

Inventories	12 Months Ended
	Dec. 31, 2013
Inventories [Abstract]	'
Inventories	'
	Note 4 — Inventories
	The components of inventories, net of allowances, are as follows (in thousands):
		December 31,
		2013			2012
	Finished goods	$	22,886		$	24,657
	Work in process		3,883			3,743
	Raw materials and supplies		29,213			24,095
		$	55,982		$	52,495
	The Company maintains an allowance for excess and obsolete inventory, as well as inventory with a carrying value in excess of its net realizable value.  The activity in the allowance for excess and obsolete inventory account for the three years ended December 31, 2013 was as follows (in thousands):
		Years Ended December 31,
		2013			2012			2011
	Balance at beginning of year	$	2,244		$	1,239		$	1,612
	Provision		2,089			2,385			598
	Charges		(1,383	)		(1,380	)		(971	)
	Balance at end of year	$	2,950		$	2,244		$	1,239

Property_Plant_and_Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment	'
	Note 5 – Property, Plant and Equipment
	Property, plant and equipment consist of the following (in thousands):
		December 31,
		2013			2012
	Land	$	2,606		$	2,715
	Buildings and leasehold improvements		46,281			43,190
	Furniture and equipment		76,536			70,874
			125,423			116,779
	Accumulated depreciation		(54,470	)		(47,635	)
			70,953			69,144
	Construction in progress		11,155			11,535
		$	82,108		$	80,679
	At December 31, 2013 and 2012, property plant and equipment carrying a net book value of $21.1 million and $23.7 million, respectively, was located outside the United States.

Financing_Arrangements

Financing Arrangements	12 Months Ended
	Dec. 31, 2013
Financing Arrangements [Abstract]	'
Financing Arrangements	'
	Note 6 — Financing Arrangements
	Convertible Notes
	On June 1, 2011, the Company closed on its offering of $120.0 million aggregate principal amount of 3.50% Convertible Senior Notes due 2016 (the “Notes”) which includes $20.0 million in aggregate principal amount of the Notes issued in connection with the full exercise by the initial purchasers of their over-allotment option. The Notes are governed by the Company’s indenture with Wells Fargo Bank, National Association, as trustee (the “Indenture”).  The Notes were offered and sold only to qualified institutional buyers.  The net proceeds from the sale of the Notes were approximately $115.3 million, after deducting underwriting fees and other related expenses.
	The Notes have a maturity date of June 1, 2016 and pay interest at an annual rate of 3.50% semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2011.  The Notes are convertible into the Company’s common stock, cash or a combination thereof at an initial conversion price of $8.76 per share, which is equivalent to an initial conversion rate of approximately 114.1553 shares per $1,000 principal amount of Notes.  The conversion price is subject to adjustment for certain events described in the Indenture, including certain corporate transactions which will increase the conversion rate and decrease the conversion price for a holder that elects to convert its Notes in connection with such corporate transaction.
	The Notes are not listed on any securities exchange or on any automated dealer quotation system, but are traded on a secondary market made by the initial purchasers.  The initial purchasers of the Notes advised the Company of their intent to make a market in the Notes following the offering, though they are not obligated to do so and may discontinue any market making at any time.
	As of December 31, 2013, the Notes were trading at approximately 284% of their face value, resulting in a total market value of $341.3 million compared to their face value of $120.0 million.  The actual conversion value of the Notes is based on the product of the conversion rate and the market price of the Company's common stock at conversion, as defined in the Indenture.  As of December 31, 2013, the Company's common stock closed at $24.62 per share, resulting in a pro forma conversion value for the Notes of approximately $337.3 million.  Increases in the market value of the Company’s common stock increase the Company’s obligation accordingly.  There is no upper limit placed on the possible conversion value of the Notes.
	The Notes may be converted at any time prior to the close of business on the business day immediately preceding December 1, 2015 only under the following circumstances:  (1) during any calendar quarter commencing after September 30, 2011, if the closing sale price of the Company’s common stock, for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the calendar quarter immediately preceding the calendar quarter in which the conversion occurs, is more than 130% of the conversion price in effect on each applicable trading day; (2) during the five consecutive trading-day period following any five consecutive trading-day period in which the trading price for the Notes per $1,000 principal amount of Notes for each such trading day was less than 98% of the closing sale price of the Company’s common stock on such date multiplied by the then-current conversion rate; or (3) upon the occurrence of specified corporate events.  On or after December 1, 2015 until the close of business on the business day immediately preceding the stated maturity date, holders may surrender all or any portion of their Notes for conversion at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver, at the Company’s option, cash, shares of the Company’s common stock, or a combination thereof.  If a fundamental change (as defined in the Indenture) occurs prior to the stated maturity date, holders may require the Company to purchase for cash all or a portion of their Notes.
	The Notes became convertible for the quarter ending on June 30, 2012 as a result of the Company’s stock trading at or above the required price of $11.39 per share for 20 of the last 30 trading days in the quarter ended March 31, 2012.  The Notes have remained convertible for each successive quarter as a result of meeting the trading price requirement at the end of each prior quarter.
	The Notes are accounted for in accordance with ASC 470-20, Debt with Conversion and Other Options.  Under ASC 470-20, issuers of convertible debt instruments that may be settled in cash upon conversion, including partial cash settlement, are required to separately account for the liability (debt) and equity (conversion option) components.  The application of ASC 470-20 resulted in the recognition of $21.3 million as the value for the equity component.  This amount was offset by $0.8 million of equity issuance costs, as described below.  At the dates indicated, the net carrying amount of the liability component and the remaining unamortized debt discount were as follows (in thousands):
		December 31,
		2013		2012
	Carrying amount of equity component	$	20,470		20,470
	Carrying amount of the liability component		108,750		104,637
	Unamortized discount of the liability component		11,250		15,363
	Unamortized debt financing costs		2,034		2,778
	The Company incurred debt issuance costs of $4.7 million related to its issuance of the Notes.  In accordance with ASC 470-20, the Company allocated this debt issuance cost ratably between the liability and equity components of the Notes, resulting in $3.9 million of debt issuance costs allocated to the liability component and $0.8 million allocated to the equity component.  The portion allocated to the liability component was classified as deferred financing costs and is being amortized by the effective interest method through the earlier of the maturity date of the Notes or the date of conversion, while the portion allocated to the equity component was recorded as an offset to additional paid-in capital upon issuance of the Notes.
	During the years ended December 31, 2013, 2012 and 2011, the Company recorded the following expenses in relation to the Notes (in thousands):
		2013		2012		2011
	Interest expense at 3.50% coupon rate	$	4,200	$	4,200	$	2,450
	Debt discount amortization		4,113		3,828		2,109
	Deferred financing cost amortization		744		692		382
		$	9,057	$	8,720	$	4,941
	Upon issuing the Notes, the Company established a deferred tax liability of $8.6 million related to the debt discount of $21.3 million, with an offsetting debit of $8.6 million to Common stock.  The deferred tax liability was established because the amortization of the debt discount generates non-cash interest expense that is not deductible for income tax purposes.  Since the Company’s net deferred tax assets were fully reserved by valuation allowance at the time the Notes were issued, the Company reduced its valuation allowance by $8.6 million upon recording the deferred tax liability related to the debt discount with an offsetting credit of $8.6 million to Common stock.  As a result, the net impact of these entries was a debit of $8.6 million to the valuation reserve against the Company’s deferred tax assets and a credit of $8.6 million to deferred tax liability.  The deferred tax liability is being amortized monthly as the Company records non-cash interest from its amortization of the debt discount on the Notes.
	Bank of America Credit Facility
	On October 7, 2011, the Company and its domestic subsidiaries (the “Borrowers”) entered into a Loan and Security Agreement (the “BoA Credit Agreement”) with Bank of America, N.A. (the “Agent”) and other financial institutions (collectively with the Agent, the “BoA Lenders”) through which it obtained a $20.0 million revolving line of credit (the “BoA Facility”), which includes a $2.0 million letter of credit facility.  On October 4, 2013, the Company and the BoA Lenders entered into an amendment which increased the total credit commitment from $20.0 million to $60.0 million.  The BoA Facility matures in March 2016.  The Company may early terminate the BoA Lenders’ commitments under the Facility upon 90 days’ notice to the Agent at any time after the first year.
	Under the terms of the BoA Credit Agreement, amounts outstanding will bear interest at the Company’s election at (a) LIBOR or (b) the bank’s Base Rate (which is the greatest of: (i) the prime rate, (ii) the federal funds rate plus 0.50%, or (iii) LIBOR plus 1.0%), plus an applicable margin, which margin is based on the consolidated fixed charge coverage ratio of the Company and its subsidiaries from time to time. Additionally, the Borrowers will pay an unused line fee of 0.250% per annum on the unused portion of the BoA Facility.  Interest and unused line fees will be accrued and paid monthly.  In addition, with respect to any letters of credit that may be issued, the Borrowers will pay: (i) a fee equal to the applicable margin times the average amount of outstanding letters of credit, (ii) a fronting fee equal to 0.125% per annum on the stated amount of each letter of credit, and (iii) any additional fees incurred by the applicable issuer in connection with issuing the letter of credit.  During an event of default, any interest or fees payable will be increased by 2% per annum.
	Availability under the revolving credit line is equal to the lesser of (a) $60.0 million reduced by outstanding letter of credit obligations or (b) the amount of a Borrowing Base (as defined in accordance with the terms of the BoA Credit Agreement) determined by reference to the value of the Borrowers’ eligible accounts receivable, eligible inventory and fixed assets as of the closing date and the end of each calendar month thereafter.
	Obligations under the BoA Credit Agreement are secured by substantially all of the assets of each of the Borrowers and a pledge by the Borrowers of their respective equity interest in each domestic subsidiary of the Company and 65% of their respective equity interests in any foreign subsidiary of the Company. The BoA Credit Agreement contains representations and warranties, and affirmative and negative covenants customary for financings of this type, including, but not limited to, limitations on:  distributions while we have any outstanding commitments or obligations under the BoA Credit Agreement; additional borrowings and liens; additional investments and asset sales; and fundamental changes to corporate structure or organization documents.  The financial covenants require the Borrowers to maintain a fixed charge coverage ratio of at least 1.1 to 1.0 during any period commencing on the date that an event of default occurs or availability under the BoA Credit Agreement is less than 15% of the aggregate BoA Lenders’ commitments under the BoA Credit Agreement.  During the term of the agreement, the Company must provide the Agent with monthly, quarterly and annual financial statements, monthly compliance certificates, annual budget projections and copies of press releases and SEC filings.
	As of December 31, 2013, the Company had availability on our line of credit of $59.1 million, there was one outstanding letter of credit in the amount of $0.5 million and there were no outstanding borrowings.
	EJ Funds Credit Facility
	On January 7, 2009, the Company entered into a Credit Agreement (the “GE/EJ Credit Agreement”) with General Electric Capital Corporation (“GE Capital”) as agent for several financial institutions (the “Lenders”).  Effective March 31, 2009, the GE/EJ Credit Agreement was assigned to EJ Funds, a company controlled by Dr. Kapoor, the Chairman of the Company’s board of directors.  Pursuant to the GE/EJ Credit Agreement, the Lenders agreed to extend loans to the Company under a revolving credit facility up to an aggregate principal amount of $25.0 million (the “Credit Facility”). The maximum loan commitment was decreased to $5.7 million upon assignment of the GE/EJ Credit Agreement to EJ Funds, and was subsequently increased on August 17, 2009 to $10.0 million.  The Credit Facility was scheduled to terminate, and all amounts outstanding thereunder were to become due and payable, on January 7, 2013, or on an earlier date as specified in the GE/EJ Credit Agreement.  The Company elected to early terminate the GE/EJ Credit Agreement on June 17, 2011.  It had not borrowed against the Credit Facility since the first quarter of 2010.  A more detailed timeline of certain events regarding the GE/EJ Credit Agreement follows.
	On February 19, 2009, GE Capital informed the Company that it was applying a reserve against availability which effectively restricted the Company’s borrowings under the GE/EJ Credit Agreement to the balance outstanding as of February 19, 2009, which was $5.5 million. GE Capital advised that it had applied this reserve due to concerns about financial performance, including the Company’s prospective compliance with certain covenants in the GE/EJ Credit Agreement for the quarter ended March 31, 2009.
	On March 31, 2009, the Company consented to an Assignment Agreement (“Assignment”) between GE Capital and EJ Funds which transferred to EJ Funds all of GE Capital’s rights and obligations under the GE/EJ Credit Agreement. Pursuant to the Assignment, EJ Funds became the agent and lender under the GE/EJ Credit Agreement. Dr. Kapoor is the President of EJ Financial Enterprises, Inc., a healthcare consulting investment company (“EJ Financial”) and EJ Financial is the general partner of EJ Funds.  In connection with the Assignment, on April 13, 2009, the Company entered into a Modification, Warrant and Investor Rights Agreement (the “Modification Agreement”) with EJ Funds that, among other things, (i) reduced the revolving loan commitment under the GE/EJ Credit Agreement to $5.7 million, and (ii) set the interest rate for all amounts outstanding under the GE/EJ Credit Agreement at an annual rate of 10% with interest payable monthly.  The Modification Agreement also granted EJ Funds the right to require the Company to nominate two directors to serve on its Board of Directors. The Kapoor Trust is entitled to require the Company to nominate a third director under its Stock Purchase Agreement dated November 15, 1990 with the Kapoor Trust.
	Pursuant to the Modification Agreement, on April 13, 2009, the Company granted EJ Funds a warrant (the “Modification Warrant”) to purchase 1,939,639 shares of its common stock at an exercise price of $1.11 per share, subject to certain adjustments. The Modification Warrant expires five years after its issuance and is exercisable upon payment of the exercise price in cash or by means of a cashless exercise yielding a net share figure.
	On August 17, 2009, the Company completed negotiations with EJ Funds for additional capacity on its Credit Facility, increasing the loan commitment from $5.7 million to $10.0 million.  In consideration of this amendment, EJ Funds was granted a warrant to acquire 1,650,806 shares of the Company’s common stock at $1.16 per share, the closing market price on August 14, 2009 (the “Restatement Warrants”). The estimated fair value of the Restatement Warrants, using a Black-Scholes valuation model, was $1.2 million on date of grant.  This amount plus $7,000 in other associated costs was capitalized as financing costs and was being amortized.  Upon termination of the Credit Facility on June 17, 2011, the remaining unamortized cost was written off.
	On June 17, 2011, the Company elected to early terminate its $10.0 million revolving GE/EJ Credit Agreement with EJ Funds.  The Company had not borrowed against the GE/EJ Credit Agreement since repaying its outstanding balance in the first quarter of 2010.  Upon terminating the GE/EJ Credit Agreement, the Company expensed $1.2 million in remaining unamortized deferred financing costs related to the GE/EJ Credit Agreement. The Company incurred no fees or penalties related to its early termination of the GE/EJ Credit Agreement.

Earnings_per_Common_Share

Earnings per Common Share	12 Months Ended
	Dec. 31, 2013
Earnings per Common Share [Abstract]	'
Earnings per Common Share	'
	Note 7 — Earnings per Common Share
	Basic net income per common share is based upon the weighted average common shares outstanding during the period. Diluted net income per common share is based upon the weighted average number of common shares outstanding, including the dilutive effect, if any, of stock options, warrants and the conversion feature of convertible notes using the treasury stock method.
	The Company’s potentially dilutive shares consist of: (i) vested and unvested stock options that are in-the-money, (ii) unvested RSAs, (iii) warrants that are in-the-money, and (iv) shares potentially issuable upon conversion of the Notes.  The Company calculates and includes in dilutive securities incremental shares issuable related to the Notes to the extent that the conversion value of each note exceeds $1,000.
	A reconciliation of the earnings per share data from a basic to a fully diluted basis is detailed below (amounts in thousands, except per share data):
		2013		2012		2011
	Net income	$	52,362	$	35,378	$	43,013
	Net income per share:
	Basic	$	0.54	$	0.37	$	0.45
	Diluted	$	0.46	$	0.32	$	0.41
	Shares used in computing net income per share:
	Weighted average basic shares outstanding		96,181		95,189		94,549
	Dilutive securities:
	Stock options and unvested RSAs		4,516		4,289		3,281
	Stock warrants		6,702		6,564		6,082
	Shares issuable on conversion of the Notes		6,499		4,468		—
	Total dilutive securities		17,717		15,321		9,363
	Weighted average diluted shares outstanding		113,898		110,510		103,912

Leasing_Arrangements

Leasing Arrangements	12 Months Ended
	Dec. 31, 2013
Leasing Arrangements [Abstract]	'
Leasing Arrangements	'
	Note 8 — Leasing Arrangements
	The Company leases real and personal property in the normal course of business under various operating leases, including non-cancelable and month-to-month agreements. Rental expense under these leases was $2.9 million, $2.3 million and $2.4 million for the years ended December 31, 2013, 2012 and 2011, respectively.
	Landlord incentives are recorded as deferred rent and amortized on a straight-line basis over the lease term.  Rent escalations are recorded on a straight-line basis over the lease term.  The Company’s main operating leases for its Lake Forest and Gurnee facilities have original terms of ten years.  The Lake Forest facility lease allows for a five-year renewal at the option of the Company.
	The following is a schedule, by year, of future minimum rental payments required under non-cancelable operating and capital leases in place as of December 31, 2013 (in thousands):
	Year ending December 31,
	2014	$	1,973
	2015		1,970
	2016		2,000
	2017		1,791
	2018		529
	2019 and thereafter		340
	Total	$	8,603
	On December 1, 2012, the Company entered into a lease for a new R&D center in Vernon Hills, Illinois.  This lease extends through April 30, 2020, and obligates the Company to pay total base rent of $1,324,000, plus proportionate real estate taxes and common area maintenance, over the life of the agreement.  Prior to moving its R&D activities to Vernon Hills, Illinois, the Company had leased space for its R&D activities within the Illinois Science & Technology Park in Skokie, Illinois.  This lease commenced on February 1, 2010, and extended through its early termination date of February 1, 2014.  Upon vacating the Skokie space shortly after moving R&D operations to Vernon Hills, Illinois, the Company accrued to expense its remaining obligations under the Skokie lease.
	On July 27, 2010, the Company, through its wholly-owned subsidiary, Akorn (New Jersey), Inc., an Illinois corporation, entered into a seven-year building lease agreement (the “Somerset Lease”) with Veronica Development Associates, a New Jersey general partnership, extending the Company’s occupancy of its 50,000 square foot manufacturing facility located at 72-6 Veronica Avenue, Somerset, New Jersey. This lease commenced on August 1, 2010 and continues through July 31, 2017. Under terms of the new lease, base rent was initially set at $38,801 per month, subject to periodic cost of living adjustments. In addition to base rent, the Company is obligated to pay its proportionate share of estimated property taxes, assessments and maintenance costs. The lease agreement contains a renewal provision allowing the Company the option to renew for up to four additional five-year periods upon providing written notice of its intention to renew at least six months prior to termination of the original lease or any renewal period.
	On March 3, 2010, the Company entered into an eight-year sub-lease agreement with a related party, EJ Financial, for their sub-lease of a portion of the Company’s corporate offices in Lake Forest, Illinois.  John N. Kapoor, Ph.D., Chairman of the Company’s Board of Directors, is the President of EJ Financial.  This sub-lease commenced on April 1, 2010.  Per the terms of the sub-lease agreement, EJ Financial will pay monthly base rent plus a proportionate share of common area maintenance costs.   The Company and EJ Financial agreed to early terminate this agreement, and the sub-lease was terminated in July 2012 at which time the space was retrofitted for corporate purposes.  EJ Financial paid the Company approximately $240,000 in rent and common area maintenance fees during the shortened term of this sub-lease.

Stock_Options_Employee_Stock_P

Stock Options, Employee Stock Purchase Plan and Restricted Stock	12 Months Ended
	Dec. 31, 2013
Stock Options, Employee Stock Purchase Plan and Restricted Stock [Abstract]	'
Stock Options, Employee Stock Purchase Plan and Restricted Stock	'
	Note 9 — Stock Options, Employee Stock Purchase Plan and Restricted Stock
	Stock Option Plan
	The Company maintains stock options plans that allow the Company’s Board of Directors to grant stock options to eligible employees, officers and directors.  The Akorn, Inc. 2003 Stock Option Plan (“2003 Stock Option Plan”) was approved by the Company’s Board of Directors on November 6, 2003 and approved by its stockholders on July 8, 2004. Under the 2003 Stock Option Plan, 2,519,000 options were granted, none of which remained outstanding as of December 31, 2011.  On March 29, 2005, the Company’s Board of Directors approved the Amended and Restated Akorn, Inc. 2003 Stock Option Plan (the “Amended 2003 Plan”), effective as of April 1, 2005, and this was subsequently approved by its stockholders on May 27, 2005. The Amended 2003 Plan is an amendment and restatement of the 2003 Stock Option Plan and provides the Company with the ability to grant other types of equity awards to eligible participants besides stock options. Starting on May 27, 2005, all new awards have been granted under the Amended 2003 Plan.  The aggregate number of shares of the Company’s common stock initially approved for issuance pursuant to awards granted under the Amended 2003 Plan was 5,000,000.  On August 7, 2009, the Company’s stockholders voted to increase this figure to 11,000,000 at the recommendation of the Company’s Board of Directors, and on December 31, 2011 voted to increase the available shares by another 8,000,000, to a final total of 19,000,000 shares. Under the Amended 2003 Plan, 15,828,000 options have been granted to employees and directors, 2,304,000 options have been exercised, 4,296,000 options have been canceled, and 9,228,000 remain outstanding as of December 31, 2013.  Options granted under the 2003 Stock Option Plan and the Amended 2003 Plan have exercise prices equivalent to the market value of the Company’s common stock on the date of grant and expire five years from date of issuance.  All options granted during 2013 vest one quarter per year on each of the first four anniversaries of their grant dates.  Options granted in earlier years generally had a three-year vesting schedule.
	The Amended 2003 Plan reached its scheduled expiration date on November 6, 2013.  Accordingly, no additional awards may be issued under the Amended 2003 Plan beyond that date.  However, any awards outstanding as of November 6, 2013 issued under the Amended 2003 Plan will remain outstanding in accordance with their terms.  During the first quarter of 2014, the Company’s Board of Directors approved the new Akorn, Inc. 2014 Stock Option Plan.  Adoption of this plan is contingent on receipt of shareholder approval at the Company’s 2014 Annual Meeting on May 2, 2014.
	The Company accounts for stock-based compensation in accordance with ASC Topic 718, Compensation – Stock Compensation (formerly SFAS No. 123 (revised 2004), Share Based Payment (SFAS 123(R))).  Accordingly, stock-based compensation cost is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period. The Company uses the Black-Scholes model for estimating the grant date fair value of stock options. Determining the assumptions that enter into the model is highly subjective and requires judgment. The Company uses an expected volatility that is based on the historical volatility of its stock. The expected life assumption is based on historical employee exercise patterns and employee post-vesting termination behavior. The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. treasury securities in effect during the quarter in which the options were granted. The dividend yield reflects historical experience as well as future expectations over the expected term of the option. The Company estimates forfeitures at the time of grant and revises in subsequent periods, if necessary, if actual forfeitures differ from those estimates.
	The Company recorded stock option compensation expense of approximately $6.2 million, $6.4 million and $4.9 million during the years ended December 31, 2013, 2012 and 2011, respectively.  The Company uses the single-award method for allocating the compensation cost to each period.
	The Company uses the Black-Scholes model to determine the grant-date value of stock options. Expected volatility is based on the historical volatility of the Company’s common stock. The expected life assumption is based on historical employee exercise patterns and employee post-vesting termination behavior. The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. treasury securities in effect during the quarter in which the options were granted. The dividend yield reflects historical experience as well as future expectations over the expected term of the option. The Company estimates forfeitures at the time of grant and revises those estimates subsequently based on actual forfeitures.
	The assumptions used in estimating the fair value of the stock options granted during the period, along with the weighted-average grant date fair values, were as follows:
		2013			2012			2011
	Expected Volatility		49%-68	%		77% -85	%		75% - 76	%
	Expected Life (in years)		4			4			3.8
	Risk-free interest rate		0.7% - 1.4	%		0.7% - 0.8	%		1.3% - 2.0	%
	Dividend yield		-			-			-
	Fair value per stock option	$	6.95		$	7.76		$	3.71
	A summary of stock option activity within the Company’s stock-based compensation plans for the years ended December 31, 2013, 2012 and 2011 is as follows:
		Number of						Weighted Average			Aggregate
		Shares			Weighted			Remaining			Intrinsic Value
		(in thousands)			Average			Contractual Term
					Exercise Price			(Years)
	Outstanding at December 31, 2010		7,960		$	1.87
	Granted		2,030			6.63
	Exercised		(454	)		1.93
	Forfeited		(137	)		2.3
	Outstanding at December 31, 2011		9,399			2.89
	Granted		1,221			12.96
	Exercised		(806	)		1.87
	Forfeited		(87	)		4.42
	Outstanding at December 31, 2012		9,727			4.22
	Granted		321			15.76
	Exercised		(630	)		4.18
	Forfeited		(190	)		13.1
	Outstanding at December 31, 2013		9,228		$	4.45			1.61			186,169,000
	Exercisable at December 31, 2013		7,594		$	3.02			1.27			164,018,000
	The aggregate intrinsic value for stock options outstanding and exercisable is defined as the difference between the market value of the Company’s common stock at the end of the period and the exercise price of the in-the-money stock options. The total intrinsic value of stock options exercised during the years ended December 31, 2013, 2012 and 2011 was approximately $8.9 million, $9.1 million and $3.1 million, respectively. As a result of the stock options exercised, the Company received cash and recorded additional paid-in-capital of approximately $2.6 million, $1.5 million and $0.9 million during the years ended December 31, 2013, 2012 and 2011, respectively.
	As of December 31, 2013, the total amount of unrecognized compensation cost related to non-vested stock options was $8,251,000 which is expected to be recognized as expense over a weighted-average period of 2.4 years.
	Under the Amended 2003 Plan, the Company may grant restricted stock awards to certain employees and members of its Board of Directors. Restricted stock awards are valued at the closing market value of the Company’s common stock on the day of grant and the total value of the award is recognized as expense ratably over the vesting period of the grants. On May 3, 2013, the Company granted a total of 32,000 shares of restricted stock valued at approximately $0.5 million to members of its Board of Directors, of which half vested immediately and half will vest on the one year anniversary of grant.  During 2012, the Company granted 35,000 shares of restricted stock valued at approximately $0.5 million to members of its Board of Directors, of which half vested immediately and half vested on the one year anniversary of grant.  No restricted stock awards were granted in 2011.  The Company recognized compensation expense of approximately $0.6 million, $0.4 million and less than $0.1 million during the years ended December 31, 2013, 2012 and 2011, respectively, related to restricted stock awards.
	The following is a summary of non-vested restricted stock activity:
		Number of Shares			Weighted Average
		(in thousands)			Grant Date Fair Value
	Nonvested at December 31, 2010		28		$	1.89
	Granted		-			-
	Vested		(15	)		2.34
	Canceled		-			-
	Nonvested at December 31, 2011		13		$	1.34
	Granted		35			14.63
	Vested		(30	)		9.09
	Canceled		-			-
	Nonvested at December 31, 2012		18		$	14.63
	Granted		32			15.36
	Vested		(34	)		14.98
	Canceled		-			-
	Nonvested at December 31, 2013		16		$	15.36
	Employee Stock Purchase Plan
	The Akorn, Inc. Employee Stock Purchase Plan (the “ESPP”) permits eligible employees to acquire shares of the Company’s common stock through payroll deductions.  The ESPP has been structured to qualify under Section 423 of the Internal Revenue Code (“IRC”).  Employees who elect to participate in the ESPP may withhold from 1% to 15% of base wages toward the purchase of stock.  Shares are purchased at a 15% discount off the lesser of the market price at the beginning or the ending of the applicable offering period.  The ESPP has two offering periods each year, one running from January 1st to December 31st and the other running from July 1st to December 31st.  In a given year, employees may enroll in either plan, but not both.  Per IRC rules, annual purchases per employee are limited to $25,000 worth of stock, valued as of the beginning of the offering period.  Accordingly, with the 15% discount, employees may withhold no more than $21,250 per year toward the purchase of stock under the ESPP.
	A maximum of 2,000,000 shares of the Company’s common stock may be issued under the ESPP.  Including shares issues in early 2014 related to employee participation in the ESPP during 2013, a total of 1,353,407 shares have been issued thus far under the ESPP, leaving 646,593 shares available for future issuance.  The Company issued approximately 73,000, 61,000 and 71,000 shares of its common stock related to employee participation in the ESPP during 2013, 2012 and 2011, respectively.  For the years ended December 31, 2013, 2012 and 2011, the Company recorded compensation expense of approximately $0.2 million in each period related to the ESPP.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Taxes [Abstract]	'
Income Taxes	'
	Note 10 — Income Taxes
	The income tax provision (benefit) consisted of the following (in thousands):
		Current			Deferred			Total
	Year ended December 31, 2013
	Federal	$	27,985		$	(3,050	)	$	24,935
	State		4,145			2,051			6,196
	Foreign		-			(598	)		(598	)
		$	32,130		$	(1,597	)	$	30,533
	Year ended December 31, 2012
	Federal	$	20,843		$	(504	)	$	20,339
	State		4,232			(911	)		3,321
	Foreign		-			(1,538	)		(1,538	)
		$	25,075		$	(2,953	)	$	22,122
	Year ended December 31, 2011
	Federal	$	-		$	(460	)	$	(460	)
	State		2,704			(3,951	)		(1,247	)
		$	2,704		$	(4,411	)	$	(1,707	)
	Income tax expense differs from the “expected” tax expense (benefit) computed by applying the U.S. Federal corporate income tax rates of 35% to income before income taxes, as follows (in thousands):
		Years Ended December 31,
		2013			2012			2011
	Computed “expected” tax expense	$	29,013		$	20,125		$	14,457
	Change in income taxes resulting from:
	State income taxes, net of federal income tax		4,027			2,159			2,217
	Foreign income tax expense (benefit)		622			1,468			-
	Deduction for domestic production activities		(1,361	)		(1,277	)		-
	R&D tax credits		(1,652	)		(508	)
	Other, net		(116	)		155			(876	)
	Valuation allowance change		-			-			(17,505	)
	Income tax expense (benefit)	$	30,533		$	22,122		$	(1,707	)
	The geographical allocation of the Company’s income before income taxes between U.S. and foreign operations was as follows (in thousands):
		2013			2012			2011
	Pre-tax income from U.S. operations	$	86,382		$	66,087		$	41,306
	Pre-tax loss from foreign operations		(3,487	)		(8,587	)		—
	Total pre-tax income	$	82,895		$	57,500		$	41,306
	Net deferred income taxes at December 31, 2013 and 2012 include (in thousands):
		31-Dec-13						31-Dec-12
		Current			Noncurrent			Current			Noncurrent
	Deferred tax assets:
	Net operating loss carry-forward	$	439		$	14,061		$	-		$	4,328
	Stock-based compensation		-			6,630			-			4,912
	Reserve for product returns		3,189			-			2,787			-
	Inventory valuation reserve		2,193			-			3,980			-
	Other		3,325			1,751			2,974			1,349
	Total deferred tax assets		9,146			22,442			9,741			10,589
	Deferred tax liabilities:
	Prepaid expenses		(1,120	)		-			(551	)		-
	Unamortized discount – convertible notes		-			(4,223	)		-			(5,815	)
	Depreciation & amortization – tax over book		-			(16,576	)		-			(5,835	)
	Other		(81	)		-			-			-
	Total deferred tax liabilities		(1,201	)		(20,799	)		(551	)		(11,650	)
	Net deferred income tax asset (liability)	$	7,945		$	1,643		$	9,190		$	(1,061	)
	The Company records a valuation allowance to reduce net deferred income tax assets to the amount that is more likely than not to be realized. In performing its analysis of whether a valuation allowance to reduce the deferred income tax asset was necessary, the Company evaluated the data and determined that as of December 31, 2013 and 2012 its deferred income tax assets were more likely than not to be realized. Accordingly, no valuation allowance was in place as of either December 31, 2013 or December 31, 2012.  The deferred tax balances have been reflected gross on the balance sheet, and are permitted to be netted only if within the same jurisdiction.
	As a result of operating losses in past years, the Company was carrying a 100% valuation allowance against its deferred tax assets until the quarter ended September 30, 2011.  At that time, the Company determined that based on earnings in recent periods, and expectations for future taxable income, it would be expected to realize the full net value of its deferred tax assets.  Accordingly, the Company reversed its valuation allowances in that quarter.  This reversal accounts for the Company’s net income tax benefit recorded for the year 2011.
	The Company’s net operating loss (“NOL”) carry-forwards as of December 31, 2013 consist of three component pieces: (i) U.S. Federal NOL carry-forwards valued at $7.9 million, (ii) Illinois NOL carry-forwards valued at $2.2 million, and (iii) foreign (Indian) NOLs of $4.4 million.  The U.S. Federal NOL carry-forwards belong to Inspire Pharmaceuticals, Inc. and were obtained through the Merck Acquisition completed in the fourth quarter of 2013.  The Illinois NOL carry-forwards relate to the Company’s tax losses in the decade of the 2000s and have not yet been fully utilized due to the State of Illinois’s suspension of the use of NOLs for the years 2011, 2012 and 2013.  These NOLs would be due to expire from 2021 to 2025, and are expected to be utilized well before their expiration dates.  The foreign NOL carry-forwards relate to operating losses by the Company’s subsidiary in India, which was acquired in 2012.  The foreign NOLs can be carried forward indefinitely, and the Company has concluded that they are more likely than not to be utilized and therefore has not established a valuation allowance against them.  The Company previously had valued NOL carry-forwards in the State of New Jersey.  However, due to a change in the tax law, the Company determined that these NOLs could no longer be utilized and wrote them off during 2013.
	In 2013, the Company amended its Federal income tax returns to claim research and experimentation tax credits for the years 2003 through 2010 that were not originally claimed due to operating losses incurred in those years.  The net benefit of these claims totaled $0.8 million, and was recorded as a reduction to income tax expense for the year ended December 31, 2013.
	On January 2, 2013 President Obama signed the American Taxpayer Relief Act of 2012.  The Act included an extension of the research and experimentation tax credit for periods ending in 2012 and 2013.  Since this extension was not signed into law until 2013, the Company did not include the benefit of R&D tax credits for the tax year 2012 into its effective rate for 2012.  The benefit of 2012 R&D tax credit, which totaled approximately $0.6 million, was reflected in the Company’s tax provision in 2013.
	The Company’s U.S. Federal income tax returns filed for years 2010 through 2012 are open for examination by the Internal Revenue Service.  The majority of the Company’s state and local income tax returns filed for years 2010 through 2012 remain open for examination as well.  In the quarter ended December 31, 2013, the Company received notice from the Illinois Department of Revenue that its Illinois income tax returns for the years ended December 31, 2010 and 2011 would be examined.  No other examinations of the Company’s income tax returns have been initiated.
	In accordance with ASC 740-10-25, Income Taxes – Recognition, the Company performs reviews of its tax positions to determine whether it is “more likely than not” that its tax positions will be sustained upon examination, and if any tax positions are deemed to fall short of that standard, the Company reserves based on the financial exposure and the likelihood of its tax positions not being sustained.  Based on its reviews as of and for the years ended December 31, 2012 and December 31, 2013, the Company determined that it would not recognize tax benefits as follows (in thousands):
	Balance at December 31, 2011	$	-
	Additions relating to current year		1,265
	Additions relating to prior years		220
	Balance at December 31, 2012	$	1,485
	Additions relating to current year		589
Terminations of exposures relating to prior years		(1,229	)
Balance at December 31, 2013	$	845
If recognized, the entire $0.8 million of the above positions will impact the Company’s effective rate.  Due to the uncertainty of both timing and resolution of potential income tax examinations, the Company is unable to determine whether any amounts included in the December 31, 2013 balance of unrecognized tax benefits represent tax positions that could significantly change during the next twelve months.  The Company accounts for interest and penalties as income tax expense.  There were no uncertain tax positions prior to 2012.

Retirement_Plan

Retirement Plan	12 Months Ended
	Dec. 31, 2013
Retirement Plan [Abstract]	'
Retirement Plan	'
	Note 11 — Retirement Plan
	All Akorn employees are eligible to participate in the Company’s 401(k) Plan. During the years ended December 31, 2013, 2012 and 2011, plan-related expense totaled approximately $0.8 million, $0.8 million and $0.5 million, respectively. The Company provides a matching contribution based on a percentage of the amount contributed by each employee, which is funded on a current basis.  The Company suspended its match on 401(k) contributions during 2009 and did not match 401(k) contributions through March 31, 2010.  Effective April 1, 2010, the Company reinstituted a matching contribution at a rate of 25% of the first 6% contributed by employees.  On January 1, 2011, the Company increased its matching contribution to 50% of the first 6% contributed, and has maintained this match rate through December 31, 2013.  Company matching contributions vest 50% after two years of credited service and 100% after three years of credited service.

Segment_Information

Segment Information	12 Months Ended
	Dec. 31, 2013
Segment Information [Abstract]	'
Segment Information	'
	Note 12 — Segment Information
	The Company reports its results of operations for the three-year period ended December 31, 2013 in three segments:
		-	Ophthalmic
		-	Hospital Drugs & Injectables
		-	Contract Services
	The ophthalmic segment manufactures, markets and distributes diagnostic and therapeutic pharmaceuticals. The hospital drugs & injectables segment manufactures, markets and distributes drugs and injectable pharmaceuticals, primarily in niche markets, as well as certain vaccines.  The majority of the drug products included in this segment are injectables, though also included are a number of drugs administered to patients by other methods.  The contract services segment manufactures products for third party pharmaceutical and biotechnology customers based on their specifications.
	The Company’s reportable segments are based upon internal financial reports that aggregate certain operating information. The Company’s chief operating decision maker, as defined in ASC Topic 280, Segment Reporting, is its chief executive officer, or CEO. The Company’s CEO oversees operational assessments and resource allocations based upon the results of the Company’s reportable segments, all of which have available discrete financial information.
	Selected financial information by segment is presented below (in thousands):
			Years ended December 31,
			2013		2012		2011
	REVENUES
	Hospital drugs & injectables		$	179,625	$	129,723	$	55,077
	Ophthalmic			114,515		103,765		68,591
	Contract services			23,571		22,670		13,252
	Total revenues		$	317,711	$	256,158	$	136,920
	GROSS PROFIT
	Hospital drugs & injectables		$	104,473	$	83,413	$	30,057
	Ophthalmic			63,481		58,785		43,054
	Contract services			3,950		6,494		6,578
	Total gross profit		$	171,904	$	148,692	$	79,689
	The Company manages its business segments to the gross profit level and manages its operating and other costs on a company-wide basis. Inter-segment activity at the gross profit level is minimal. The Company does not have discrete assets by segment, as certain manufacturing and warehouse facilities support more than one segment, and therefore does not report assets by segment.
	During 2013, 2012 and 2011, approximately $27.3 million, $29.4 million and $5.3 million of the Company’s net revenue, respectively, was from customers located in foreign countries.  Sales generated by Akorn India Private Limited (“AIPL”), the Company’s wholly owned subsidiary in India, accounted for $15.8 million and $16.7 million of the foreign sales amounts for 2013 and 2012, respectively.  In these years, AIPL sold product exclusively to contract customers in India and to export customers in unregulated world markets, outside the United States.
	The ophthalmic segment carries goodwill from the Company’s acquisition of Advanced Vision Research, Inc. in May 2011, and the contract services segment carries goodwill related to the Company’s acquisition of selected assets of Kilitch Drugs (India) Limited in February 2012.  The carrying amounts of goodwill by segment were as follows (in thousands):
			December 31,
	Goodwill:		2013		2012
	Ophthalmic segment		$	11,863	$	11,863
	Contract services segment			17,968		20,296
	Total		$	29,831	$	32,159
	The decline in contract segment goodwill from December 31, 2012 to December 31, 2013 was due to changes in the foreign currency exchange rate between Indian rupees and U.S. dollars.  The Company performed impairment tests of its goodwill during the fourth quarter of 2013 and identified no impairment.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies [Abstract]	'
Commitments and Contingencies	'
	Note 13 — Commitments and Contingencies
	On December 22, 2011, the Company acquired the rights to three NDA products from H. Lundbeck A/S ("Lundbeck").  The Company paid $45.0 million in initial consideration at closing and has a commitment to pay additional consideration of $15.0 million to Lundbeck on December 22, 2014, the third anniversary of the acquisition date.  Both the initial $45.0 million paid at closing and the additional $15.0 million are subject to claw-back provisions if sales of the three underlying products fail to achieve certain minimum amounts specified in the Lundbeck Agreement.  The discounted value of the additional consideration has been recorded by the Company as a current liability on its December 31, 2013 balance sheet.  The liability was discounted at 9.0%, the Company’s approximate cost of long-term capital, to an initial value of $11.6 million.  The accrual of non-cash interest expense during 2013 increased the carrying amount of this current liability to $14.7 million as of December 31, 2013.
	As part of the Lundbeck Agreement, the Company assumed Lundbeck’s obligations under a supply agreement with the third party manufacturer of two of the three products acquired.  The supply agreement committed the Company to purchase $13.3 million of product in total over the years 2012 through 2015.  The Company determined that its committed purchase quantities exceeded the amount that it anticipated being able to sell.  Accordingly, as part of the initial accounting for the Lundbeck Agreement, the Company recorded a long-term liability of $2.5 million, which equaled the estimated present value of the unfavorable contract terms.  A portion of this liability was amortized during 2012 and 2013.  In the fourth quarter of 2013, the Company determined that no future liability existed related to excess inventory purchase commitments, and accordingly, the Company wrote off the remaining liability balance of $1.3 million.
	Also included within the Lundbeck Agreement is a commitment to pay royalties to Lundbeck based on the Company’s sales of a generic form of one of the acquired products.  This commitment is more fully described in Note 16 – Business Combinations and Other Strategic Investments.  The dollar amount of this commitment is not estimable since it is subject to future sales volumes, prices and margins for the applicable product.
	The Company has entered into strategic business agreements for the development and marketing of finished dosage form pharmaceutical products with various pharmaceutical development companies.
	Each strategic business agreement includes a future payment schedule for contingent milestone payments and in certain strategic business agreements, minimum royalty payments.  The Company will be responsible for contingent milestone payments and minimum royalty payments to these strategic business partners based upon the occurrence of future events.  Each strategic business agreement defines the triggering event of its future payment schedule, such as meeting product development progress timelines, successful product testing and validation, successful clinical studies, various FDA and other regulatory approvals and other factors as negotiated in each agreement.  None of the contingent milestone payments or minimum royalty payments is individually material to the Company.  These costs, when realized, will be reported as part of research and development expense or as a component of cost of sales in the Company’s Consolidated Statement of Income.
	The table below summarizes contingent potential milestone payments due to strategic partners in the years 2014 and beyond, assuming all such contingencies occur (in thousands):
	Year ending	Milestone
	December 31,	Payments
	2014	$	4,524
	2015		598
	2016		200
	Total	$	5,322
	On October 17, 2012, the Company entered into an exclusive distribution agreement with MBL for the Company’s marketing of MBL-manufactured tetanus-diphtheria vaccine (“Td vaccine”) over an initial contract term of two years.  The exclusive distribution agreement commits the Company to acquire $9.2 million in Td vaccine during calendar year 2014.  The agreement contains a provision for automatic annual renewals if neither party delivers notice of non-renewal at least six months prior to the end of the initial two-year term or any subsequent annual term.
	The Company had an outstanding product warranty reserve which related to a ten year expiration guarantee on DTPA sold to HHS in 2006. The Company was performing yearly stability studies for this product and, if the annual stability did not support the ten-year product life, it would replace the product at no charge. The Company’s supplier, Hameln Pharmaceuticals, was to share one-half of this cost if the product did not meet the stability requirement.
	During the quarter ended June 30, 2013, Hameln and the Company terminated and settled their contractual relationship related to the Company’s marketing of DTPA products supplied by Hameln.  As part of the settlement arrangement, the Company was released from its remaining product warranty obligations.  Accordingly, during the quarter ended June 30, 2013, the Company reversed its $1.3 million product warranty reserve and recognized a corresponding reduction to cost of sales.
	The Company is a party in legal proceedings and potential claims arising in the ordinary course of its business. The amount, if any, of ultimate liability with respect to such matters cannot be determined. Despite the inherent uncertainties of litigation, management of the Company believes that the ultimate disposition of such proceedings and exposures will not have a material adverse impact on the financial condition, results of operations, or cash flows of the Company.

Supplemental_Cash_Flow_Informa

Supplemental Cash Flow Information	12 Months Ended
	Dec. 31, 2013
Supplemental Cash Flow Information [ Abstract]	'
Supplemental Cash Flow Information	'
	Note 14 — Supplemental Cash Flow Information (in thousands)
		Year ended December 31,
		2013		2012		2011
	Leasehold improvements funded by lessor	$	-	$	-	$	22
	Interest and taxes paid:
	Interest paid		4,320		4,200		2,125
	Income taxes paid		27,450		21,455		2,778

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	12 Months Ended
	Dec. 31, 2013
Recent Accounting Pronouncements [Abstract]	'
Recent Accounting Pronouncements	'
	Note 15 — Recent Accounting Pronouncements
	In July 2012, the FASB issued ASU No. 2012-02, Intangibles – Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment. The amendments in this update aim to simplify the impairment test for indefinite-lived intangible assets by permitting an entity the option to first assess qualitative factors to determine whether it is more likely than not (defined as having a likelihood of more than 50 percent) that an indefinite-lived intangible asset is impaired as a basis for determining whether the quantitative impairment test included in Accounting Standards Codification Subtopic 350-30, Intangibles – Goodwill and Other – General Intangibles Other than Goodwill must be performed. The amendment is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. Adoption of this amendment did not, and is not expected to, have a material effect on the Company’s financial position or operating results.
	On February 5, 2013, the FASB issued ASU No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income.  This amendment requires an entity to present either parenthetically on the face of the financial statements or in the notes significant amounts reclassified from each component of accumulated other comprehensive income and the line item(s) affected by the reclassification.  An entity would not need to show the income statement line item affected for certain components that are not required to be reclassified in their entirety to net income, such as amounts amortized into net periodic pension cost.   For public companies, this amendment became effective for annual periods beginning after December 15, 2012, and for interim periods within those annual periods.  Adoption of ASU No. 2013-02 did not impact the Company’s financial position or results of operations, and did not have a significant effect on the Company’s financial reporting.
	In July 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists.  ASU 2013-11 was issued to eliminate the diversity in practice in presentation of unrecognized tax benefits, and amends Accounting Standards Codification (“ASC”) 740, “Income Taxes,” to provide clarification of the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. According to the new guidance, unrecognized tax benefits will be netted against all available same-jurisdiction loss or other tax carryforward that would be utilized, rather than only being netted against carryforwards that are created by the unrecognized tax benefits. The revised guidance is effective for interim and annual periods beginning after December 15, 2013, with early adoption permitted.  The Company does not expect the adoption of this guidance to have a material impact on its financial statements.

Business_Combinations_and_Othe

Business Combinations and Other Strategic Investments	12 Months Ended
	Dec. 31, 2013
Business Combinations and Other Strategic Investments [Abstract]	'
Business Combinations and Other Strategic Investments	'
	Note 16 – Business Combinations and Other Strategic Investments
	Hi-Tech Pharmacal Co., Inc.
	On August 26, 2013, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) to acquire Hi-Tech Pharmacal Co., Inc., a Delaware corporation (“Hi-Tech”) for a total purchase price of approximately $640 million, calculated before considering the Hi-Tech cash the Company will assume through the acquisition, which will net against the total purchase price.  As agreed to by the parties and subsequently approved by the shareholders of Hi-Tech, the Company will pay $43.50 per share for the outstanding common stock of Hi-Tech.  The Merger Agreement will involve the merger of Hi-Tech with and into Akorn Enterprises, Inc., a wholly-owned subsidiary of the Company (the “Purchaser”), with Hi-Tech continuing as the surviving entity.  The acquisition is expected to close early in the second quarter of 2014, following the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “ HSR Act ”).
	Hi-Tech is a specialty pharmaceutical company developing, manufacturing and marketing generic and branded prescription and over-the-counter (OTC) products.  Hi-Tech specializes in difficult to manufacture liquid and semi-solid dosage forms and produces and markets a range of oral solutions and suspensions, as well as topical ointments and creams, nasal sprays, otics, sterile ophthalmics and sterile ointment and gels products.  Hi-Tech’s Health Care Products division is a leading developer and marketer of OTC products.  Hi-Tech's ECR Pharmaceuticals subsidiary markets branded prescription products.
	The Hi-Tech acquisition is expected to complement and expand the Company’s product portfolio by diversifying its offering to its retail customers beyond ophthalmics to other niche dosage forms such as oral liquids, topical creams and ointments, nasal sprays and otics.  The acquisition is also expected to enhance the Company’s new product pipeline.  Further, the acquisition of Hi-Tech will add branded OTC products in the categories of cough & cold, nasals, and topicals to the Company’s existing TheraTears® brand of eye care products, and will provide additional domestic manufacturing capacity for the Company.
	The Merger Agreement provides for the terms and conditions of the Merger.  Subject to the terms and conditions of the Merger Agreement, upon completion of the Merger, each share of Hi-Tech’s common stock (the “Hi-Tech Stock ”), par value $0.01 (each a “ Hi-Tech Share ”), issued and outstanding immediately prior to such time, other than treasury shares of Hi-Tech and shares of Common Stock owned by Hi-Tech, Akorn, Purchaser or any other wholly-owned subsidiary of Akorn or Hi-Tech (each of which will be cancelled), and other than shares of Hi-Tech Stock as to which dissenters’ rights have been properly exercised, will be cancelled and converted into the right to receive $43.50 in cash (the “Merger Consideration”), without interest, less any applicable withholding taxes, upon surrender of the outstanding Hi-Tech Shares.
	In addition, Hi-Tech is required to take all actions necessary to cause each outstanding option, restricted stock grant, restricted stock subject to vesting or similar rights to purchase or acquire Shares (“Stock Rights”), whether or not vested, to be canceled in exchange for the right to receive a cash payment equal to the Merger Consideration, less the applicable exercise price of such Stock Right and any applicable withholding taxes, if any.
	Pursuant to the Merger Agreement, the parties have made certain customary representations, warranties and covenants to each other, including using reasonable best efforts to take, or cause to be taken, all actions and do all things necessary, proper or advisable to consummate and make effective the Merger and the other transactions contemplated thereby, including the satisfaction of each of the parties’ respective closing conditions set forth in the Merger Agreement.  Hi-Tech has also agreed to various covenants, including, among other things and subject to certain exceptions, (i) to conduct its business in the ordinary course of business consistent with past practices during the period between the execution of the Merger Agreement and the effective date of the Merger and not to engage in certain transactions during such period, and (ii) not to solicit competing acquisition proposals or, subject to certain exceptions, enter into discussions concerning, or provide confidential information in connection with, any alternative acquisition proposal.
	The completion of the Merger is subject to certain conditions, including, among others, (i) the expiration or termination of the applicable waiting periods under the HSR Act, as amended, (ii) subject to certain materiality exceptions, the accuracy of the representations and warranties made by Hi-Tech, the Company and Purchaser, respectively, (iii) compliance in all material respects by Hi-Tech, the Company and Purchaser with their respective obligations under the Merger Agreement, (iv) the absence of any change or effect that, individually or in the aggregate, has had a Material Adverse Effect or Purchaser Material Adverse Effect (as such terms are defined in the Merger Agreement) and (v) the absence of any order, injunction or decree or any statute, rule or regulation that prohibits or makes illegal the consummation of the Merger.
	The Merger Agreement contains termination rights for Hi-Tech, Purchaser and the Company.  The Merger Agreement provides that the Company will be required to pay Hi-Tech a termination fee of approximately $41.6 million if, on or prior to April 26, 2014, (i) the Merger Agreement is terminated by Hi-Tech as a result of a Financing Failure (as defined in the Merger Agreement) or (ii) the Merger Agreement is terminated as a result of a failure to obtain regulatory approval or clearance with respect to the HSR Act or other applicable antitrust laws.  In certain circumstances, Akorn has the right to extend the date on which the Merger Agreement automatically terminates to May 26, 2014.  In the event that Akorn exercises such right and the Merger Agreement is terminated after April 26, 2014 for either of the reasons set forth in the first sentence of this paragraph, Akorn will be required to pay Hi-Tech a termination fee of approximately $48.0 million.
	The Merger Agreement also provides that Hi-Tech would be required to pay Akorn a termination fee of approximately $20.8 million under certain circumstances, including if (i) Hi-Tech terminated the Merger Agreement due to the receipt of an unsolicited superior proposal or Akorn or Purchaser terminates the Merger Agreement due to a Change of Recommendation (as defined in the Merger Agreement); provided however, if Akorn or Purchaser terminates the Merger Agreement, or Hi-Tech stockholders fail to approve the Merger, as a result of a Change of Recommendation related to an Intervening Event (as defined in the Merger Agreement), Hi-Tech will be required to pay a termination fee of $32.0 million, or (ii) (a) the Merger Agreement is terminated because Hi-Tech’s stockholders fail to approve the Merger or because of certain Company breaches of the Merger Agreement, (b) a third party publicly discloses or makes known to the Board of Directors a bona fide alternative acquisition proposal prior to such termination and (c) Hi-Tech enters into or consummates an alternative acquisition agreement within 12 months of the termination of the Merger Agreement.
	The Company expects to fund the Hi-Tech acquisition through a $600.0 million term loan and the cash reserves on the balance sheet of Hi-Tech.  The Company obtained a loan commitment from JP Morgan Chase Bank, N.A. (“JP Morgan”) for a $600 million term loan to finance the acquisition (the “JPM Term Loan”). As negotiated, the JPM Term Loan will mature in seven (7) years and accrue interest at a variable margin over either prime or LIBOR.  Full or partial prepayments of principal will be allowed.  JP Morgan completed syndication of the loan in the quarter ended December 31, 2013.  The Company expect that the JPM Term Loan agreement will be signed after the Company receives FTC clearance for the Hi-Tech Acquisition and once a closing date has been agreed upon by the parties. The loan itself will take place upon closing the Hi-Tech Acquisition. (For further details regarding JP Morgan’s commitments to us regarding the JPM Term Loan and JPM Revolver, please refer to Exhibit 4 to the Company’s Schedule 13D filed with the SEC on September 5, 2013.)
	During 2013, the Company capitalized $3.4 million in deferred financing fees related to the JPM Term Loan.  These deferred financing fees, which will be amortized straight-line over the term of the JPM Term Loan, principally consist of fees charged by JPM and initial charges from Moody’s and Standard & Poor’s for establishing the Company’s credit ratings, as required by JPM in order to obtain the term loan.  In addition, the Company recorded $1.6 million of acquisition-related expenses relation to the Hi-Tech acquisition, principally consisting of various legal fees.
	Merck Products Acquisition – AzaSite, Cosopt and Cosopt PF
	On November 15, 2013, the Company acquired from Merck the U.S. rights to three branded ophthalmic products for $52.8 million in cash (the “Merck Acquisition”).  The acquired assets met the definition of a business, and accordingly, have been accounted for as a business combination in accordance with ASC 805 – Business Combinations.  Through the Merck Acquisition, the Company purchased Inspire Pharmaceuticals, Inc., a wholly-owned subsidiary of Merck.  This legal entity owns the U.S. rights to AzaSite, a prescription eye drop used to treat bacterial conjunctivitis.  The U.S. rights to the other two products involved in the acquisition, Cosopt and Cosopt PF (preservative free), were purchased directly from Merck.  The Cosopt products are prescription sterile eye drop solutions used to lower the pressure in the eye in people with open-angle glaucoma or ocular hypertension.  The acquisition of these products expands the Company’s ophthalmic product portfolio to include branded, prescription eye drops, and is complementary to the Company’s existing portfolio of products.  The Company believes that this acquisition leverages its existing sales force and ophthalmic and optometric physician relationships.
	The following table sets forth the consideration paid for the Merck Acquisition and the fair values of the assets acquired and the liabilities assumed (in thousands):
	Product rights:
	AzaSite	$	13,800
	Cosopt		21,600
	Cosopt PF		20,300
	Product rights total	$	55,700
	Prepaid expenses		48
	Deferred tax assets, net		759
	Total fair value of acquired assets	$	56,507
	Consideration paid	$	52,800
	Gain from bargain purchase	$	3,707
	Through its acquisition of Inspire Pharmaceuticals, Inc. the Company assumed that entity’s net operating loss carry-forwards (“NOLs”) and unamortized start-up costs.  The deferred tax assets, net listed above represents the difference between the acquired deferred tax assets, the NOLs and unamortized start-up costs, and the acquired deferred tax liabilities, which represent the book versus tax basis differences in the product rights.  The bargain purchase amount was largely derived from the difference between the fair value and the economic value, as calculated through discounted cash flow analysis, of the deferred tax assets, net.  In particular, due to the long-term nature of the NOLs acquired, the book value of the resulting deferred tax asset significantly exceeded its discounted cash flow value.
	The Company anticipates amortizing the acquired products on a straight-line basis from the Merck Acquisition date through December 31, 2019.  The Merck Acquisition agreement specified the tax values assigned to each product.  The tax value of AzaSite product rights will not be amortizable for tax purposes, as these rights were obtained through the stock acquisition of Inspire Pharmaceuticals, Inc.  That Company anticipates that the assigned tax values of Cosopt and Cosopt PF will be amortizable for tax purposes over a 15-year period.
	During the period from November 15, 2013 through December 31, 2013, the Company recorded revenue of $1.6 million and pre-tax income of $1.4 million related to sales of the products acquired through the Merck Acquisition.  The Company has not provided pro forma revenue and earnings of the Company as if the Merck Acquisition was completed as of January 1, 2012 or 2013 because to do so would be impracticable.  The products acquired from Merck were not managed as a discrete business by Merck.  Accordingly, determining the pro forma revenue and earnings of the Company including the Merck Acquisition would require significant estimates of amounts, and it is impossible to distinguish objectively information about such estimates that (i) provides evidence of circumstances that existed on the dates at which those amounts would be recognized and measured, and (ii) would have been available when the financial statements for that prior period were issued.
	Kilitch Acquisition
	On February 28, 2012, Akorn India Private Limited (“AIPL”), a wholly owned subsidiary of the Company completed and closed on its acquisition of selected assets of Kilitch Drugs (India) Limited (“KDIL”).  This acquisition (the “Kilitch Acquisition”) was pursuant to the terms of the Business Transfer Agreement (the “BTA”) entered into among the Company, KDIL and the members of the promoter group of KDIL on October 5, 2011.  In accordance with terms contained in the BTA, the Company also closed on a related Product Transfer Agreement between the Company and NBZ Pharma Limited (“NBZ”), a company associated with KDIL.  The primary asset transferred in the Kilitch Acquisition was KDIL’s manufacturing plant in Paonta Sahib, Himachal Pradesh, India, along with its existing book of business.  KDIL was engaged in the manufacture and sale of pharmaceutical products for contract customers in India and for export to various unregulated world markets.  While the Paonta Sahib manufacturing facility is not currently certified by the U.S. Food and Drug Administration (the “FDA”) for the exporting of drugs to the U.S., the facility was designed with future FDA certification in mind.  Accordingly, the Kilitch Acquisition provided the Company with the potential for future expansion of its manufacturing capacity for products to be sold in the U.S., as well as the opportunity to expand the Company’s footprint into markets outside the U.S.  The Company has determined that the assets acquired through the Kilitch Acquisition constitute a “business” as defined by Rule 11-01(d) of Regulation S-X and ASC 805, Business Combinations.  Accordingly, the Company has accounted for the Kilitch Acquisition as a business combination.
	AIPL paid the equivalent of approximately USD $60.1 million at closing.  Total purchase consideration was approximately $55.2 million which consisted of approximately $51.2 million in base consideration and $4.0 million in reimbursement for capital expenditures made by KDIL from April 1, 2011 to the closing date.  AIPL also paid $7.3 million related to compensation earned from the achievement of acquisition-related milestones, and $1.6 million in stamp duties paid to transfer title to the land and buildings at Paonta Sahib from Kilitch to AIPL.  In addition, the Company expects to pay up to an additional $0.5 million for future services that would be expensed as the services are provided.  The compensation for acquisition-related milestones and other acquisition costs have been recorded within “acquisition related costs” as part of operating expenses in the Company’s condensed consolidated statement of comprehensive income.  The BTA also contains a working capital guarantee that calls for KDIL or AIPL to reimburse the other party for any shortfall or excess, respectively, in the actual acquired working capital compared to the target working capital as established in the BTA.
	The following table sets forth the consideration paid for the Kilitch Acquisition, the acquisition-related costs incurred, and the fair values of the assets acquired and the liabilities assumed (U.S. dollar amounts in thousands):
	Consideration:	Initial Fair Valuation			Changes in Estimate			Adjusted Fair Valuation
	Cash paid	$	55,224					$	55,224
	Less working capital shortfall refunded by sellers		(890	)		(138	)		(1,028	)
		$	54,334		$	(138	)	$	54,196
	Acquisition-related costs:
	Stamp duties paid for transfer of land and buildings	$	1,583					$	1,583
	Acquisition-related compensation expense		6,741			511			7,252
	Due diligence, legal, travel and other acquisition-related costs		557			119			676
		$	8,881		$	630		$	9,511
	Recognized amounts of identifiable assets acquired and liabilities assumed:
	Accounts receivable	$	2,130					$	2,130
	Inventory		1,799						1,799
	Land		3,714			(1,131	)		2,583
	Buildings, plant and equipment		8,474						8,474
	Construction in progress		14,231						14,231
	Goodwill, deductible		21,609			1,004			22,613
	Other intangible assets, deductible		5,806			102			5,908
	Other assets		38						38
	Assumed liabilities		(2,099	)		(779	)		(2,878	)
	Deferred tax liabilities		(1,368	)		666			(702	)
		$	54,334		$	(138	)	$	54,196
	The Adjusted Fair Valuation presented above is final.  The changes in estimate recorded subsequent to the initial accounting estimate were primarily related to refining the calculated fair value of certain acquired assets, adjustments to the working capital settlement amount due from the sellers to the Company, and final determination regarding the tax-deductibility of the acquired intangible assets.  The acquisition-related compensation expense during 2012 was primarily related to pre-negotiated compensation paid to members of the sellers’ family based on achievement of various operational milestones.
	Goodwill represents expected synergies and intangible assets that do not qualify for separate recognition.  Based on an Indian Supreme Court ruling in 2012 upholding the deductibility of goodwill for India tax purposes, the Company anticipates being able to deduct the value of goodwill for income tax purposes in India.  A later Indian Supreme Court ruling raised doubt as to the tax deductibility of the cost of the non-compete agreement entered into between AIPL and the sellers.  Accordingly, the Company amended its acquisition accounting to establish a deferred tax liability related to this intangible asset. The Company had initially recorded a deferred tax liability valued at $1.4 million and subsequently adjusted to $0.7 million related to intangible assets and other accrued liabilities that it does not believe will be amortizable for Indian tax purposes.  This remaining deferred tax liability of $0.7 million was reversed against goodwill during 2012.
	For book purposes, the other intangible assets acquired are being amortized over lives of four to five years. Goodwill is not amortized for book purposes but is subject to impairment testing.  The tangible assets acquired consist primarily of construction in progress fair valued at $14.2 million, buildings, plant and equipment fair valued at a combined $8.5 million, land fair valued at $2.6 million, accounts receivable fair valued at $2.1 million and inventory fair valued at $1.8 million.
	Lundbeck Products
	On December 22, 2011, the Company entered into an Asset Sale and Purchase Agreement (the “Lundbeck Agreement”) to acquire the NDA rights to three branded, injectable drug products from the U.S. subsidiary of Lundbeck for an estimated purchase price of approximately $63.4 million (the “Lundbeck Acquisition”).  Per terms of the Lundbeck Agreement, the Company made an upfront payment of $45.0 million.  The Company also acquired inventory from Lundbeck for a price of $4.6 million, which was paid early in 2012.  The Company will owe a subsequent milestone payment of $15.0 million in cash to Lundbeck on the third anniversary of closing of the Lundbeck Agreement, for which contingent consideration of $11.6 million was initially recorded.  The initial purchase consideration and the subsequent milestone payment are subject to a reduction if certain sales targets are not met in the first three years and the subsequent three years post-closing. The acquired products include Nembutal®, a Schedule II controlled drug, Diuril® and Cogentin®.  This acquisition adds to the Company’s portfolio of injectable drug products, allowing the Company to leverage its existing sales infrastructure to promote sales of these products.
	The Company determined that the acquired assets represented a “business” as defined per Rule 11-01(d) of Regulation S-X and ASC 805, Business Combinations.  Accordingly, the Company accounted for the Lundbeck Acquisition as a business combination.
	The following table sets forth the consideration paid related to the Lundbeck Acquisition, the total acquisition-related costs incurred by the Company, and the fair values of the assets acquired and the liabilities assumed (in thousands):
		Initial Fair			Change in			Adjusted
		Value			Estimate			Fair Value
Consideration:
Cash paid	$	49,559					$	49,559
Present value of contingent consideration		11,300			300			11,600
Total consideration	$	60,859		$	300		$	61,159
Acquisition-related costs:	$	50					$	50
Recognized amounts of identifiable assets acquired and liabilities assumed:
Product licensing rights	$	59,525		$	300		$	59,825
Inventory		3,825						3,825
Fixed assets		50						50
Assumed liability – unfavorable contract		(2,541	)					(2,541	)
	$	60,859		$	300		$	61,159
The Company identified Product licensing rights as the only intangible assets acquired in the Lundbeck Acquisition, and is amortizing this intangible asset straight-line over its anticipated useful life of 15 years for both book and tax purposes.  The contingent consideration of $15.0 million was initially discounted to present value using a 9% discount rate, which took into account the Company’s cost of long-term credit.  The contingent consideration is being adjusted to fair value at each balance sheet date based on the remaining term and updated discount rate. The “Assumed liability – unfavorable contract” is in relation to a supply agreement assumed by the Company which obligates the Company to acquire more inventory of one of the three acquired products than the Company projects it would be able to sell based on historical sales volumes and future projections.  This liability has been discounted in determining its fair value.
The tangible assets acquired consist of inventory of approximately $3.8 million and fixed assets of approximately $50,000.   The acquired inventory has been valued below its acquisition cost based on the Company’s determination that not all of the acquired inventory can be sold at least six months prior to its expiration.
The Lundbeck Agreement commits the Company to paying royalties to Lundbeck based on the Company’s future sales of an authorized generic of one of the acquired products.  There are currently generics of this product on the market.  The Lundbeck Agreement calls for payment of royalties equal to 55% of the gross profit margin on sales of this authorized generic for a period of six years following the Company’s initial sale of this generic product.  For purposes of the royalty calculation, brand sales in excess of a specified annual unit volume will be treated as generic sales and will therefore be subject to royalties.
AVR Acquisition
On May 3, 2011, the Company purchased all the outstanding shares of stock of Advanced Vision Research, Inc. (“AVR”), paying approximately $26.0 million in cash, net of cash held by AVR.  The acquisition of AVR is being accounted for as a business combination.  The purchase price was subject to adjustment based on a working capital guarantee contained in the purchase agreement.  During the quarter ended September 30, 2011, the Company paid an additional $0.7 million to reimburse the sellers for the net cash balance in AVR’s bank accounts as of the acquisition date, as required by terms of the AVR purchase agreement.  Akorn has further agreed to reimburse AVR Business Trust, Advanced Vision Research, Inc., Advanced Vision Pharmaceuticals, LLC , and the shareholders of AVR Business Trust (collectively, the “Sellers”) for any incremental income tax expense they should incur related to the parties making an Internal Revenue Code (“IRC”) Section 338(h)(10) election.  In relation to this agreement, the Company paid approximately $0.7 million to the Sellers at closing, which represents the Seller’s initial estimate of their incremental income tax burden as a result of the IRC Section 338(h)(10) election.
The acquisition of AVR is a strategic extension of the Company’s ophthalmic business, allowing the Company to expand its presence in the OTC eye care product space.  The Company is leveraging its existing operating infrastructure that markets products to ophthalmologists, optometrists, and retailers nationwide and also expects to attain cost savings and synergies as the Company continues to integrate the AVR business into its existing operations.
AVR markets a line of OTC eye care products under the TheraTears® brand name.  Akorn had been a contract manufacturer of certain TheraTears® products since 2008.  During 2011, the Company generated revenues of approximately $0.6 million from the sale of contract manufactured TheraTears® products to AVR.
The following table summarizes the consideration paid for AVR, the total acquisition-related costs incurred by the Company during 2011 in connection with the acquisition, and the fair values of the assets acquired and liabilities assumed (amounts in thousands):
Consideration:
Cash paid at closing	$	26,011
Additional consideration paid		723
Fair value of total consideration transferred	$	26,734
Acquisition-related costs:	$	246
Recognized amounts of identifiable assets acquired and liabilities assumed:
Accounts receivable, net	$	611
Inventories, net		3,407
Prepaid expenses and other current assets		730
Property and equipment		250
Goodwill, deductible		11,863
Trademarks and technology		9,500
Customer relationships		3,900
Estimated additional consideration due		(181	)
Accounts payable & other assumed liabilities		(3,346	)
	$	26,734
The adjustment to purchase consideration and the fair valuation of acquired assets and assumed liabilities was primarily related to paying to the Sellers an additional cash amount of $0.7 million, which represented the net cash balance on AVR’s balance sheet on the acquisition date, as well as finalizing the valuation of the acquired intangible assets.
The Company identified Trademarks and technology and Customer relationships as finite-lived intangible assets acquired as part of the AVR acquisition.  Both of these assets were valued based on the projected net present value of future cash flows to be generated from these assets.   Goodwill represents both expected synergies and intangible assets that do not qualify for separate recognition and equals the excess of purchase price over the fair value of the identifiable tangible and intangible assets acquired.  The net tangible assets acquired consist primarily of inventory of approximately $3.4 million, accounts receivable of $0.6 million, prepaid expenses and other currents assets of $0.7 million and property and equipment of $0.3 million.  The fair value of inventory was determined based on its net realizable value which was adjusted to include all net costs allocable to the manufacturing effort.
For income tax purposes, the Company is able to deduct the goodwill and other intangible assets resulting from the acquisition ratably over 15 years.  Goodwill will not be amortized for book purposes but will be subject to impairment testing.  Other intangible assets are being amortized straight-line over their estimated useful lives, which for Trademarks and technology is 30 years and for Customer relationships is 15 years.
Gross accounts receivable of approximately $2.7 million acquired as part of the AVR acquisition were recorded net of the following reserves: (i) product returns of approximately $1.8 million; (ii) doubtful accounts of $0.2 million, and (iii) cash discounts of approximately $0.1 million.  The product returns reserve is an estimate of future returns of all products historically sold by AVR that are still potentially subject to return by the customer.
Other Strategic Investments
On August 1, 2011, the Company entered into a Series A-2 Preferred Stock Purchase Agreement (the “Aciex Agreement”) to acquire a minority ownership interest in Aciex Therapeutics Inc. (“Aciex”), based in Westborough, MA, for $8.0 million in cash.  Subsequently, on September 30, 2011, the Company entered into Amendment No. 1 to Series A-2 Preferred Stock Purchase Agreement (the “Aciex Amendment”) to acquire additional shares of Series A-2 Preferred Stock in Aciex for approximately $2.0 million in cash.  The Company’s investment in Aciex is being carried at cost on the Company’s Condensed Consolidated Balance Sheet.  Aciex is an ophthalmic drug development company focused on developing novel therapeutics to treat ocular diseases. Aciex’s pipeline consists of both clinical stage assets and pre-Investigational New Drug stage assets.  The investments detailed above have provided the Company with an ownership interest in Aciex of below 20%.  The Aciex Agreement and Aciex Amendment contain certain customary rights and preferences over the common stock of Aciex and further provide that the Company shall have the right to a seat on the Aciex board of directors.  The Company performs an impairment test of its investment in Aciex annually, or more frequently if there is any indication of possible impairment.  The most recent impairment review was completed in the fourth quarter of 2013 and no impairment was identified.
During 2013, 2012 and 2011, the Company paid $2.7 million, $0.8 million and $5.7 million, respectively, for the acquisition of drug product licensing rights (NDA and ANDA rights). Along with the product rights acquired in 2011, the Company also acquired inventory valued at approximately $0.3 million.  In the 2012 and 2013 acquisitions, there were no assets acquired other than the drug rights, and no liabilities assumed.

Unconsolidated_Joint_Venture

Unconsolidated Joint Venture	12 Months Ended
	Dec. 31, 2013
Unconsolidated Joint Venture [Abstract]	'
Unconsolidated Joint Venture	'
	Note 17 — Unconsolidated Joint Venture
	The Company has been a 50% partner in a joint venture agreement with an Indian drug development company since September 2004.  This joint venture launched its first product in 2008 and generated revenue from 2008 until its business assets were sold and transferred in the second quarter of 2011.  While the joint venture still exists legally, it ceased operations upon the completion of the sale and transfer of its operating assets to Pfizer, Inc. (“Pfizer”) in the second quarter of 2011.
	Akorn-Strides, LLC, a Delaware limited liability company (the “Joint Venture Company”) was formed in 2004 upon the Company’s entry into a joint venture agreement with Strides Arcolab Limited (“Strides”) for the development, manufacturing and marketing of grandfathered products, patent-challenge products and ANDA products for sales to the U.S. hospital and retail markets.  Strides was responsible for developing, manufacturing and supplying the products, while the Company was responsible for marketing and selling those products to customers in the U.S. in exchange for a fee equal to 7.5% of net sales.  The Joint Venture Company launched its first commercialized product in 2008.  In 2010 and 2011, the Company supplemented Strides’ manufacturing capabilities by producing one of the Joint Venture Company’s products at its plant in Decatur, Illinois.  In 2011, the Company recorded revenue of $0.8 million related to sales of this product to the Joint Venture Company.
	Strides and Akorn each own 50% of the Joint Venture Company with equal management representation. The Company accounts for the Joint Venture Company’s earnings and losses on the equity method of accounting in accordance with its 50% ownership interest. The Company’s share of the Joint Venture Company net income is reflected as “Equity in earnings of unconsolidated joint venture” on the Company’s consolidated statements of operations and consolidated statements of cash flows.
	On December 29, 2010, the Joint Venture Company entered into an Asset Purchase Agreement with Pfizer, Inc. (“Pfizer”) to sell the rights to all of its ANDAs to Pfizer for $63.2 million in cash (the “Pfizer ANDA Sale”).  In accordance with an amendment to the joint venture operating agreement, the Company and Strides agreed to an uneven split of the proceeds, with the Company receiving $35.0 million, or approximately 55.4% of the sale proceeds, and Strides receiving $28.2 million, or approximately 44.6%.  Costs of $0.1 million related to the sale were allocated to each partner in the same proportion as the sales proceeds.  Transfer of ownership of the ANDAs took place in two steps, with dormant and in-development products transferred to Pfizer on December 29, 2010 and actively-marketed products transferred on May 1, 2011.  This arrangement allowed the Joint Venture Company time to liquidate existing inventory of the actively-marketed products and allowed Pfizer the opportunity to manufacture and label its own stock.  No assets or liabilities of the Joint Venture Company other than its ANDA rights were transferred to Pfizer.  The Joint Venture Company essentially ceased operations in the second quarter of 2011, though it continues to exist as a legal entity.  The Company does not expect any future activity of the Joint Venture Company to have a material impact on its results of operations in future periods.
	The Joint Venture Company recorded a total gain of approximately $63.1 million from the Pfizer ANDA Sale, of which $38.9 million, or 61.7%, was recognized in the fourth quarter of 2010 and the remaining $24.2 million, or 38.3%, was recognized in the second quarter of 2011.  During the years ended December 31, 2011 and 2010, the Company recorded $14.6 million and $23.4 million, respectively, as its equity in earnings of the Joint Venture Company.  The net income recorded in 2013 was primarily related to adjustments to the Joint Venture Company’s reserves for product returns upon expiration of the period for which product returns could be made.
	The following tables sets forth a condensed statements of income for the three years ended December 31, 2013 and condensed balance sheets as of December 31, 2013 and 2012 for Akorn-Strides, LLC, along with information regarding the amount of earnings allocated to each member-partner of the LLC (in thousands):
	CONDENSED STATEMENTS OF INCOME
		(Unaudited)
		Year ended December 31,
		2013			2012		2011
	REVENUES	$	163		$	-	$	6,364
	Cost of sales		(1	)		-		3,562
	GROSS PROFIT		164			-		2,802
	Operating expenses		3			-		499
	OPERATING INCOME		161			-		2,303
	Gain from Pfizer ANDA Sale		-			-		24,160
	INCOME BEFORE INCOME TAXES		161			-		26,463
	Income tax (benefit) / provision		-			-		(38	)
	NET INCOME	$	161		$	-	$	26,501
	CONDENSED BALANCE SHEETS
		(Unaudited)
		December 31,
		2013			2012
	ASSETS
	Cash	$	25		$	794
	Other current assets		1
	TOTAL ASSETS	$	26		$	794
	LIABILITIES & MEMBERS’ EQUITY (DEFICIT)
	Trade accounts payable & other accrued liabilities	$	-		$	431
	TOTAL LIABILITIES	-				431
	Members’ equity		26			363
	TOTAL LIABILITIES & MEMBERS’ EQUITY (DEFICIT)	$	26		$	794
	Trade accounts payable & other accrued liabilities as of December 31, 2012 primarily consists of accruals for potential product returns.  As of December 31, 2013, no future product returns are expected.

Customer_Supplier_and_Product_

Customer, Supplier and Product Concentration	12 Months Ended
	Dec. 31, 2013
Customer, Supplier and Product Concentration [Abstract]	'
Customer, Supplier and Product Concentration	'
	Note 18 — Customer, Supplier and Product Concentration
	Customer Concentration
	In 2013, 2012 and 2011, a significant portion of the Company’s gross and net sales reported for its Ophthalmic and Hospital drugs & injectables segments were through three large wholesale drug distributors, and a significant portion of  the Company’s accounts receivable as of December 31, 2013, 2012 and 2011 were due from these wholesale drug distributors as well. AmerisourceBergen Health Corporation (“Amerisource”), Cardinal Health, Inc. (“Cardinal”) and McKesson Drug Company (“McKesson”) are all distributors of the Company’s products, as well as suppliers of a broad range of health care products.  Aside from these three wholesale drug distributors, no other customers accounted for more than 10% of gross sales, net revenues or gross trade receivables for the indicated dates and periods.
	The following table sets forth the percentage of the Company’s gross and net sales and gross accounts receivable attributable to these three distributors for the periods indicated:
		2013									2012									2011
								Gross									Gross									Gross
		Gross			Net			Accounts			Gross			Net			Accounts			Gross			Net			Accounts
		Sales			Revenue			Receivable			Sales			Revenue			Receivable			Sales			Revenue			Receivable
	Amerisource		19	%		14	%		25	%		19	%		14	%		29	%		23	%		23	%		29	%
	Cardinal		23	%		16	%		26	%		23	%		17	%		30	%		27	%		25	%		34	%
	McKesson		16	%		11	%		12	%		16	%		11	%		14	%		16	%		15	%		9	%
	Total		58	%		41	%		63	%		58	%		42	%		73	%		66	%		63	%		72	%
	If sales to Amerisource, Cardinal or McKesson were to diminish or cease, the Company believes that the end users of its products would find little difficulty obtaining the Company’s products either directly from the Company or from another distributor.
	Supplier Concentration
	The Company requires a supply of quality raw materials and components to manufacture and package pharmaceutical products for its own use and for third parties with which it has contracted. The principal components of the Company’s products are active and inactive pharmaceutical ingredients and certain packaging materials. Many of these components are available from only a single source and, in the case of many of the Company’s ANDAs and NDAs, only one supplier of raw materials has been identified. Because FDA approval of drugs requires manufacturers to specify their proposed suppliers of active ingredients and certain packaging materials in their applications, FDA approval of any new supplier would be required if active ingredients or such packaging materials were no longer available from the specified supplier. The qualification of a new supplier could delay the Company’s development and marketing efforts. If for any reason the Company is unable to obtain sufficient quantities of any of the raw materials or components required to produce and package its products, it may not be able to manufacture its products as planned, which could have a material adverse effect on the Company’s business, financial condition and results of operations.
	No individual supplier represented 10% or more of the Company’s purchases in any of the years ended December 31, 2013, 2012 or 2011.
	Product Concentration
	During the years 2013 and 2012, one of the Company’s injectable products represented 11.8% and 12.5% of the Company’s total net revenue, respectively.  For the year 2011, one of the Company’s ophthalmic products represented 10.4% of the Company’s total net revenue for that year.  No other products represented 10% or more of the Company’s net revenue in 2013, 2012 or 2011.  The Company attempts to minimize the risk associated with product concentrations by continuing to acquire and develop new products to add to its portfolio.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	Note 19 — Related Party Transactions
	In the recent past, the Company engaged in various related party transactions with John N. Kapoor, Ph.D, Chairman of the Company’s Board of Directors and a significant holder of the Company’s common stock.
	On March 3, 2010, the Company entered into an 8-year agreement with EJ Financial for their sub-lease of a portion of the Company’s corporate offices in Lake Forest, Illinois.  This sub-lease commenced on April 1, 2010.  Subsequently, the Company and EJ Financial agreed to early terminate this agreement, and accordingly the sub-lease was terminated in July 2012.  EJ Financial paid the Company a total of approximately $240,000 in rent and common area maintenance fees over the shortened term of this sub-lease.
	From March 31, 2009 until June 17, 2011, the Company was party to a revolving credit facility for which the lender was EJ Funds, a company controlled by Dr. Kapoor.  On March 31, 2009, the Company consented to an Assignment Agreement between GE Capital and EJ Funds which transferred all of GE Capital’s rights and obligations under its existing $25.0 million GE Credit Agreement to EJ Funds.  Dr. Kapoor is the president of EJ Financial Enterprises, Inc., a healthcare consulting and investment company, and EJ Financial is the general partner of EJ Funds.  In connection with the Assignment Agreement, on April 13, 2009 the Company entered into a Modification, Warrant and Investor Rights agreement that reduced the loan commitment to $5.65 million.  Subsequently, on August 17, 2009, the parties agreed to increase the loan commitment to $10.0 million.  The Company repaid its outstanding balance under the facility in March 2010 and elected to early terminate the credit agreement on June 17, 2011.
	In connection with the various modifications agreed to during 2009 to the EJ Funds credit facility and the Subordinated Note, the Company issued various stock warrants to Dr. Kapoor (the “Kapoor Warrants”).  See Note 2, Summary of Significant Accounting Policies / Warrants, for information about the Kapoor Warrants.

Severance_Charges

Severance Charges	12 Months Ended
	Dec. 31, 2013
Severance Charges [Abstract]	'
Severance Charges	'
	Note 20 — Severance Charges
	Upon acquiring AVR on May 3, 2011, the Company entered into severance agreements with six of AVR’s employees.  Each severance agreement promised a lump-sum payout in exchange for the employee remaining with the Company through a post-acquisition transition period, as defined in each agreement.  Accordingly, severance expense was recorded ratably over the required transition period.  Four out of the six employees received their severance payments in 2011 and the remaining two received their severance payments in 2012.
	As of December 31, 2013 and 2012, the accrued severance balances on the Company’s books were less than $25,000 at each date.

Selected_Quarterly_Financial_D

Selected Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2013
Selected Quarterly Financial Data (Unaudited) [Abstract]	'
Selected Quarterly Financial Data (Unaudited)	'
	Note 21 – Selected Quarterly Financial Data (Unaudited)
								Consolidated Net Income
				Gross		Operating				Per Basic		Per Diluted
	(In thousands, except per share amounts)	Revenues		Profit		Income		Amount		Share		Share
	Year Ended December 31, 2013:
	4th Quarter	$	84,953	$	46,970	$	25,176	$	16,678	$	0.17	$	0.14
	3rd Quarter		81,892		43,697		22,188		12,205		0.13		0.11
	2nd Quarter		77,012		42,092		22,251		12,637		0.13		0.11
	1st Quarter		73,854		39,145		18,589		10,842		0.11		0.1
	Year Ended December 31, 2012:
	4th Quarter	$	71,520	$	41,971	$	19,715	$	8,811	$	0.09	$	0.08
	3rd Quarter		69,634		40,093		22,603		13,753		0.14		0.12
	2nd Quarter		63,287		35,727		18,776		9,706		0.1		0.09
	1st Quarter		51,717		30,901		7,662		3,108		0.03		0.03

Legal_Proceedings

Legal Proceedings	12 Months Ended
	Dec. 31, 2013
Legal Proceedings [Abstract]	'
Legal Proceedings	'
	Note 22 – Legal Proceedings.
	On September 12, 2012, Fera Pharmaceuticals, LLC (“Fera”) filed a civil complaint against the Company and certain individual defendants (together, the “Defendants”) in the Supreme Court of New York (the “Fera lawsuit”). The complaint alleges, among other things, breach of manufacturing and confidentiality agreements and misappropriation of the plaintiff’s trade secrets. On October 15, 2012, the case was removed to the Federal District Court for the Southern District of New York. Fera filed an amended complaint on December 21, 2012.  The Company intends to vigorously defend these allegations. However, no assurance may be given regarding the ultimate outcome of this lawsuit.
	In April 2012, Allergan Sales (“Allergan”) filed a lawsuit alleging patent infringement claims against the Company relating to the 0.4% ketorolac tromethamine formulation.  Allergan sought unspecified monetary damages in this case.  The Company had asserted invalidity and non-infringement.  The Company and Allergan entered into a confidential settlement agreement, which did not have a material impact on the Company or its operations, and on September 28, 2013, the court entered an order dismissing the lawsuit.
	In April 2011, Inspire received a Notice Letter from Sandoz, Inc. (“Sandoz”) providing notice that Sandoz has filed an Abbreviated New Drug Application (ANDA) with the FDA seeking marketing approval for a 1% azithromycin ophthalmic solution prior to the expiration of the five U.S. patents licensed to us and listed in the Orange Books for AzaSite. On May 26, 2011, Merck, InSite Vision Incorporated (“InSite”) and Pfizer filed a complaint against Sandoz and related entities in the district court of New Jersey alleging that their proposed product infringes the listed patents. On October 4, 2013, the court issued judgment in favor of us and the other plaintiffs finding all the asserted claims of the patents in the litigation valid and infringed by Sandoz and related entities. Sandoz has appealed this decision. The Company intends to vigorously contest any Sandoz assertions that these patents should have been found not infringed, invalid or unenforceable.
	In May 2013, Inspire received a Notice Letter that Mylan Pharmaceuticals, Inc. (“Mylan”), had filed an ANDA with the FDA seeking marketing approval for a 1% azithromycin ophthalmic solution (the “Mylan Product”) prior to the expiration of the five U.S. patents licensed to us and listed in the Orange Books for AzaSite. On June 14, 2013, Insite, Merck, Inspire and Pfizer filed a complaint against Mylan and a related entity alleging that their proposed product infringes the listed patents. The Company intends to vigorously contest any Mylan assertions that these patents are invalid or unenforceable.
	The Company is party to legal proceedings and potential claims arising in the ordinary course of our business. The amount, if any, of ultimate liability with respect to such matters cannot be determined. Despite the inherent uncertainties of litigation, the Company at this time does not believe that such proceedings will have a material adverse impact on its financial condition, results of operations, or cash flows.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Summary of Significant Accounting Policies [Abstract]	'
Consolidation	'
	Consolidation: The accompanying consolidated financial statements include the accounts of Akorn, Inc. and its wholly owned domestic and foreign subsidiaries.  All inter-company transactions and balances have been eliminated in consolidation, and the financial statements of AIPL have been translated from Indian rupees to U.S. dollars based on the currency translation rates in effect during the period or as of the date of consolidation, as applicable.  The Company has no involvement with variable interest entities.
	The Company is a 50% owner of a dormant joint venture, Akorn-Strides, LLC (the “Joint Venture Company”) (See Note 17.).  The Company and its strategic partner each have equal voting rights and shared operational control.  Accordingly, the Company accounts for its investment in the Joint Venture Company using the equity method of accounting.  The Company’s proportionate share of the Joint Venture Company’s income has been recorded under the caption “Equity in earnings of unconsolidated joint venture” in the Company’s consolidated statements of operations.  The Joint Venture Company sold all of its abbreviated new drug application (“ANDA”) rights to Pfizer, Inc. in December 2010 and ceased operations during 2011.
Use of Estimates	'
	Use of Estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. Significant estimates and assumptions for the Company relate to the allowances for doubtful accounts, chargebacks, rebates, product returns and coupons and promotions, and the reserve for slow-moving and obsolete inventories, the carrying value and lives of intangible assets, the useful lives of fixed assets, the carrying value of deferred income tax assets, the assumptions underlying share-based compensation and accrued but unreported employee benefit costs.
Revenue Recognition	'
	Revenue Recognition: Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the sales price is fixed or determinable, and collectability is reasonably assured.  Revenue from product sales is recognized when title and risk of loss have passed to the customer.
	Provision for estimated doubtful accounts, chargebacks, coupon redemption, rebates, discounts and product returns is made at the time of sale and is analyzed and adjusted, if necessary, at each balance sheet date.
Freight	'
	Freight:  The Company records amounts billed to customers for shipping and handling as revenue, and records shipping and handling expense related to product sales as cost of sales.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents: The Company considers all unrestricted, highly liquid investments with maturity of three months or less when purchased to be cash and cash equivalents.  At December 31, 2013 and 2012, approximately $2.7 million and $3.2 million of cash held by our India operations as of those respective dates was restricted, and was reported within other long term assets.
Accounts Receivable	'
	Accounts Receivable: Trade accounts receivable are stated at their net realizable value.  The nature of the Company’s business involves, in the ordinary course, significant judgments and estimates relating to chargebacks, coupon redemption, product returns, rebates, discounts given to customers and allowances for doubtful accounts.  Depending on the products, the end-user customers, the specific terms of national supply contracts and the particular arrangements with the Company’s wholesaler customers, certain rebates, chargebacks and other credits are recorded as deductions to the Company’s trade accounts receivable.
	Unless otherwise noted, the provisions and allowances for the following customer deductions are reflected in the accompanying consolidated financial statements as reductions of revenues and trade accounts receivable, respectively.
Chargebacks and Rebates	'
	Chargebacks and Rebates: The Company enters into contractual agreements with third parties such as hospitals and group-purchasing organizations to sell certain products at predetermined prices. The parties have elected to have these contracts administered through wholesalers that buy the product from the Company and subsequently sell it to these third parties. When a wholesaler sells products to one of these third parties that are subject to a contractual price agreement, the difference between the price paid to the Company by the wholesaler and the price under the specific contract is charged back to the Company by the wholesaler. The Company tracks sales and submitted chargebacks by product number and contract for each wholesaler. Utilizing this information, the Company estimates a chargeback percentage for each product and records an allowance as a reduction of gross sales when the Company records its sale of the products. The Company reduces the chargeback allowance when a chargeback request from a wholesaler is processed. Actual chargebacks processed by the Company can vary materially from period to period based upon actual sales volume through the wholesalers. However, the Company’s provision for chargebacks is fully reserved for at the time when sales revenues are recognized.
	Management obtains certain wholesaler inventory reports to aid in analyzing the reasonableness of the chargeback allowance. The Company assesses the reasonableness of its chargeback allowance by applying the product chargeback percentage based on historical activity to the quantities of inventory on hand per the wholesaler inventory reports. In accordance with its accounting policy, the Company estimates the percentage amount of wholesaler inventory that will ultimately be sold to third parties that are subject to contractual price agreements based on a six-quarter trend of such sales through wholesalers. The Company uses this percentage estimate until historical trends indicate that a revision should be made. On an ongoing basis, the Company evaluates its actual chargeback rate experience, and new trends are factored into its estimates each quarter as market conditions change.
	Set forth below are the Company’s historical estimates of the percentage of sales that are subject to chargebacks that were used during each quarterly period in the three years ended December 31, 2013:
	Year			Q1			Q2			Q3				Q4
	2013			90.00%			90.00%			90.00%				90.00%
	2012			98.50%			98.50%			95.00%				90.00%
	2011			98.50%			98.50%			98.50%				98.50%
	Similarly, the Company maintains an allowance for rebates related to contract and other programs with certain customers. Rebate percentages vary by product and by volume purchased by each eligible customer. The Company tracks sales by product number for each eligible customer and then applies the applicable rebate percentage, using both historical trends and actual experience to estimate its rebate allowance. The Company reduces gross sales and increases the rebate allowance by the estimated rebate amount when the Company sells its products to its rebate-eligible customers. The Company reduces the rebate allowance when it processes a customer request for a rebate. At each balance sheet date, the Company analyzes the allowance for rebates against actual rebates processed and makes necessary adjustments as appropriate. Actual rebates processed can vary materially from period to period.
	The recorded allowances reflect the Company’s current estimate of the future chargeback and rebate liabilities to be paid or credited to its wholesaler and other customers under the applicable contracts and programs. For the years ended December 31, 2013, 2012 and 2011, the Company recorded chargeback and rebate expense of $183.4 million, $112.2 million, and $68.1 million, respectively. The allowance for chargebacks and rebates was $12.9 million and $13.5 million as of December 31, 2013 and 2012, respectively.
Sales Returns	'
	Sales Returns: Certain of the Company’s products are sold with the customer having the right to return the product within specified periods and guidelines for a variety of reasons, including but not limited to, pending expiration dates. Provisions are made at the time of sale based upon tracked historical experience, by customer in some cases.  Historical factors such as one-time events as well as pending new developments that would impact the expected level of returns are taken into account to determine the appropriate reserve estimate at each balance sheet date. As part of the evaluation of the balance required, the Company considers actual returns to date that are in process, the expected impact of any product recalls and the wholesaler’s inventory information to assess the magnitude of unconsumed product that may result in a sales returns to the Company in the future. The sales returns level can be impacted by factors such as overall market demand and market competition and availability for substitute products which can increase or decrease the end-user pull through for sales of the Company’s products and ultimately impact the level of sales returns. Actual returns experience and trends are factored into the Company’s estimates each quarter as market conditions change. Actual returns processed can vary materially from period to period.
	For the years ended December 31, 2013, 2012 and 2011, the Company recorded a net expense for product returns of $5.0 million, $3.8 million and $2.7 million, respectively.  The Company’s allowance for potential product returns was $8.2 million and $8.4 million at December 31, 2013 and 2012, respectively.
Allowance for Coupons and Promotions	'
	Allowance for Coupons and Promotions: The Company issues coupons from time to time redeemable against our TheraTears® eye care products.  Upon release of coupons into the market, the Company records an estimate of the dollar value of coupons expected to be redeemed.  This estimate is based on historical experience and is adjusted as needed based on actual redemptions.   In addition to couponing, from time to time the Company authorizes various retailers to run in-store promotional sales of our products. Upon confirmation that a promotion was run, the Company accrues an estimate of the dollar amount expected to be owed back to the retailer.  This estimate is trued up upon receipt of invoice from the retailer.
	For the years ended December, 31, 2013, 2012 and 2011, the Company recorded provisions for coupons and promotions totaling $4.5 million, $3.0 million and $1.9 million, respectively.  As of December 31, 2013 and 2012, the balances in the Company’s reserve for coupons and promotions were $0.7 million and $0.8 million, respectively.
Doubtful Accounts	'
	Doubtful Accounts: Provisions for doubtful accounts, which reflect trade receivable balances owed to the Company that are believed to be uncollectible, are recorded as a component of SG&A expenses. In estimating the allowance for doubtful accounts, the Company considers its historical experience with collections and write-offs, the credit quality of its customers and any recent or anticipated changes thereto, and the outstanding balances and past due amounts from its customers.  Accounts are considered past due when they remain uncollected beyond the due date specified in the applicable contract or on the applicable invoice, whichever is deemed to take precedence.
	For the years ended December 31, 2013, 2012 and 2011, the Company recorded net provisions for doubtful accounts that were insignificant in amount, at less than $0.1 million in each year.
	As of December 31, 2013, the Company had a total of $6.1 million of past due gross accounts receivable, of which $0.8 million was more than 60 days past due. The Company performs monthly a detailed analysis of the receivables due from its wholesaler customers and provides a specific reserve against known uncollectible items. The Company also includes in the allowance for doubtful accounts an amount that it estimates to be uncollectible for all other customers, based on a percentage of the past due receivables. The percentage reserved increases as the age of the receivables increases.  Accounts are written off once all reasonable collections efforts have been exhausted and/or when facts or circumstances regarding the customer (i.e. bankruptcy filing) indicate that the chance of collection is remote.
Advertising and Promotional Allowances to Customers	'
	Advertising and Promotional Allowances to Customers: The Company routinely sells its non-prescription ophthalmic and other drug products to major retail drug chains.  From time to time, the Company may arrange for these retailers to run in-store promotional sales of the Company’s products.  The Company reserves an estimate of the dollar amount owed back to the retailer, recording this amount as a reduction to revenue at the later of the date on which the revenue is recognized or the date the sales incentive is offered. When the actual invoice for the sales promotion is received from the retailer, the Company adjusts its estimate accordingly.
	For the Company’s treatment of advertising and promotional expenses paid to customers, costs are expensed as incurred in accordance with ASC 605-50, Customer Payments and Incentives.
Inventories	'
	Inventories: Inventories are stated at the lower of cost (average cost method) or market (see Note 4 — “Inventories”). The Company maintains an allowance for slow-moving and obsolete inventory as well as inventory with a carrying value in excess of its net realizable value (“NRV”). For finished goods inventory, the Company estimates the amount of inventory that may not be sold prior to its expiration or is slow moving based upon recent sales activity by unit and wholesaler inventory information. The Company also analyzes its raw material and component inventory for slow moving items. For the years ended December 31, 2013, 2012 and 2011, the Company recorded a provision for inventory obsolescence/NRV of $2.1 million, $2.4 million, and $0.6 million, respectively. The allowances for inventory obsolescence were $2.9 million and $2.2 million as of December 31, 2013 and 2012, respectively.
	The Company capitalizes inventory costs associated with its products prior to regulatory approval when, based on management judgment, future commercialization is considered probable and the future economic benefit is expected to be realized.  The Company assesses the regulatory approval process and where the product stands in relation to that approval process including any known constraints or impediments to approval.  The Company considers the shelf life of the product in relation to the product timeline for approval.
	At December 31, 2013, the Company established a reserve of $1.0 million related to R&D raw materials that are not expected to be utilized prior to expiration.  At December 31, 2012, the Company had approximately $0.8 million in inventory for generic drugs under development which have not yet received FDA approval, the entire balance of which had been reserved, as the Company deemed it unlikely that the products would receive FDA approval far enough in advance of expiration to be sellable.
Intangible Assets	'
	Intangible Assets: Intangible assets consist primarily of goodwill, which is carried at its initial value, subject to evaluation for impairment, and product licensing costs, trademarks and other such costs, which are capitalized and amortized on a straight-line basis over their useful lives, ranging from four (4) years to thirty (30) years.  Accumulated amortization was $39.1 million and $31.9 million at December 31, 2013 and 2012, respectively.  Amortization expense was $7.4 million, $6.9 million and $1.7 million for the years ended December 31, 2013, 2012 and 2011, respectively. The Company regularly assesses its intangible assets for impairment based on several factors, including estimated fair value and anticipated cash flows.  If the Company incurs additional costs to renew or extend the life of an intangible asset, such costs are added to the remaining unamortized cost of the asset, if any, and the sum is amortized over the extended remaining life of the asset.
	Goodwill is tested for impairment annually or more frequently if changes in circumstances or the occurrence of events suggest that impairment may exist. The Company uses widely accepted valuation techniques to determine the fair value of its reporting units used in its annual goodwill impairment analysis. The Company’s valuation is primarily based on qualitative and quantitative assessments regarding the fair value of goodwill relative to its carrying value. The Company modeled the fair value of the reporting unit based on actual projected earnings and cash flows of the reporting unit. The Company performed its annual impairment test on October 1, 2013 and determined that the fair value of its reporting unit exceeded its carrying value and, therefore, no impairment charge was necessary.
	Changes in goodwill during the two years ended December 31, 2013 were as follows (in thousands):
			Goodwill
	31-Dec-11		$	11,863
	Acquisitions			22,613
	Impairments		-
	Foreign currency translation			(2,317	)
	31-Dec-12		$	32,159
	Acquisitions		-
	Impairments		-
	Foreign currency translation			(2,328	)
	31-Dec-13		$	29,831
	The following table sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of December 31, 2013 for those assets that are not already fully amortized (dollar amounts in thousands):
			Gross			Accumulated			Net			Weighted Average
			Carrying			Amortization			Carrying			Remaining
			Amount						Amount			Amortization Period
	Product licensing rights		$	151,504		$	(35,604	)	$	115,900		9.8 years
	Trademarks			9,500			(844	)		8,656		27.4 years
	Customer relationships			6,166			(1,528	)		4,638		9.8 years
	Non-Compete			2,428			(1,117	)		1,311		2.2 years
			$	169,598		$	(39,093	)	$	130,505
	Changes in intangible assets during the two years ended December 31, 2013 were as follows (in thousands):
			Product			Trademarks			Customer				Non-Compete
			licensing rights						Relationships				Agreements
	31-Dec-11		$	67,822			$9,289		$	3,727			$	-
	Acquisitions			1,100			-			2,560				2,743
	Amortization			(5,268	)		(317	)		(705	)			(580	)
	Foreign currency translation		-			-				6				8
	31-Dec-12		$	63,654		$	8,972		$	5,588			$	2,171
	Acquisitions			57,969		-			-				-
	Amortization			(5,723	)		(316	)		(740	)			(643	)
	Foreign currency translation		-			-				(210	)			(217	)
	31-Dec-13		$	115,900		$	8,656		$	4,638			$	1,311
	The amortization expense of acquired intangible assets for each of the following five years will be as follows (in thousands):
	Year ending		Amortization Expense
	December 31,
	2014		$	15,996
	2015			15,388
	2016			14,862
	2017			14,345
	2018			14,262
Property, Plant and Equipment	'
	Property, Plant and Equipment: Property, plant and equipment is stated at cost, less accumulated depreciation. Depreciation is provided using the straight-line method in amounts considered sufficient to amortize the cost of the assets to operations over their estimated useful lives or lease terms. Depreciation expense was $7.1 million, $4.6 million and $3.5 million for the years ended December 31, 2013, 2012 and 2011, respectively.  The amortization of assets under capital leases is included within depreciation expense. The following table sets forth the average estimated useful lives of the Company’s property, plant and equipment, by asset category:
	Asset category		Depreciable Life
	Buildings		30 years
	Leasehold improvements		18 years
	Furniture and equipment		10 years
	Automobiles		5 years
	Computer hardware and software		5 years
Net Income Per Common Share	'
	Net Income Per Common Share: Basic net income per common share is based upon weighted average common shares outstanding. Diluted net income per common share is based upon the weighted average number of common shares outstanding, including the dilutive effect, if any, of stock options, warrants and convertible securities using the treasury stock and if converted methods.  Anti-dilutive shares excluded from the computation of diluted net income per share for 2013, 2012 and 2011 include 975,000, 581,000 and 1,560,000 shares, respectively, related to options, warrants and convertible securities.
Income Taxes	'
	Income Taxes: Income taxes are accounted for under the asset and liability method.  Deferred income tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and net operating loss and other tax credit carry-forwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company records a valuation allowance to reduce the deferred income tax assets to the amount that is more likely than not to be realized.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments: The Company applies ASC Topic 820, which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC Topic 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company’s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC Topic 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity’s own assumptions based on market data and the entity’s judgments about the assumptions that market participants would use in pricing the asset or liability, and are to be developed based on the best information available in the circumstances.
	The valuation hierarchy is composed of three categories.  The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement.  The categories within the valuation hierarchy are described below:
		-	Level 1—Assets and liabilities with unadjusted, quoted prices listed on active market exchanges.  Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.  The carrying value of the Company‘s cash and cash equivalents are considered Level 1 assets.
		-	Level 2—Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as directly or indirectly observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.  The market value of the Company’s forward contracts to hedge against changes in currency translation rates between U.S. dollars and Indian rupees is a Level 2 asset.
		-	Level 3—Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.  The purchase consideration payable related to the Company’s acquisition on December 22, 2011 of three branded, injectable drug products from the U.S. subsidiary of H. Lundbeck A/S (the “Lundbeck Acquisition”) is a Level 3 liability.
	The following table summarizes the basis used to measure the fair values of the company’s financial instruments (amounts in thousands):
						Fair Value Measurements at Reporting Date, Using:
						Quoted Prices			Significant
						in Active			Other				Significant
						Markets for			Observable				Unobservable
			December 31,			Identical Items			Inputs				Inputs
	Description		2013			(Level 1)			(Level 2)				(Level 3)
	Cash and cash equivalents		$	34,178		$	34,178		$	-			$	-
	Foreign currency forward contracts			208			-			208				-
	Total assets		$	34,386		$	34,178		$	208			$	-
	Purchase consideration payable		$	14,728		$	-		$	-			$	14,728
	Total liabilities		$	14,728		$	-		$	-			$	14,728
						Quoted Prices			Significant
						in Active			Other				Significant
						Markets for			Observable				Unobservable
			December 31,			Identical Items			Inputs				Inputs
	Description		2012			(Level 1)			(Level 2)				(Level 3)
	Cash and cash equivalents		$	40,781		$	40,781		$	-			$	-
	Total assets		$	40,781		$	40,781		$	-			$	-
	Purchase consideration payable		$	14,208		$	-		$	-			$	14,208
	Total liabilities		$	14,208		$	-		$	-			$	14,208
	The carrying amount of the purchase consideration payable was initially determined based on the terms of the underlying contracts and the Company’s subjective evaluation of the likelihood of the additional purchase consideration becoming payable.  The purchase consideration payable is related to the Company’s obligation to pay additional consideration related to the acquisition of selected assets from H. Lundbeck A/S (“Lundbeck”) on December 22, 2011.  The underlying obligation was long-term in nature, and therefore was discounted to present value based on an assumed discount rate.  The additional consideration of $15.0 million, contingently payable to Lundbeck on December 22, 2014, was initially discounted to $11.3 million based on a discount rate of 10.0%, and subsequently adjusted in final acquisition accounting to $11.6 million based on applying a 9.0% discount rate.  At December 31, 2012, the Company performed an evaluation of the fair value of this liability based on utilizing significant unobservable inputs to derive a discount rate of 2.75%, and determined that the appropriate discounted value was $14.2 million.  Accordingly, the Company recorded non-cash interest expense of $2.6 million during 2012 to accrue the carrying value of the contingent payment liability to $14.2 million as of December 31, 2012.  At December 31, 2013, the Company once again evaluated the fair value based on utilizing significant unobservable inputs and derived a discount rate of 1.85%, determining that the appropriate discounted value was $14.7 million.  The fair value of the liability is based upon the likelihood of achieving the underlying revenue targets and a derived cost of debt based on the remaining term.
	The Company initially determined that there was a 100% likelihood of the purchase consideration ultimately becoming payable, and reaffirmed this determination as of December 31, 2012 and December 31, 2013.  Should subjective and objective evidence lead the Company to change this assessment, an adjustment to the carrying value of the liability would be recorded as “other income” in the Company’s condensed consolidated statements of comprehensive income.
	The purchase consideration payable to Lundbeck was classified as a long-term liability on the Company’s consolidated balance sheet as of December 31, 2012.  This liability was reclassified as a current liability on the Company’s a consolidated balance sheet as of December 31, 2013, since the $15.0 million payment will be due in less than a year from that date.
	The Company entered into three non-deliverable forward contracts in October 2013 to hedge planned capital expenditures at AIPL against unfavorable trends with regard to currency translation rates between U.S. dollars (“USD”) and Indian rupees (“INR”).  The three forward contracts were based on future anticipated investments of USD $3.3 million on each of April 2, 2014, July 3, 2014 and September 30, 2014 in the Company’s subsidiary in India, Akorn India Private Limited (“AIPL”).  These forward contracts include projected currency translation rates between INR and USD.  Any difference between the actual and projected foreign currency translations rates on the respective settlement dates will result in payment from the bank to the Company, or vice versa, as the case may be.  As of December 31, 2013, the bank provided the Company with a report of the fair market value of the forward contracts.  Due to strengthening of the Indian rupee against the U.S. dollar, the contracts had a positive fair value to the Company of $0.2 million as of December 31, 2013.  The Company recorded this gain in fair value as “other income” in its consolidated statements of comprehensive income and has included the asset value within “prepaid expenses and other current assets” in its consolidated balance sheet.
	As of December 31, 2013 and 2012, the Company was carrying long-term investments valued at $10.0 million and $10.3 million, respectively.  The underlying assets are cost-basis investments for which fair value is not readily determinable.
Warrants	'
	Warrants: The Company issued various warrants during 2009 to entities controlled by John N. Kapoor, Ph.D., the Chairman of the Company’s Board of Directors (the “Kapoor Warrants”).  The Company had classified the fair value of these warrants as a current liability in accordance with ASC 815-40-15-3, Derivatives and Hedging, (formerly EITF 00-19, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock). This classification was made as a result of the requirement that the shares to be issued upon exercise of the Kapoor Warrants be registered shares, which could not be absolutely assured.  The Kapoor Warrants were adjusted to fair value at the end of each quarter through Black-Scholes calculations which considered changes in the market price of the Company’s common stock, the remaining contractual life of the Kapoor Warrants, and other factors.  Any change in the fair value of the Kapoor Warrants was recorded as income or expense on the Company’s consolidated statements of operations for the applicable period.
	On June 28, 2010, the Company and Dr. Kapoor entered into an Amended and Restated Registration Rights Agreement (the “Amended Agreement”) which modified certain terms related to the Company’s obligation to obtain and maintain registration of any shares issued pursuant to exercise of the Kapoor Warrants.  The Amended Agreement still requires the Company to use “commercially reasonable efforts” to file a registration statement pursuant to Rule 415 of the Securities Act of 1933 (“Registration Statement”) for any shares of common stock that may be issued under the applicable warrant agreements, and to maintain the continuous effectiveness of such Registration Statement until the earliest of: (i) the date no shares of the Company’s common stock qualify as registrable securities, (ii) the date on which all of the registrable securities may be sold in a single transaction by the holder to the public pursuant to Rule 144 or a similar rule, or (iii) the date upon which the John N. Kapoor Trust Dated September 20, 1989 (the “Kapoor Trust”) and EJ Funds, LP (“EJ Funds”) have transferred all of the registrable securities.  However, the Registration Rights Agreement has been amended to explicitly state that in the event the Company, after using its good faith commercially reasonable efforts, is not able to obtain or maintain registration of the common stock, delivery of unregistered shares upon exercise of the Kapoor Warrants will be deemed acceptable and a net cash settlement will not be required. The Amended Agreement further provides that the term “commercially reasonable efforts” in such instance shall not mean an absolute obligation of the Company to obtain and maintain registration.
	As a result of the changes effected through the Amended Agreement, on June 28, 2010 the Company changed its accounting treatment of the Kapoor Warrants, no longer classifying them as a current liability with periodic adjustments to fair value but instead classifying them as a component of shareholders’ equity in accordance with ASC 815-40.   Accordingly, the fair value of the Kapoor Warrants, which was $17.9 million on June 28, 2010, was reclassified from a current liability to a component of shareholders’ equity on that date.  Following this change in classification, no future fair value adjustments are required.
	The liability at June 28, 2010 for the Kapoor Warrants was estimated using a Black-Scholes valuation model with the fair value per warrant ranging from $2.49 to $2.50.  The expected volatility of the Kapoor Warrants was based on the historical volatility of the Company’s common stock. The expected life assumption was based on the remaining life of the Kapoor Warrants. The risk-free interest rate for the expected term of the Kapoor Warrants was based on the average market rate on U.S. treasury securities in effect during the applicable quarter. The dividend yield reflected historical experience as well as future expectations over the expected term of the Kapoor Warrants.
	The assumptions used in estimating the fair value of the warrants at June 28, 2010 were as follows:
	Expected Volatility	79.70%
	Expected Life (in years)	3.8 – 4.1
	Risk-free interest rate	1.80%
	Dividend yield	-
	The following table provides summarized information about the Kapoor Warrants as of December 31, 2013:
				Warrants			Exercise			Book Value
	Granted To:	Grant Date		Granted			Price			($000s)
	EJ Funds	Apr.13, 2009			1,939,639		$	1.11		$	4,829
	Kapoor Trust	Apr.13, 2009			1,501,933		$	1.11			3,740
	EJ Funds	Aug.17, 2009			1,650,806		$	1.16			4,127
	Kapoor Trust	Aug.17, 2009			2,099,935		$	1.16			5,250
					7,192,313					$	17,946
Stock-Based Compensation	'
	Stock-Based Compensation: Stock-based compensation cost is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period. The Company uses the Black-Scholes model for estimating the fair value of stock options. Determining the assumptions that enter into the model is highly subjective and requires judgment. The Company uses an expected volatility that is based on the historical volatility of its stock. The expected life assumption is based on historical employee exercise patterns and employee post-vesting termination behavior. The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. treasury securities in effect during the quarter in which the options were granted. The dividend yield reflects historical experience as well as future expectations over the expected term of the option. The Company estimates forfeitures at the time of grant and revises in subsequent periods, if necessary, if actual forfeitures differ from those estimates.
Warranty Liability	'
	Warranty Liability: The product warranty liability relates to a ten year expiration guarantee on DTPA Products sold to the United States Department of Health and Human Services (“HHS”) in 2006. The Company had been performing yearly stability studies for the DTPA Products and, if the annual stability did not support the ten-year product life, it would replace the product at no charge. The Company’s supplier, Hameln Pharmaceuticals (“Hameln”), was to share one-half of this cost if the product did not meet the stability requirement.  During 2013, the Company and Hameln agreed to settle the remaining obligations under this arrangement.  Pursuant to the settlement, the Company was released from its remaining obligations with regard to product stability testing.  Once this occurred, the Company reversed its product warranty reserve balance against cost of sales.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Summary of Significant Accounting Policies [Abstract]	'
Historical percentages of chargeback	'
	Set forth below are the Company’s historical estimates of the percentage of sales that are subject to chargebacks that were used during each quarterly period in the three years ended December 31, 2013:
	Year			Q1			Q2			Q3				Q4
	2013			90.00%			90.00%			90.00%				90.00%
	2012			98.50%			98.50%			95.00%				90.00%
	2011			98.50%			98.50%			98.50%				98.50%
Changes in goodwill	'
	Changes in goodwill during the two years ended December 31, 2013 were as follows (in thousands):
			Goodwill
	31-Dec-11		$	11,863
	Acquisitions			22,613
	Impairments		-
	Foreign currency translation			(2,317	)
	31-Dec-12		$	32,159
	Acquisitions		-
	Impairments		-
	Foreign currency translation			(2,328	)
	31-Dec-13		$	29,831
Major categories of intangible assets and weighted-average remaining amortization period	'
	The following table sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of December 31, 2013 for those assets that are not already fully amortized (dollar amounts in thousands):
			Gross			Accumulated			Net			Weighted Average
			Carrying			Amortization			Carrying			Remaining
			Amount						Amount			Amortization Period
	Product licensing rights		$	151,504		$	(35,604	)	$	115,900		9.8 years
	Trademarks			9,500			(844	)		8,656		27.4 years
	Customer relationships			6,166			(1,528	)		4,638		9.8 years
	Non-Compete			2,428			(1,117	)		1,311		2.2 years
			$	169,598		$	(39,093	)	$	130,505
Changes in intangible assets	'
	Changes in intangible assets during the two years ended December 31, 2013 were as follows (in thousands):
			Product			Trademarks			Customer				Non-Compete
			licensing rights						Relationships				Agreements
	31-Dec-11		$	67,822			$9,289		$	3,727			$	-
	Acquisitions			1,100			-			2,560				2,743
	Amortization			(5,268	)		(317	)		(705	)			(580	)
	Foreign currency translation		-			-				6				8
	31-Dec-12		$	63,654		$	8,972		$	5,588			$	2,171
	Acquisitions			57,969		-			-				-
	Amortization			(5,723	)		(316	)		(740	)			(643	)
	Foreign currency translation		-			-				(210	)			(217	)
	31-Dec-13		$	115,900		$	8,656		$	4,638			$	1,311
Amortization expense of acquired intangible assets	'
	The amortization expense of acquired intangible assets for each of the following five years will be as follows (in thousands):
	Year ending		Amortization Expense
	December 31,
	2014		$	15,996
	2015			15,388
	2016			14,862
	2017			14,345
	2018			14,262
Average estimated useful lives of property, plant and equipment	'
	The following table sets forth the average estimated useful lives of the Company’s property, plant and equipment, by asset category:
	Asset category		Depreciable Life
	Buildings		30 years
	Leasehold improvements		18 years
	Furniture and equipment		10 years
	Automobiles		5 years
	Computer hardware and software		5 years
Summary used to measure fair values of financial instruments	'
	The following table summarizes the basis used to measure the fair values of the company’s financial instruments (amounts in thousands):
						Fair Value Measurements at Reporting Date, Using:
						Quoted Prices			Significant
						in Active			Other				Significant
						Markets for			Observable				Unobservable
			December 31,			Identical Items			Inputs				Inputs
	Description		2013			(Level 1)			(Level 2)				(Level 3)
	Cash and cash equivalents		$	34,178		$	34,178		$	-			$	-
	Foreign currency forward contracts			208			-			208				-
	Total assets		$	34,386		$	34,178		$	208			$	-
	Purchase consideration payable		$	14,728		$	-		$	-			$	14,728
	Total liabilities		$	14,728		$	-		$	-			$	14,728
						Quoted Prices			Significant
						in Active			Other				Significant
						Markets for			Observable				Unobservable
			December 31,			Identical Items			Inputs				Inputs
	Description		2012			(Level 1)			(Level 2)				(Level 3)
	Cash and cash equivalents		$	40,781		$	40,781		$	-			$	-
	Total assets		$	40,781		$	40,781		$	-			$	-
	Purchase consideration payable		$	14,208		$	-		$	-			$	14,208
	Total liabilities		$	14,208		$	-		$	-			$	14,208
Assumptions used in estimating fair value of warrants	'
	The assumptions used in estimating the fair value of the warrants at June 28, 2010 were as follows:
	Expected Volatility	79.70%
	Expected Life (in years)	3.8 – 4.1
	Risk-free interest rate	1.80%
	Dividend yield	-
Warrants	'
	The following table provides summarized information about the Kapoor Warrants as of December 31, 2013:
				Warrants			Exercise			Book Value
	Granted To:	Grant Date		Granted			Price			($000s)
	EJ Funds	Apr.13, 2009			1,939,639		$	1.11		$	4,829
	Kapoor Trust	Apr.13, 2009			1,501,933		$	1.11			3,740
	EJ Funds	Aug.17, 2009			1,650,806		$	1.16			4,127
	Kapoor Trust	Aug.17, 2009			2,099,935		$	1.16			5,250
					7,192,313					$	17,946

Allowance_for_Customer_Deducti1

Allowance for Customer Deductions (Tables)	12 Months Ended
	Dec. 31, 2013
Allowance for Customer Deductions [Abstract]	'
Activity in Allowance for Customer Deductions Accounts	'
	The annual activity in the Company’s allowance for customer deductions accounts for the three years ended December 31, 2013 is as follows (in thousands):
		Returns			Chargebacks			Discounts			Doubtful			Advert. &			TOTAL
					& Rebates						Accounts			Promotions
	Balance at December 31, 2010	$	3,463		$	2,522		$	345		$	3		$	-		$	6,333
	Provision		2,687			68,067			3,431			25			1,135			75,345
	Additions from business combinations		1,845			-			50			187			132			2,214
	Charges processed		(1,149	)		(64,640	)		(3,083	)		(116	)		(881	)		(69,869	)
	Balance at December 31, 2011		6,846			5,949			743			99			386			14,023
	Provision		3,783			112,243			6,074			(82	)		2,063			124,081
	Charges processed		(2,220	)		(104,740	)		(5,455	)		13			(1,864	)		(114,266	)
	Balance at December 31, 2012		8,409			13,452			1,362			30			585			23,838
	Provision		5,001			183,403			8,464			(5	)		4,524			201,387
	Charges processed		(5,246	)		(183,973	)		(8,182	)		—			(4,657	)		(202,058	)
	Balance at December 31, 2013	$	8,164		$	12,882		$	1,644		$	25		$	452		$	23,167

Inventories_Tables

Inventories (Tables)	12 Months Ended
	Dec. 31, 2013
Inventories [Abstract]	'
Inventory	'
	The components of inventories, net of allowances, are as follows (in thousands):
		December 31,
		2013			2012
	Finished goods	$	22,886		$	24,657
	Work in process		3,883			3,743
	Raw materials and supplies		29,213			24,095
		$	55,982		$	52,495
Summary of allowance for excess and obsolete inventory account	'
	The activity in the allowance for excess and obsolete inventory account for the three years ended December 31, 2013 was as follows (in thousands):
		Years Ended December 31,
		2013			2012			2011
	Balance at beginning of year	$	2,244		$	1,239		$	1,612
	Provision		2,089			2,385			598
	Charges		(1,383	)		(1,380	)		(971	)
	Balance at end of year	$	2,950		$	2,244		$	1,239

Property_Plant_and_Equipment_T

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment	'
	Property, plant and equipment consist of the following (in thousands):
		December 31,
		2013			2012
	Land	$	2,606		$	2,715
	Buildings and leasehold improvements		46,281			43,190
	Furniture and equipment		76,536			70,874
			125,423			116,779
	Accumulated depreciation		(54,470	)		(47,635	)
			70,953			69,144
	Construction in progress		11,155			11,535
		$	82,108		$	80,679

Financing_Arrangements_Tables

Financing Arrangements (Tables)	12 Months Ended
	Dec. 31, 2013
Financing Arrangements [Abstract]	'
Carrying Amount of Liability Component and Remaining Unamortized Debt Discount	'
	At the dates indicated, the net carrying amount of the liability component and the remaining unamortized debt discount were as follows (in thousands):
		December 31,
		2013		2012
	Carrying amount of equity component	$	20,470		20,470
	Carrying amount of the liability component		108,750		104,637
	Unamortized discount of the liability component		11,250		15,363
	Unamortized debt financing costs		2,034		2,778
Expenses in Relation to Convertible Notes	'
	During the years ended December 31, 2013, 2012 and 2011, the Company recorded the following expenses in relation to the Notes (in thousands):
		2013		2012		2011
	Interest expense at 3.50% coupon rate	$	4,200	$	4,200	$	2,450
	Debt discount amortization		4,113		3,828		2,109
	Deferred financing cost amortization		744		692		382
		$	9,057	$	8,720	$	4,941

Earnings_per_Common_Share_Tabl

Earnings per Common Share (Tables)	12 Months Ended
	Dec. 31, 2013
Earnings per Common Share [Abstract]	'
Reconciliation of earnings per share data	'
	A reconciliation of the earnings per share data from a basic to a fully diluted basis is detailed below (amounts in thousands, except per share data):
		2013		2012		2011
	Net income	$	52,362	$	35,378	$	43,013
	Net income per share:
	Basic	$	0.54	$	0.37	$	0.45
	Diluted	$	0.46	$	0.32	$	0.41
	Shares used in computing net income per share:
	Weighted average basic shares outstanding		96,181		95,189		94,549
	Dilutive securities:
	Stock options and unvested RSAs		4,516		4,289		3,281
	Stock warrants		6,702		6,564		6,082
	Shares issuable on conversion of the Notes		6,499		4,468		—
	Total dilutive securities		17,717		15,321		9,363
	Weighted average diluted shares outstanding		113,898		110,510		103,912

Leasing_Arrangements_Tables

Leasing Arrangements (Tables)	12 Months Ended
	Dec. 31, 2013
Leasing Arrangements [Abstract]	'
Future Minimum Rental Payments Under Non-cancelable Operating and Capital Leases	'
	The following is a schedule, by year, of future minimum rental payments required under non-cancelable operating and capital leases in place as of December 31, 2013 (in thousands):
	Year ending December 31,
	2014	$	1,973
	2015		1,970
	2016		2,000
	2017		1,791
	2018		529
	2019 and thereafter		340
	Total	$	8,603

Stock_Options_Employee_Stock_P1

Stock Options, Employee Stock Purchase Plan and Restricted Stock (Tables)	12 Months Ended
	Dec. 31, 2013
Stock Options, Employee Stock Purchase Plan and Restricted Stock [Abstract]	'
Weighted-Average Assumptions Used in Estimating Grant Date Fair Value Of Stock Options Granted	'
	The assumptions used in estimating the fair value of the stock options granted during the period, along with the weighted-average grant date fair values, were as follows:
		2013			2012			2011
	Expected Volatility		49%-68	%		77% -85	%		75% - 76	%
	Expected Life (in years)		4			4			3.8
	Risk-free interest rate		0.7% - 1.4	%		0.7% - 0.8	%		1.3% - 2.0	%
	Dividend yield		-			-			-
	Fair value per stock option	$	6.95		$	7.76		$	3.71
Summary of Stock Option Activity	'
	A summary of stock option activity within the Company’s stock-based compensation plans for the years ended December 31, 2013, 2012 and 2011 is as follows:
		Number of						Weighted Average			Aggregate
		Shares			Weighted			Remaining			Intrinsic Value
		(in thousands)			Average			Contractual Term
					Exercise Price			(Years)
	Outstanding at December 31, 2010		7,960		$	1.87
	Granted		2,030			6.63
	Exercised		(454	)		1.93
	Forfeited		(137	)		2.3
	Outstanding at December 31, 2011		9,399			2.89
	Granted		1,221			12.96
	Exercised		(806	)		1.87
	Forfeited		(87	)		4.42
	Outstanding at December 31, 2012		9,727			4.22
	Granted		321			15.76
	Exercised		(630	)		4.18
	Forfeited		(190	)		13.1
	Outstanding at December 31, 2013		9,228		$	4.45			1.61			186,169,000
	Exercisable at December 31, 2013		7,594		$	3.02			1.27			164,018,000
Non-Vested Restricted Stock Activity	'
	The following is a summary of non-vested restricted stock activity:
		Number of Shares			Weighted Average
		(in thousands)			Grant Date Fair Value
	Nonvested at December 31, 2010		28		$	1.89
	Granted		-			-
	Vested		(15	)		2.34
	Canceled		-			-
	Nonvested at December 31, 2011		13		$	1.34
	Granted		35			14.63
	Vested		(30	)		9.09
	Canceled		-			-
	Nonvested at December 31, 2012		18		$	14.63
	Granted		32			15.36
	Vested		(34	)		14.98
	Canceled		-			-
	Nonvested at December 31, 2013		16		$	15.36

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Taxes [Abstract]	'
Income Tax Provision (Benefit)	'
	The income tax provision (benefit) consisted of the following (in thousands):
		Current			Deferred			Total
	Year ended December 31, 2013
	Federal	$	27,985		$	(3,050	)	$	24,935
	State		4,145			2,051			6,196
	Foreign		-			(598	)		(598	)
		$	32,130		$	(1,597	)	$	30,533
	Year ended December 31, 2012
	Federal	$	20,843		$	(504	)	$	20,339
	State		4,232			(911	)		3,321
	Foreign		-			(1,538	)		(1,538	)
		$	25,075		$	(2,953	)	$	22,122
	Year ended December 31, 2011
	Federal	$	-		$	(460	)	$	(460	)
	State		2,704			(3,951	)		(1,247	)
		$	2,704		$	(4,411	)	$	(1,707	)
Schedule of Income Tax Reconciliation	'
	Income tax expense differs from the “expected” tax expense (benefit) computed by applying the U.S. Federal corporate income tax rates of 35% to income before income taxes, as follows (in thousands):
		Years Ended December 31,
		2013			2012			2011
	Computed “expected” tax expense	$	29,013		$	20,125		$	14,457
	Change in income taxes resulting from:
	State income taxes, net of federal income tax		4,027			2,159			2,217
	Foreign income tax expense (benefit)		622			1,468			-
	Deduction for domestic production activities		(1,361	)		(1,277	)		-
	R&D tax credits		(1,652	)		(508	)
	Other, net		(116	)		155			(876	)
	Valuation allowance change		-			-			(17,505	)
	Income tax expense (benefit)	$	30,533		$	22,122		$	(1,707	)
Geographical Allocation of Entity's Income Before Income Taxes	'
	The geographical allocation of the Company’s income before income taxes between U.S. and foreign operations was as follows (in thousands):
		2013			2012			2011
	Pre-tax income from U.S. operations	$	86,382		$	66,087		$	41,306
	Pre-tax loss from foreign operations		(3,487	)		(8,587	)		—
	Total pre-tax income	$	82,895		$	57,500		$	41,306
Net Deferred Income Taxes	'
	Net deferred income taxes at December 31, 2013 and 2012 include (in thousands):
		31-Dec-13						31-Dec-12
		Current			Noncurrent			Current			Noncurrent
	Deferred tax assets:
	Net operating loss carry-forward	$	439		$	14,061		$	-		$	4,328
	Stock-based compensation		-			6,630			-			4,912
	Reserve for product returns		3,189			-			2,787			-
	Inventory valuation reserve		2,193			-			3,980			-
	Other		3,325			1,751			2,974			1,349
	Total deferred tax assets		9,146			22,442			9,741			10,589
	Deferred tax liabilities:
	Prepaid expenses		(1,120	)		-			(551	)		-
	Unamortized discount – convertible notes		-			(4,223	)		-			(5,815	)
	Depreciation & amortization – tax over book		-			(16,576	)		-			(5,835	)
	Other		(81	)		-			-			-
	Total deferred tax liabilities		(1,201	)		(20,799	)		(551	)		(11,650	)
	Net deferred income tax asset (liability)	$	7,945		$	1,643		$	9,190		$	(1,061	)
Summary of Unrecognized Tax Benefits	'
	Based on its reviews as of and for the years ended December 31, 2012 and December 31, 2013, the Company determined that it would not recognize tax benefits as follows (in thousands):
	Balance at December 31, 2011	$	-
	Additions relating to current year		1,265
	Additions relating to prior years		220
	Balance at December 31, 2012	$	1,485
	Additions relating to current year		589
	Terminations of exposures relating to prior years		(1,229	)
	Balance at December 31, 2013	$	845

Segment_Information_Tables

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2013
Segment Information [Abstract]	'
Selected Financial Information by Segment	'
	Selected financial information by segment is presented below (in thousands):
		Years ended December 31,
		2013		2012		2011
	REVENUES
	Hospital drugs & injectables	$	179,625	$	129,723	$	55,077
	Ophthalmic		114,515		103,765		68,591
	Contract services		23,571		22,670		13,252
	Total revenues	$	317,711	$	256,158	$	136,920
	GROSS PROFIT
	Hospital drugs & injectables	$	104,473	$	83,413	$	30,057
	Ophthalmic		63,481		58,785		43,054
	Contract services		3,950		6,494		6,578
	Total gross profit	$	171,904	$	148,692	$	79,689
Carrying Amount of Goodwill by Segment	'
	The carrying amounts of goodwill by segment were as follows (in thousands):
		December 31,
	Goodwill:	2013		2012
	Ophthalmic segment	$	11,863	$	11,863
	Contract services segment		17,968		20,296
	Total	$	29,831	$	32,159

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies [Abstract]	'
Contingent Potential Milestone Payments to Strategic Business Partners	'
	The table below summarizes contingent potential milestone payments due to strategic partners in the years 2014 and beyond, assuming all such contingencies occur (in thousands):
	Year ending	Milestone
	December 31,	Payments
	2014	$	4,524
	2015		598
	2016		200
	Total	$	5,322

Supplemental_Cash_Flow_Informa1

Supplemental Cash Flow Information (Tables)	12 Months Ended
	Dec. 31, 2013
Supplemental Cash Flow Information [ Abstract]	'
Supplemental Cash Flow Information	'
		Year ended December 31,
		2013		2012		2011
	Leasehold improvements funded by lessor	$	-	$	-	$	22
	Interest and taxes paid:
	Interest paid		4,320		4,200		2,125
	Income taxes paid		27,450		21,455		2,778

Business_Combinations_and_Othe1

Business Combinations and Other Strategic Investments (Tables)	12 Months Ended
	Dec. 31, 2013
Merck Products Acquisition [Member]	'
Business Acquisition [Line Items]	'
Consideration Paid For Acquisition-Related Costs Incurred, and Fair Values of Assets Acquired and Liabilities Assumed	'
	The following table sets forth the consideration paid for the Merck Acquisition and the fair values of the assets acquired and the liabilities assumed (in thousands):
	Product rights:
	AzaSite	$	13,800
	Cosopt		21,600
	Cosopt PF		20,300
	Product rights total	$	55,700
	Prepaid expenses		48
	Deferred tax assets, net		759
	Total fair value of acquired assets	$	56,507
	Consideration paid	$	52,800
	Gain from bargain purchase	$	3,707
Kilitch Drugs (India) Limited [Member]	'
Business Acquisition [Line Items]	'
Consideration Paid For Acquisition-Related Costs Incurred, and Fair Values of Assets Acquired and Liabilities Assumed	'
	The following table sets forth the consideration paid for the Kilitch Acquisition, the acquisition-related costs incurred, and the fair values of the assets acquired and the liabilities assumed (U.S. dollar amounts in thousands):
	Consideration:	Initial Fair Valuation			Changes in Estimate			Adjusted Fair Valuation
	Cash paid	$	55,224					$	55,224
	Less working capital shortfall refunded by sellers		(890	)		(138	)		(1,028	)
		$	54,334		$	(138	)	$	54,196
	Acquisition-related costs:
	Stamp duties paid for transfer of land and buildings	$	1,583					$	1,583
	Acquisition-related compensation expense		6,741			511			7,252
	Due diligence, legal, travel and other acquisition-related costs		557			119			676
		$	8,881		$	630		$	9,511
	Recognized amounts of identifiable assets acquired and liabilities assumed:
	Accounts receivable	$	2,130					$	2,130
	Inventory		1,799						1,799
	Land		3,714			(1,131	)		2,583
	Buildings, plant and equipment		8,474						8,474
	Construction in progress		14,231						14,231
	Goodwill, deductible		21,609			1,004			22,613
	Other intangible assets, deductible		5,806			102			5,908
	Other assets		38						38
	Assumed liabilities		(2,099	)		(779	)		(2,878	)
	Deferred tax liabilities		(1,368	)		666			(702	)
		$	54,334		$	(138	)	$	54,196
H. Lundbeck AS [Member]	'
Business Acquisition [Line Items]	'
Consideration Paid For Acquisition-Related Costs Incurred, and Fair Values of Assets Acquired and Liabilities Assumed	'
	The following table sets forth the consideration paid related to the Lundbeck Acquisition, the total acquisition-related costs incurred by the Company, and the fair values of the assets acquired and the liabilities assumed (in thousands):
		Initial Fair			Change in			Adjusted
		Value			Estimate			Fair Value
	Consideration:
	Cash paid	$	49,559					$	49,559
	Present value of contingent consideration		11,300			300			11,600
	Total consideration	$	60,859		$	300		$	61,159
	Acquisition-related costs:	$	50					$	50
	Recognized amounts of identifiable assets acquired and liabilities assumed:
	Product licensing rights	$	59,525		$	300		$	59,825
	Inventory		3,825						3,825
	Fixed assets		50						50
	Assumed liability – unfavorable contract		(2,541	)					(2,541	)
		$	60,859		$	300		$	61,159
Advanced Vision Research, Inc. [Member]	'
Business Acquisition [Line Items]	'
Consideration Paid For Acquisition-Related Costs Incurred, and Fair Values of Assets Acquired and Liabilities Assumed	'
	The following table summarizes the consideration paid for AVR, the total acquisition-related costs incurred by the Company during 2011 in connection with the acquisition, and the fair values of the assets acquired and liabilities assumed (amounts in thousands):
	Consideration:
	Cash paid at closing	$	26,011
	Additional consideration paid		723
	Fair value of total consideration transferred	$	26,734
	Acquisition-related costs:	$	246
	Recognized amounts of identifiable assets acquired and liabilities assumed:
	Accounts receivable, net	$	611
	Inventories, net		3,407
	Prepaid expenses and other current assets		730
	Property and equipment		250
	Goodwill, deductible		11,863
	Trademarks and technology		9,500
	Customer relationships		3,900
	Estimated additional consideration due		(181	)
	Accounts payable & other assumed liabilities		(3,346	)
		$	26,734

Unconsolidated_Joint_Venture_T

Unconsolidated Joint Venture (Tables)	12 Months Ended
	Dec. 31, 2013
Unconsolidated Joint Venture [Abstract]	'
Joint Venture Investment Summarized Financial Information	'
	The following tables sets forth a condensed statements of income for the three years ended December 31, 2013 and condensed balance sheets as of December 31, 2013 and 2012 for Akorn-Strides, LLC, along with information regarding the amount of earnings allocated to each member-partner of the LLC (in thousands):
	CONDENSED STATEMENTS OF INCOME
		(Unaudited)
		Year ended December 31,
		2013			2012		2011
	REVENUES	$	163		$	-	$	6,364
	Cost of sales		(1	)		-		3,562
	GROSS PROFIT		164			-		2,802
	Operating expenses		3			-		499
	OPERATING INCOME		161			-		2,303
	Gain from Pfizer ANDA Sale		-			-		24,160
	INCOME BEFORE INCOME TAXES		161			-		26,463
	Income tax (benefit) / provision		-			-		(38	)
	NET INCOME	$	161		$	-	$	26,501
	CONDENSED BALANCE SHEETS
		(Unaudited)
		December 31,
		2013			2012
	ASSETS
	Cash	$	25		$	794
	Other current assets		1
	TOTAL ASSETS	$	26		$	794
	LIABILITIES & MEMBERS’ EQUITY (DEFICIT)
	Trade accounts payable & other accrued liabilities	$	-		$	431
	TOTAL LIABILITIES	-				431
	Members’ equity		26			363
	TOTAL LIABILITIES & MEMBERS’ EQUITY (DEFICIT)	$	26		$	794

Customer_Supplier_and_Product_1

Customer, Supplier and Product Concentration (Tables)	12 Months Ended
	Dec. 31, 2013
Customer, Supplier and Product Concentration [Abstract]	'
Company's Gross and Net Sales and Gross Accounts Receivable	'
	The following table sets forth the percentage of the Company’s gross and net sales and gross accounts receivable attributable to these three distributors for the periods indicated:
		2013									2012									2011
								Gross									Gross									Gross
		Gross			Net			Accounts			Gross			Net			Accounts			Gross			Net			Accounts
		Sales			Revenue			Receivable			Sales			Revenue			Receivable			Sales			Revenue			Receivable
	Amerisource		19	%		14	%		25	%		19	%		14	%		29	%		23	%		23	%		29	%
	Cardinal		23	%		16	%		26	%		23	%		17	%		30	%		27	%		25	%		34	%
	McKesson		16	%		11	%		12	%		16	%		11	%		14	%		16	%		15	%		9	%
	Total		58	%		41	%		63	%		58	%		42	%		73	%		66	%		63	%		72	%

Selected_Quarterly_Financial_D1

Selected Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2013
Selected Quarterly Financial Data (Unaudited) [Abstract]	'
Selected Quarterly Financial Data (Unaudited)	'
								Consolidated Net Income
				Gross		Operating				Per Basic		Per Diluted
	(In thousands, except per share amounts)	Revenues		Profit		Income		Amount		Share		Share
	Year Ended December 31, 2013:
	4th Quarter	$	84,953	$	46,970	$	25,176	$	16,678	$	0.17	$	0.14
	3rd Quarter		81,892		43,697		22,188		12,205		0.13		0.11
	2nd Quarter		77,012		42,092		22,251		12,637		0.13		0.11
	1st Quarter		73,854		39,145		18,589		10,842		0.11		0.1
	Year Ended December 31, 2012:
	4th Quarter	$	71,520	$	41,971	$	19,715	$	8,811	$	0.09	$	0.08
	3rd Quarter		69,634		40,093		22,603		13,753		0.14		0.12
	2nd Quarter		63,287		35,727		18,776		9,706		0.1		0.09
	1st Quarter		51,717		30,901		7,662		3,108		0.03		0.03

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)

3 Months Ended

6 Months Ended

12 Months Ended

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2011

Sep. 30, 2011

Jun. 30, 2011

Mar. 31, 2011

Jun. 28, 2010

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Contract

Quarter

Summary of Significant Accounting Policies [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ownership interest in joint venture (in hundredths)

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

Restricted cash

$2,700,000

'

'

'

$3,200,000

'

'

'

'

'

'

'

'

$2,700,000

$3,200,000

'

'

Number of quarters in trend basis

'

'

'

'

'

'

'

'

'

'

'

'

'

6

'

'

'

Estimated % of wholesaler inventory that will be subject to contractual price agreements (in hundredths)

90.00%

90.00%

90.00%

90.00%

90.00%

95.00%

98.50%

98.50%

98.50%

98.50%

98.50%

98.50%

'

'

'

'

'

Chargeback and rebate expense

'

'

'

'

'

'

'

'

'

'

'

'

'

183,400,000

112,200,000

68,100,000

'

Allowance for chargebacks and rebates

12,900,000

'

'

'

13,500,000

'

'

'

'

'

'

'

'

12,900,000

13,500,000

'

'

Net expense for product returns

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

3,800,000

2,700,000

'

Allowance for potential product returns

'

'

'

'

'

'

'

'

'

'

'

'

'

8,200,000

8,400,000

'

'

Provisions for coupons and promotions

'

'

'

'

'

'

'

'

'

'

'

'

'

4,500,000

3,000,000

1,900,000

'

Reserve for coupons and promotions

700,000

'

'

'

800,000

'

'

'

'

'

'

'

'

700,000

800,000

'

'

Net provision for doubtful accounts

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

100,000

100,000

'

Past due gross accounts receivable

6,100,000

'

'

'

'

'

'

'

'

'

'

'

'

6,100,000

'

'

'

60 days past due gross accounts receivable

800,000

'

'

'

'

'

'

'

'

'

'

'

'

800,000

'

'

'

Provision for inventory obsolescence

'

'

'

'

'

'

'

'

'

'

'

'

'

2,100,000

2,400,000

600,000

'

Allowance for inventory obsolescence

2,950,000

'

'

'

2,244,000

'

'

'

1,239,000

'

'

'

'

2,950,000

2,244,000

1,239,000

1,612,000

Research and development inventory reserve

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

Reserve for inventory of products not yet FDA approved

'

'

'

'

800,000

'

'

'

'

'

'

'

'

'

800,000

'

'

Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization expense

'

'

'

'

'

'

'

'

'

'

'

'

'

7,422,000

6,870,000

1,733,000

'

Intangible assets and weighted-average remaining amortization period [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross Carrying Amount

169,598,000

'

'

'

'

'

'

'

'

'

'

'

'

169,598,000

'

'

'

Accumulated Amortization

-39,093,000

'

'

'

31,900,000

'

'

'

'

'

'

'

'

-39,093,000

31,900,000

'

'

Net Carrying Amount

130,505,000

'

'

'

'

'

'

'

'

'

'

'

'

130,505,000

'

'

'

Changes in intangible assets [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization

'

'

'

'

'

'

'

'

'

'

'

'

'

7,422,000

6,870,000

1,733,000

'

Ending Balance

130,505,000

'

'

'

'

'

'

'

'

'

'

'

'

130,505,000

'

'

'

Changes in goodwill [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Beginning Balance

'

'

'

32,159,000

'

'

'

11,863,000

'

'

'

'

'

32,159,000

11,863,000

'

'

Acquisitions

'

'

'

'

'

'

'

'

'

'

'

'

'

0

22,613,000

'

'

Impairments

0

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

Foreign currency translation

'

'

'

'

'

'

'

'

'

'

'

'

'

-2,328,000

-2,317,000

'

'

Ending Balance

29,831,000

'

'

'

32,159,000

'

'

'

11,863,000

'

'

'

'

29,831,000

32,159,000

11,863,000

'

Amortization expense of acquired intangible assets [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2014

15,996,000

'

'

'

'

'

'

'

'

'

'

'

'

15,996,000

'

'

'

2015

15,388,000

'

'

'

'

'

'

'

'

'

'

'

'

15,388,000

'

'

'

2016

14,862,000

'

'

'

'

'

'

'

'

'

'

'

'

14,862,000

'

'

'

2017

14,345,000

'

'

'

'

'

'

'

'

'

'

'

'

14,345,000

'

'

'

2018

14,262,000

'

'

'

'

'

'

'

'

'

'

'

'

14,262,000

'

'

'

Property, Plant and Equipment [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Depreciation

'

'

'

'

'

'

'

'

'

'

'

'

'

7,100,000

4,600,000

3,500,000

'

Anti-dilutive shares excluded from computation of diluted net income (loss) per share (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

975,000

581,000

1,560,000

'

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash and cash equivalents

34,178,000

'

'

'

40,781,000

'

'

'

'

'

'

'

'

34,178,000

40,781,000

'

'

Foreign currency forward contracts

208,000

'

'

'

'

'

'

'

'

'

'

'

'

208,000

'

'

'

Total assets

34,386,000

'

'

'

40,781,000

'

'

'

'

'

'

'

'

34,386,000

40,781,000

'

'

Purchase consideration payable

14,728,000

'

'

'

14,208,000

'

'

'

'

'

'

'

'

14,728,000

14,208,000

'

'

Total liabilities

14,728,000

'

'

'

14,208,000

'

'

'

'

'

'

'

'

14,728,000

14,208,000

'

'

Underlying obligation of purchase consideration

'

'

'

'

'

'

'

'

15,000,000

'

'

'

'

'

'

15,000,000

'

Initial value of purchase consideration

'

'

'

'

'

'

'

'

11,300,000

'

'

'

'

'

'

11,300,000

'

Original discount rate used (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

Corrected value of long term obligation

'

'

'

'

'

'

'

'

'

'

'

'

'

14,700,000

14,200,000

11,600,000

'

Assumed discount rate (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

'

9.00%

'

'

'

Discount rate (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

'

1.85%

2.75%

'

'

Non-cash interest expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,600,000

'

'

Percentage of likelihood of purchase consideration becoming payable (in hundredths)

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

'

'

'

Number of non-deliverable forward contracts

'

'

'

'

'

'

'

'

'

'

'

'

'

3

'

'

'

Future anticipated investments

'

'

'

'

'

'

'

'

'

'

'

'

'

3,300,000

'

'

'

Long-term investments

10,006,000

'

'

'

10,299,000

'

'

'

'

'

'

'

'

10,006,000

10,299,000

'

'

Purchase consideration payable, current

14,728,000

'

'

'

0

'

'

'

'

'

'

'

'

14,728,000

0

'

'

Class of Warrant or Right [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Original fair value of warrant

'

'

'

'

'

'

'

'

'

'

'

'

17,900,000

'

'

'

'

Assumptions used in estimating fair value of warrants [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected Volatility (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

79.70%

'

'

'

'

Risk-free interest rate (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

1.80%

'

'

'

'

Dividend yield (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

'

'

'

'

Warrants Granted (in shares)

7,192,313

'

'

'

'

'

'

'

'

'

'

'

'

7,192,313

'

'

'

Fair Value

17,946,000

'

'

'

'

'

'

'

'

'

'

'

'

17,946,000

'

'

'

Product warranty expiration period

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

Modification Warrants [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Assumptions used in estimating fair value of warrants [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Grant Date

'

'

'

'

'

'

'

'

'

'

'

'

'

13-Apr-09

'

'

'

Warrants Granted (in shares)

1,939,639

'

'

'

'

'

'

'

'

'

'

'

'

1,939,639

'

'

'

Exercise price (in dollars per share)

$1.11

'

'

'

'

'

'

'

'

'

'

'

'

$1.11

'

'

'

Fair Value

4,829,000

'

'

'

'

'

'

'

'

'

'

'

'

4,829,000

'

'

'

Reimbursement Warrants [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Assumptions used in estimating fair value of warrants [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Grant Date

'

'

'

'

'

'

'

'

'

'

'

'

'

13-Apr-09

'

'

'

Warrants Granted (in shares)

1,501,933

'

'

'

'

'

'

'

'

'

'

'

'

1,501,933

'

'

'

Exercise price (in dollars per share)

$1.11

'

'

'

'

'

'

'

'

'

'

'

'

$1.11

'

'

'

Fair Value

3,740,000

'

'

'

'

'

'

'

'

'

'

'

'

3,740,000

'

'

'

Credit Facility Warrants [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Assumptions used in estimating fair value of warrants [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Grant Date

'

'

'

'

'

'

'

'

'

'

'

'

'

17-Aug-09

'

'

'

Warrants Granted (in shares)

1,650,806

'

'

'

'

'

'

'

'

'

'

'

'

1,650,806

'

'

'

Exercise price (in dollars per share)

$1.16

'

'

'

'

'

'

'

'

'

'

'

'

$1.16

'

'

'

Fair Value

4,127,000

'

'

'

'

'

'

'

'

'

'

'

'

4,127,000

'

'

'

Subordinated Note Warrants [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Assumptions used in estimating fair value of warrants [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Grant Date

'

'

'

'

'

'

'

'

'

'

'

'

'

17-Aug-09

'

'

'

Warrants Granted (in shares)

2,099,935

'

'

'

'

'

'

'

'

'

'

'

'

2,099,935

'

'

'

Exercise price (in dollars per share)

$1.16

'

'

'

'

'

'

'

'

'

'

'

'

$1.16

'

'

'

Fair Value

5,250,000

'

'

'

'

'

'

'

'

'

'

'

'

5,250,000

'

'

'

Kapoor Warrants [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrants using Black-Scholes valuation model, minimum (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

$2.49

'

'

'

'

Fair value of warrants using Black-Scholes valuation model, maximum (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

$2.50

'

'

'

'

Forward Contracts [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of forward contract

200,000

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

'

Quoted Prices in Active Markets for Identical Items (Level 1) [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash and cash equivalents

34,178,000

'

'

'

40,781,000

'

'

'

'

'

'

'

'

34,178,000

40,781,000

'

'

Foreign currency forward contracts

0

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

Total assets

34,178,000

'

'

'

40,781,000

'

'

'

'

'

'

'

'

34,178,000

40,781,000

'

'

Purchase consideration payable

0

'

'

'

0

'

'

'

'

'

'

'

'

0

0

'

'

Total liabilities

0

'

'

'

0

'

'

'

'

'

'

'

'

0

0

'

'

Significant Other Observable Inputs (Level 2) [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash and cash equivalents

0

'

'

'

0

'

'

'

'

'

'

'

'

0

0

'

'

Foreign currency forward contracts

208,000

'

'

'

'

'

'

'

'

'

'

'

'

208,000

'

'

'

Total assets

208,000

'

'

'

0

'

'

'

'

'

'

'

'

208,000

0

'

'

Purchase consideration payable

0

'

'

'

0

'

'

'

'

'

'

'

'

0

0

'

'

Total liabilities

0

'

'

'

0

'

'

'

'

'

'

'

'

0

0

'

'

Significant Unobservable Inputs (Level 3) [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash and cash equivalents

0

'

'

'

0

'

'

'

'

'

'

'

'

0

0

'

'

Foreign currency forward contracts

0

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

Total assets

0

'

'

'

0

'

'

'

'

'

'

'

'

0

0

'

'

Purchase consideration payable

14,728,000

'

'

'

14,208,000

'

'

'

'

'

'

'

'

14,728,000

14,208,000

'

'

Total liabilities

14,728,000

'

'

'

14,208,000

'

'

'

'

'

'

'

'

14,728,000

14,208,000

'

'

Buildings [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Property, Plant and Equipment [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Depreciable Life

'

'

'

'

'

'

'

'

'

'

'

'

'

'30 years

'

'

'

Leasehold Improvements [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Property, Plant and Equipment [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Depreciable Life

'

'

'

'

'

'

'

'

'

'

'

'

'

'18 years

'

'

'

Furniture and Equipment [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Property, Plant and Equipment [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Depreciable Life

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

Automobiles [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Property, Plant and Equipment [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Depreciable Life

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

Computer Hardware and Software [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Property, Plant and Equipment [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Depreciable Life

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

Minimum [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Useful lives of intangible assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'4 years

'

'

'

Assumptions used in estimating fair value of warrants [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected Life (in years)

'

'

'

'

'

'

'

'

'

'

'

'

'3 years 9 months 18 days

'

'

'

'

Maximum [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Useful lives of intangible assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'30 years

'

'

'

Assumptions used in estimating fair value of warrants [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected Life (in years)

'

'

'

'

'

'

'

'

'

'

'

'

'4 years 1 month 6 days

'

'

'

'

Product Licensing Rights [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization expense

'

'

'

'

'

'

'

'

'

'

'

'

'

-5,723,000

-5,268,000

'

'

Intangible assets and weighted-average remaining amortization period [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross Carrying Amount

151,504,000

'

'

'

'

'

'

'

'

'

'

'

'

151,504,000

'

'

'

Accumulated Amortization

-35,604,000

'

'

'

'

'

'

'

'

'

'

'

'

-35,604,000

'

'

'

Net Carrying Amount

115,900,000

'

'

'

63,654,000

'

'

'

'

'

'

'

'

115,900,000

63,654,000

'

'

Weighted Average Remaining Amortization Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'9 years 9 months 18 days

'

'

'

Changes in intangible assets [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Beginning Balance

'

'

'

63,654,000

'

'

'

67,822,000

'

'

'

'

'

63,654,000

67,822,000

'

'

Acquisitions

'

'

'

'

'

'

'

'

'

'

'

'

'

57,969,000

1,100,000

'

'

Amortization

'

'

'

'

'

'

'

'

'

'

'

'

'

-5,723,000

-5,268,000

'

'

Foreign currency translation

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

Ending Balance

115,900,000

'

'

'

63,654,000

'

'

'

'

'

'

'

'

115,900,000

63,654,000

'

'

Trademarks [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization expense

'

'

'

'

'

'

'

'

'

'

'

'

'

-316,000

-317,000

'

'

Intangible assets and weighted-average remaining amortization period [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross Carrying Amount

9,500,000

'

'

'

'

'

'

'

'

'

'

'

'

9,500,000

'

'

'

Accumulated Amortization

-844,000

'

'

'

'

'

'

'

'

'

'

'

'

-844,000

'

'

'

Net Carrying Amount

8,656,000

'

'

'

8,972,000

'

'

'

'

'

'

'

'

8,656,000

8,972,000

'

'

Weighted Average Remaining Amortization Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'27 years 4 months 24 days

'

'

'

Changes in intangible assets [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Beginning Balance

'

'

'

8,972,000

'

'

'

9,289,000

'

'

'

'

'

8,972,000

9,289,000

'

'

Acquisitions

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

Amortization

'

'

'

'

'

'

'

'

'

'

'

'

'

-316,000

-317,000

'

'

Foreign currency translation

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

Ending Balance

8,656,000

'

'

'

8,972,000

'

'

'

'

'

'

'

'

8,656,000

8,972,000

'

'

Customer Relationships [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization expense

'

'

'

'

'

'

'

'

'

'

'

'

'

-740,000

-705,000

'

'

Intangible assets and weighted-average remaining amortization period [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross Carrying Amount

6,166,000

'

'

'

'

'

'

'

'

'

'

'

'

6,166,000

'

'

'

Accumulated Amortization

-1,528,000

'

'

'

'

'

'

'

'

'

'

'

'

-1,528,000

'

'

'

Net Carrying Amount

4,638,000

'

'

'

5,588,000

'

'

'

'

'

'

'

'

4,638,000

5,588,000

'

'

Weighted Average Remaining Amortization Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'9 years 9 months 18 days

'

'

'

Changes in intangible assets [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Beginning Balance

'

'

'

5,588,000

'

'

'

3,727,000

'

'

'

'

'

5,588,000

3,727,000

'

'

Acquisitions

'

'

'

'

'

'

'

'

'

'

'

'

'

0

2,560,000

'

'

Amortization

'

'

'

'

'

'

'

'

'

'

'

'

'

-740,000

-705,000

'

'

Foreign currency translation

'

'

'

'

'

'

'

'

'

'

'

'

'

-210,000

6,000

'

'

Ending Balance

4,638,000

'

'

'

5,588,000

'

'

'

'

'

'

'

'

4,638,000

5,588,000

'

'

Non-Compete [Member]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization expense

'

'

'

'

'

'

'

'

'

'

'

'

'

-643,000

-580,000

'

'

Intangible assets and weighted-average remaining amortization period [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross Carrying Amount

2,428,000

'

'

'

'

'

'

'

'

'

'

'

'

2,428,000

'

'

'

Accumulated Amortization

-1,117,000

'

'

'

'

'

'

'

'

'

'

'

'

-1,117,000

'

'

'

Net Carrying Amount

1,311,000

'

'

'

2,171,000

'

'

'

'

'

'

'

'

1,311,000

2,171,000

'

'

Weighted Average Remaining Amortization Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'2 years 2 months 12 days

'

'

'

Changes in intangible assets [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Beginning Balance

'

'

'

2,171,000

'

'

'

0

'

'

'

'

'

2,171,000

0

'

'

Acquisitions

'

'

'

'

'

'

'

'

'

'

'

'

'

0

2,743,000

'

'

Amortization

'

'

'

'

'

'

'

'

'

'

'

'

'

-643,000

-580,000

'

'

Foreign currency translation

'

'

'

'

'

'

'

'

'

'

'

'

'

-217,000

8,000

'

'

Ending Balance

$1,311,000

'

'

'

$2,171,000

'

'

'

'

'

'

'

'

$1,311,000

$2,171,000

'

'

Allowance_for_Customer_Deducti2

Allowance for Customer Deductions (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Valuation and Qualifying Accounts Disclosure [Line Items]	'	'	'
Balance at beginning of year	$23,838	$14,023	$6,333
Provision	201,387	124,081	75,345
Additions from business combinations	'	'	2,214
Charges processed	-202,058	-114,266	-69,869
Balance at end of year	23,167	23,838	14,023
Returns [Member]	'	'	'
Valuation and Qualifying Accounts Disclosure [Line Items]	'	'	'
Balance at beginning of year	8,409	6,846	3,463
Provision	5,001	3,783	2,687
Additions from business combinations	'	'	1,845
Charges processed	-5,246	-2,220	-1,149
Balance at end of year	8,164	8,409	6,846
Chargebacks & Rebates [Member]	'	'	'
Valuation and Qualifying Accounts Disclosure [Line Items]	'	'	'
Balance at beginning of year	13,452	5,949	2,522
Provision	183,403	112,243	68,067
Additions from business combinations	'	'	0
Charges processed	-183,973	-104,740	-64,640
Balance at end of year	12,882	13,452	5,949
Discounts [Member]	'	'	'
Valuation and Qualifying Accounts Disclosure [Line Items]	'	'	'
Balance at beginning of year	1,362	743	345
Provision	8,464	6,074	3,431
Additions from business combinations	'	'	50
Charges processed	-8,182	-5,455	-3,083
Balance at end of year	1,644	1,362	743
Doubtful Accounts [Member]	'	'	'
Valuation and Qualifying Accounts Disclosure [Line Items]	'	'	'
Balance at beginning of year	30	99	3
Provision	-5	-82	25
Additions from business combinations	'	'	187
Charges processed	0	13	-116
Balance at end of year	25	30	99
Advert. & Promotions [Member]	'	'	'
Valuation and Qualifying Accounts Disclosure [Line Items]	'	'	'
Balance at beginning of year	585	386	0
Provision	4,524	2,063	1,135
Additions from business combinations	'	'	132
Charges processed	-4,657	-1,864	-881
Balance at end of year	$452	$585	$386

Inventories_Details

Inventories (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Inventories [Abstract]	'	'	'
Finished goods	$22,886	$24,657	'
Work in process	3,883	3,743	'
Raw materials and supplies	29,213	24,095	'
Inventories, net	55,982	52,495	'
Allowance for excess and obsolete inventory [Roll Forward]	'	'	'
Balance at beginning of year	2,244	1,239	1,612
Provision	2,089	2,385	598
Charges	-1,383	-1,380	-971
Balance at end of year	$2,950	$2,244	$1,239

Property_Plant_and_Equipment_D

Property, Plant and Equipment (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	$125,423	$116,779
Accumulated depreciation	-54,470	-47,635
Property, plant and equipment, net	82,108	80,679
Outside United States [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, net	21,100	23,700
Land [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	2,606	2,715
Building and Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	46,281	43,190
Furniture and Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	76,536	70,874
Property, Plant and Equipment Placed in Service, Net [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, net	70,953	69,144
Construction in Progress [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	$11,155	$11,535

Financing_Arrangements_Details

Financing Arrangements (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Jun. 01, 2011
Convertible Notes [Abstract]	'	'	'	'
Carrying amount of the liability component	$108,750,000	$104,637,000	'	'
Deferred financing cost amortization	842,000	782,000	1,948,000	'
Convertible Senior Notes [Member]	'	'	'	'
Convertible Notes [Abstract]	'	'	'	'
Aggregate principal amount in debt offering	'	'	'	120,000,000
Interest rate (in hundredths)	3.50%	'	'	'
Aggregate principal amount of debt issued upon exercise by the buyers of their full over-allotment option	'	'	'	20,000,000
Net proceeds from the issuance of debt	'	'	115,300,000	'
Maturity date	1-Jun-16	'	'	'
Debt conversion price (in dollars per share)	$8.76	'	'	'
Debt conversion ratio	114.1553	'	'	'
Debt conversion ratio numerator	1,000	'	'	'
Notes Trading Price to Face Value (in hundredths)	284.00%	'	'	'
Fair market value of Convertible Notes	341,300,000	'	'	'
Closing price of common stock (in dollars per share)	$24.62	'	'	'
Pro forma debt instrument conversion amount	337,300,000	'	'	'
Terms of conversion feature	'The Notes may be converted at any time prior to the close of business on the business day immediately preceding December 1, 2015 only under the following circumstances:B B (1) during any calendar quarter commencing after September 30, 2011, if the closing sale price of the Companybs common stock, for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the calendar quarter immediately preceding the calendar quarter in which the conversion occurs, is more than 130% of the conversion price in effect on each applicable trading day; (2) during the five consecutive trading-day period following any five consecutive trading-day period in which the trading price for the Notes per $1,000 principal amount of Notes for each such trading day was less than 98% of the closing sale price of the Companybs common stock on such date multiplied by the then-current conversion rate; or (3) upon the occurrence of specified corporate events.	'	'	'
Required price of common stock for note convertibility (in dollars per share)	$11.39	'	'	'
Carrying amount of equity component	20,470,000	20,470,000	'	'
Carrying amount of the liability component	108,750,000	104,637,000	'	'
Unamortized discount of the liability component	11,250,000	15,363,000	'	'
Unamortized debt financing costs	2,034,000	2,778,000	'	'
Debt issuance costs	4,700,000	'	'	'
Debt issuance cost allocated to the liability component of debt	3,900,000	'	'	'
Debt issuance cost allocated to the equity component of debt	800,000	'	'	'
Coupon rate (in hundredths)	3.50%	3.50%	3.50%	'
Interest expense at 3.50% coupon rate	4,200,000	4,200,000	2,450,000	'
Debt discount amortization	4,113,000	3,828,000	2,109,000	'
Deferred financing cost amortization	744,000	692,000	382,000	'
Total expenses	9,057,000	8,720,000	4,941,000	'
Deferred tax liability	'	'	'	8,600,000
Debt discount	'	'	'	$21,300,000

Financing_Arrangements_Lines_o

Financing Arrangements, Lines of credit (Details) (USD $)

12 Months Ended

3 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Oct. 03, 2013

Mar. 31, 2009

Dec. 31, 2013

Dec. 31, 2011

Aug. 17, 2009

Apr. 13, 2009

Mar. 01, 2009

Feb. 19, 2009

Jan. 07, 2009

Dec. 31, 2013

Line of Credit [Member]

Line of Credit [Member]

Line of Credit [Member]

Line of Credit [Member]

Line of Credit [Member]

Line of Credit [Member]

Line of Credit [Member]

Line of Credit [Member]

Line of Credit [Member]

Line of Credit [Member]

Letter of Credit [Member]

Bank of America [Member]

Bank of America [Member]

EJ Funds, LP [Member]

EJ Funds, LP [Member]

EJ Funds, LP [Member]

EJ Funds, LP [Member]

EJ Funds, LP [Member]

EJ Funds, LP [Member]

EJ Funds, LP [Member]

EJ Funds, LP [Member]

Bank of America [Member]

Director

Line of Credit Facility [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Borrowing capacity

'

'

'

'

$20,000,000

'

'

'

$10,000,000

'

$25,000,000

'

$5,700,000

$2,000,000

Maximum borrowing capacity

'

'

'

60,000,000

'

'

'

'

'

'

'

'

'

'

Maturity date

'

'

'

1-Mar-16

'

'

'

'

'

'

'

'

'

'

Required notice of termination

'

'

'

'90 days

'

'

'

'

'

'

'

'

'

'

Basis spread on federal funds rate (in hundredths)

'

'

'

0.50%

'

'

'

'

'

'

'

'

'

'

Description of variable rate basis

'

'

'

'LIBOR

'

'

'

'

'

'

'

'

'

'

Basis spread on variable rate (in hundredths)

'

'

'

1.00%

'

'

'

'

'

'

'

'

'

'

Unused line fee (in hundredths)

'

'

'

0.25%

'

'

'

'

'

'

'

'

'

'

Letter of credit facility, commitment fee percentage (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

'

0.13%

Increase in fee during an event of default (in hundredths)

'

'

'

2.00%

'

'

'

'

'

'

'

'

'

2.00%

Percentage of respective equity interests in any foreign subsidiary (in hundredths)

'

'

'

65.00%

'

'

'

'

'

'

'

'

'

'

Fixed charge coverage ratio

'

'

'

1.1

'

'

'

'

'

'

'

'

'

'

Percentage of Lender's commitment (in hundredths)

'

'

'

15.00%

'

'

'

'

'

'

'

'

'

'

Borrowing availability

'

'

'

59,100,000

'

'

'

'

'

'

'

'

'

'

Outstanding amount

'

'

'

'

'

'

'

'

'

'

'

5,500,000

'

500,000

Interest rate (in hundredths)

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

Number of required Directors

'

'

'

'

'

'

2

'

'

'

'

'

'

'

Warrants granted (in shares)

'

'

'

'

'

'

'

'

1,650,806

1,939,639

'

'

'

'

Warrant exercise price (in dollars per share)

'

'

'

'

'

'

'

'

$1.16

$1.11

'

'

'

'

Expiration of warrant

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

Restatement warrants fair value

'

'

'

'

'

'

'

'

1,200,000

'

'

'

'

'

Other associated costs capitalized as financing costs

'

'

'

'

'

'

'

'

7,000

'

'

'

'

'

Unamortized deferred financing cost expensed

$842,000

$782,000

$1,948,000

'

'

'

'

$1,200,000

'

'

'

'

'

'

Earnings_per_Common_Share_Deta

Earnings per Common Share (Details) (USD $)	3 Months Ended								12 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Earnings per Common Share [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Conversion value of notes to invoke inclusion in dilutive securities incremental shares issuable	'	'	'	'	'	'	'	'	$1,000	'	'
Net income	$16,678,000	$12,205,000	$12,637,000	$10,842,000	$8,811,000	$13,753,000	$9,706,000	$3,108,000	$52,362,000	$35,378,000	$43,013,000
Net income per share [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Basic (in dollars per share)	$0.17	$0.13	$0.13	$0.11	$0.09	$0.14	$0.10	$0.03	$0.54	$0.37	$0.45
Diluted (in dollars per share)	$0.14	$0.11	$0.11	$0.10	$0.08	$0.12	$0.09	$0.03	$0.46	$0.32	$0.41
Shares used in computing net income per share [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Weighted average basic shares outstanding (in shares)	'	'	'	'	'	'	'	'	96,181	95,189	94,549
Dilutive securities [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Stock options and unvested RSAs (in shares)	'	'	'	'	'	'	'	'	4,516	4,289	3,281
Stock warrants (in shares)	'	'	'	'	'	'	'	'	6,702	6,564	6,082
Shares issuable on conversion of the Notes (in shares)	'	'	'	'	'	'	'	'	6,499	4,468	0
Total dilutive securities (in shares)	'	'	'	'	'	'	'	'	17,717	15,321	9,363
Weighted average diluted shares outstanding (in shares)	'	'	'	'	'	'	'	'	113,898	110,510	103,912

Leasing_Arrangements_Details

Leasing Arrangements (Details) (USD $)	12 Months Ended					12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Jul. 27, 2010	Dec. 01, 2012	Dec. 31, 2013	Mar. 03, 2010
				Somerset, NJ Manufacturing Facility [Member]	Vernon Hills, IL Research and Development Center [Member]	EJ Financial Enterprises, Inc [Member]	EJ Financial Enterprises, Inc [Member]
				Period
				sqft
Leasing Arrangements [Abstract]	'	'	'	'	'	'	'
Rental expense	$2,900,000	$2,300,000	$2,400,000	'	'	'	'
Period of operating leases	'10 years	'	'	'	'	'	'
Renewal period for operating leases	'5 years	'	'	'	'	'	'
Future minimum rental payments under non-cancelable operating and capital leases [Abstract]	'	'	'	'	'	'	'
2014	1,973,000	'	'	'	'	'	'
2015	1,970,000	'	'	'	'	'	'
2016	2,000,000	'	'	'	'	'	'
2017	1,791,000	'	'	'	'	'	'
2018	529,000	'	'	'	'	'	'
2019 and thereafter	340,000	'	'	'	'	'	'
Total	8,603,000	'	'	'	'	'	'
Somerset , NJ manufacturing facility [Abstract]	'	'	'	'	'	'	'
Period of building lease agreement	'	'	'	'7 years	'	'	'
Area of manufacturing facility	'	'	'	50,000	'	'	'
Base rent per month under lease agreement	'	'	'	38,801	'	'	'
Number of additional five years lease renewal periods	'	'	'	4	'	'	'
Notice period for renewal of lease before termination or renewal	'	'	'	'6 months	'	'	'
Vernon Hills, IL R&D Center [Abstract]	'	'	'	'	'	'	'
Base rent commitment for lease agreement	'	'	'	'	1,324,000	'	'
Sub-lease with EJ Financial [Abstract]	'	'	'	'	'	'	'
Period term of sub-lease agreement	'	'	'	'	'	'	'8 years
Sublease rentals	'	'	'	'	'	$240,000	'

Stock_Options_Employee_Stock_P2

Stock Options, Employee Stock Purchase Plan and Restricted Stock (Details) (USD $)

12 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2011

Aug. 07, 2009

27-May-05

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

4-May-13

Dec. 31, 2012

2003 Stock Option Plan [Member]

Amended 2003 Plan [Member]

Amended 2003 Plan [Member]

Amended 2003 Plan [Member]

Amended 2003 Plan [Member]

Employee Stock Purchase Plan [Member]

Employee Stock Purchase Plan [Member]

Employee Stock Purchase Plan [Member]

Employee Stock Purchase Plan [Member]

Employee Stock Purchase Plan [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Minimum [Member]

Maximum [Member]

Director [Member]

Director [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock approved for issuance (in shares)

'

'

'

'

'

19,000,000

11,000,000

5,000,000

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Increase in common stock approved for issuance (in shares)

'

'

'

'

'

8,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vesting period

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

Expiration period

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

Stock-based compensation expense

$7,050,000

$7,032,000

$5,159,000

'

'

'

'

'

$200,000

$200,000

$200,000

'

'

$6,200,000

$6,400,000

$4,900,000

$600,000

$400,000

$100,000

'

'

Assumptions used in estimating fair value of stock options granted [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected Volatility, minimum ( in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

'

49.00%

77.00%

75.00%

'

'

'

'

'

Expected Volatility, maximum ( in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

'

68.00%

85.00%

76.00%

'

'

'

'

'

Expected Life (in years)

'

'

'

'

'

'

'

'

'

'

'

'

'

'4 years

'4 years

'3 years 9 months 18 days

'

'

'

'

'

Risk-free interest rate, minimum (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

'

0.70%

0.70%

1.30%

'

'

'

'

'

Risk-free interest rate, maximum (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

'

1.40%

0.80%

2.00%

'

'

'

'

'

Dividend yield (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

0.00%

0.00%

'

'

'

'

'

Fair value per stock option (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

$6.95

$7.76

$3.71

'

'

'

'

'

Number of Shares [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding, beginning balance (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

9,727,000

9,399,000

7,960,000

'

'

'

'

'

Granted (in shares)

'

'

'

2,519,000

15,828,000

'

'

'

'

'

'

'

'

321,000

1,221,000

2,030,000

'

'

'

'

'

Exercised (in shares)

'

'

'

'

2,304,000

'

'

'

'

'

'

'

'

-630,000

-806,000

-454,000

'

'

'

'

'

Forfeited (in shares)

'

'

'

'

4,296,000

'

'

'

'

'

'

'

'

-190,000

-87,000

-137,000

'

'

'

'

'

Outstanding, ending balance (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

9,228,000

9,727,000

9,399,000

'

'

'

'

'

Exercisable, ending balance (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

7,594,000

'

'

'

'

'

'

'

Weighted Average Exercise Price [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding, beginning balance (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

$4.22

$2.89

$1.87

'

'

'

'

'

Granted (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

$15.76

$12.96

$6.63

'

'

'

'

'

Exercised (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

$4.18

$1.87

$1.93

'

'

'

'

'

Forfeited (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

$13.10

$4.42

$2.30

'

'

'

'

'

Outstanding, ending balance (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

$4.45

$4.22

$2.89

'

'

'

'

'

Exercisable, end of period (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

$3.02

'

'

'

'

'

'

'

Outstanding Options, Weighted Average Remaining Contractual Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'1 year 7 months 10 days

'

'

'

'

'

'

'

Exercisable Options, Weighted Average Remaining Contractual Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'1 year 3 months 7 days

'

'

'

'

'

'

'

Outstanding Options, Aggregate Intrinsic Value

'

'

'

'

'

'

'

'

'

'

'

'

'

186,169,000

'

'

'

'

'

'

'

Exercisable Options, Aggregate Intrinsic Value

'

'

'

'

'

'

'

'

'

'

'

'

'

164,018,000

'

'

'

'

'

'

'

Total intrinsic value of stock options exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

8,900,000

9,100,000

3,100,000

'

'

'

'

'

Additional paid in capital for stock options exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

2,600,000

1,500,000

900,000

'

'

'

'

'

Unrecognized compensation cost related to non-vested stock options

'

'

'

'

'

'

'

'

'

'

'

'

'

8,251,000

'

'

'

'

'

'

'

Weighted-average recognition period for unrecognized compensation cost

'

'

'

'

'

'

'

'

'

'

'

'

'

'2 years 4 months 24 days

'

'

'

'

'

'

'

Value of restricted stock awards granted

579,000

351,000

17,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

500,000

Non-vested restricted stock activity, Number of Shares [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Non-vested beginning of period (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

18,000

13,000

28,000

'

'

Granted (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

32,000

35,000

0

32,000

35,000

Vested (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-34,000

-30,000

-15,000

'

'

Canceled (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

0

'

'

Non-vested end of period (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

16,000

18,000

13,000

'

'

Non-vested restricted stock activity, Weighted Average Grant Date Fair Value [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Non-vested beginning of period (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$14.63

$1.34

$1.89

'

'

Granted (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$15.36

$14.63

$0

'

'

Vested (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$14.98

$9.09

$2.34

'

'

Canceled (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0

$0

$0

'

'

Non-vested end of period (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$15.36

$14.63

$1.34

'

'

Percentage of base wages withheld for the purchase of stock (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

1.00%

15.00%

'

'

'

'

'

'

'

'

Annual purchase of stock per employee

'

'

'

'

'

'

'

'

'

'

'

'

25,000

'

'

'

'

'

'

'

'

Base wages subject to withholding towards stock purchase

'

'

'

'

'

'

'

'

'

'

'

'

$21,250

'

'

'

'

'

'

'

'

Percentage of discount on shares purchased (in hundredths)

'

'

'

'

'

'

'

'

15.00%

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued under ESPP ( in shares)

'

'

'

'

'

'

'

'

1,353,407

'

'

'

'

'

'

'

'

'

'

'

'

Employee stock purchase plan issuances (in shares)

'

'

'

'

'

'

'

'

73,000

61,000

71,000

'

'

'

'

'

'

'

'

'

'

ESPP Shares available for future issuance (in shares)

'

'

'

'

'

'

'

'

646,593

'

'

'

'

'

'

'

'

'

'

'

'

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Current [Abstract]	'	'	'
Federal	$27,985,000	$20,843,000	$0
State	4,145,000	4,232,000	2,704,000
Foreign	0	0	'
Total	32,130,000	25,075,000	2,704,000
Deferred [Abstract]	'	'	'
Federal	-3,050,000	-504,000	-460,000
State	2,051,000	-911,000	-3,951,000
Foreign	-598,000	-1,538,000	'
Total	-1,597,000	-2,953,000	-4,411,000
Federal, Total	24,935,000	20,339,000	-460,000
State, Total	6,196,000	3,321,000	-1,247,000
Foreign, Total	-598,000	-1,538,000	'
Total	30,533,000	22,122,000	-1,707,000
U.S. Federal corporate income tax rate (in hundredths)	35.00%	35.00%	35.00%
Income tax expense (benefit), reconciliation [Abstract]	'	'	'
Computed "expected" tax expense	29,013,000	20,125,000	14,457,000
Change in income taxes resulting from [Abstract]	'	'	'
State income taxes, net of federal income tax	4,027,000	2,159,000	2,217,000
Foreign income tax expense (benefit)	622,000	1,468,000	0
Deduction for domestic production activities	-1,361,000	-1,277,000	0
R&D tax credits	-1,652,000	-508,000	'
Other, net	-116,000	155,000	-876,000
Valuation allowance change	0	0	-17,505,000
Income tax expense (benefit)	30,533,000	22,122,000	-1,707,000
Geographical allocation of entity's income before income taxes [Abstract]	'	'	'
Pre-tax income from U.S. operations	86,382,000	66,087,000	41,306,000
Pre-tax loss from foreign operations	-3,487,000	-8,587,000	0
Total pre-tax income	82,895,000	57,500,000	41,306,000
Deferred tax liabilities [Abstract]	'	'	'
Percentage of valuation allowance against deferred tax assets (in hundredths)	'	'	100.00%
Unrecognized tax benefits [Roll Forward]	'	'	'
Balance	1,485,000	0	'
Additions relating to current year	589,000	1,265,000	'
Additions relating to prior years	'	220,000	'
Terminations of exposures relating to prior years	-1,229,000	'	'
Balance	845,000	1,485,000	0
Amount of unrecognized tax positions that will impact effective tax rate	845,000	'	'
Foreign Tax Authority [Member]	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'
NOL carry-forward	4,400,000	'	'
Federal Tax Authority [Member]	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'
NOL carry-forward	7,900,000	'	'
Federal Tax Authority [Member] | Research and Experimentation Tax Credit Carryforward [Member]	'	'	'
R&D Tax Credit Carryforward [Line Items]	'	'	'
R&D tax credit carryforward	600,000	'	'
Federal Tax Authority [Member] | Research and Experimentation Tax Credit Carryforward [Member] | 2003 through 2010 [Member]	'	'	'
R&D Tax Credit Carryforward [Line Items]	'	'	'
R&D tax credit carryforward	800,000	'	'
State and Local Jurisdiction [Member] | Illinois [Member]	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'
NOL carry-forward	2,200,000	'	'
Current [Member]	'	'	'
Deferred tax assets [Abstract]	'	'	'
Net operating loss carry-forward	439,000	0	'
Stock-based compensation	0	0	'
Reserve for product returns	3,189,000	2,787,000	'
Inventory valuation reserve	2,193,000	3,980,000	'
Other	3,325,000	2,974,000	'
Total deferred tax assets	9,146,000	9,741,000	'
Deferred tax liabilities [Abstract]	'	'	'
Prepaid expenses	-1,120,000	-551,000	'
Unamortized discount - convertible notes	0	0	'
Depreciation & amortization - tax over book	0	0	'
Other	-81,000	0	'
Total deferred tax liabilities	-1,201,000	-551,000	'
Net deferred income tax asset (liability)	7,945,000	9,190,000	'
Noncurrent [Member]	'	'	'
Deferred tax assets [Abstract]	'	'	'
Net operating loss carry-forward	14,061,000	4,328,000	'
Stock-based compensation	6,630,000	4,912,000	'
Reserve for product returns	0	0	'
Inventory valuation reserve	0	0	'
Other	1,751,000	1,349,000	'
Total deferred tax assets	22,442,000	10,589,000	'
Deferred tax liabilities [Abstract]	'	'	'
Prepaid expenses	0	0	'
Unamortized discount - convertible notes	-4,223,000	-5,815,000	'
Depreciation & amortization - tax over book	-16,576,000	-5,835,000	'
Other	0	0	'
Total deferred tax liabilities	-20,799,000	-11,650,000	'
Net deferred income tax asset (liability)	$1,643,000	($1,061,000)	'

Retirement_Plan_Details

Retirement Plan (Details) (USD $)	9 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2010	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Retirement Plan [Abstract]	'	'	'	'
401(k) Plan-related expense	'	$0.80	$0.80	$0.50
Percentage of gross wages as each employee participating contribution (in hundredths)	'	6.00%	'	'
Percentage of gross wages set aside for matching contribution (in hundredths)	25.00%	50.00%	'	'
Percentage of employers matching contributions vests after two years of credited service (in hundredths)	'	50.00%	'	'
Percentage of employers matching contributions vests after three years of credited service (in hundredths)	'	100.00%	'	'

Segment_Information_Details

Segment Information (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
									Segment
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Number of reportable segments	'	'	'	'	'	'	'	'	3	'	'
REVENUES [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	$84,953,000	$81,892,000	$77,012,000	$73,854,000	$71,520,000	$69,634,000	$63,287,000	$51,717,000	$317,711,000	$256,158,000	$136,920,000
Net revenue from customers located in foreign countries	'	'	'	'	'	'	'	'	27,300,000	29,400,000	5,300,000
GROSS PROFIT [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Total gross profit	46,970,000	43,697,000	42,092,000	39,145,000	41,971,000	40,093,000	35,727,000	30,901,000	171,904,000	148,692,000	79,689,000
Goodwill [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Goodwill	29,831,000	'	'	'	32,159,000	'	'	'	29,831,000	32,159,000	11,863,000
Impairment of goodwill	0	'	'	'	'	'	'	'	0	0	'
Akorn India Private Limited [Member]	'	'	'	'	'	'	'	'	'	'	'
REVENUES [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Net revenue from customers located in foreign countries	'	'	'	'	'	'	'	'	15,800,000	16,700,000	'
Hospital Drugs & Injectables [Member]	'	'	'	'	'	'	'	'	'	'	'
REVENUES [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	'	'	'	'	'	'	'	'	179,625,000	129,723,000	55,077,000
GROSS PROFIT [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Total gross profit	'	'	'	'	'	'	'	'	104,473,000	83,413,000	30,057,000
Ophthalmic [Member]	'	'	'	'	'	'	'	'	'	'	'
REVENUES [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	'	'	'	'	'	'	'	'	114,515,000	103,765,000	68,591,000
GROSS PROFIT [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Total gross profit	'	'	'	'	'	'	'	'	63,481,000	58,785,000	43,054,000
Goodwill [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Goodwill	11,863,000	'	'	'	11,863,000	'	'	'	11,863,000	11,863,000	'
Contract Services [Member]	'	'	'	'	'	'	'	'	'	'	'
REVENUES [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	'	'	'	'	'	'	'	'	23,571,000	22,670,000	13,252,000
GROSS PROFIT [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Total gross profit	'	'	'	'	'	'	'	'	3,950,000	6,494,000	6,578,000
Goodwill [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Goodwill	$17,968,000	'	'	'	$20,296,000	'	'	'	$17,968,000	$20,296,000	'

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	3 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 22, 2011
			Td Vaccine Products [Member]	H Lundbeck AS [Member]	H Lundbeck AS [Member]
				Product
Strategic Business Agreement [Abstract]	'	'	'	'	'
Contingent future milestone payments - 2014	'	$4,524,000	'	'	'
Contingent future milestone payments - 2015	'	598,000	'	'	'
Contingent future milestone payments - 2016	'	200,000	'	'	'
Contingent future milestone payments - Total	'	5,322,000	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'
Number of NDAs off patent, branded injectable products	'	'	'	3	'
Cash paid at closing	'	'	'	'	45,000,000
Additional consideration owed	'	'	'	15,000,000	'
Cost of capital on additional consideration to be paid (in hundredths)	'	'	'	9.00%	'
Discounted value of liability related to additional consideration in a business acquisition	'	'	'	'	11,600,000
Liability related to additional consideration in a business acquisition including accrual of non-cash interest expense	'	'	'	14,700,000	'
Number of products related to minimum annual purchase obligations	'	'	'	2	'
Number of products acquired	'	'	'	3	'
Supply purchase agreement commitment	'	'	'	13,300,000	'
Fair value of long-term liability on a purchase obligation	'	'	'	'	2,500,000
Number of years related to warranty expiration	'	'10 years	'	'	'
Reduction in cost of sales due to warranty reserve reversal	1,300,000	'	'	'	'
Initial contract term of distribution agreement	'	'	'2 years	'	'
Commitment to acquire inventory under distribution agreement	'	'	9,200,000	'	'
Minimum notice period for non-renewal of MBL Settlement Agreement	'	'	'6 months	'	'
Write-off of contract liability	'	$1,300,000	'	'	'

Supplemental_Cash_Flow_Informa2

Supplemental Cash Flow Information (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Supplemental Cash Flow Information [ Abstract]	'	'	'
Leasehold improvements funded by lessor	$0	$0	$22
Interest and taxes paid [Abstract]	'	'	'
Interest paid	4,320	4,200	2,125
Income taxes paid	$27,450	$21,455	$2,778

Business_Combinations_and_Othe2

Business Combinations and Other Strategic Investments (Details) (USD $)

3 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Sep. 30, 2011

Aug. 01, 2011

Dec. 31, 2013

Feb. 28, 2012

Dec. 31, 2013

Dec. 31, 2013

Feb. 28, 2012

Feb. 28, 2012

Feb. 28, 2012

Dec. 31, 2013

Dec. 22, 2011

Dec. 22, 2011

Dec. 22, 2011

Dec. 22, 2011

Dec. 31, 2013

Aug. 26, 2013

Jan. 31, 2014

Dec. 31, 2013

3-May-11

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Nov. 15, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Aciex Therapeutics Inc. [Member]

Aciex Therapeutics Inc. [Member]

Aciex Therapeutics Inc. [Member]

Kilitch Drugs (India) Limited [Member]

Kilitch Drugs (India) Limited [Member]

Kilitch Drugs (India) Limited [Member]

Kilitch Drugs (India) Limited [Member]

Kilitch Drugs (India) Limited [Member]

Kilitch Drugs (India) Limited [Member]

Kilitch Drugs (India) Limited [Member]

H. Lundbeck AS [Member]

H. Lundbeck AS [Member]

H. Lundbeck AS [Member]

H. Lundbeck AS [Member]

H. Lundbeck AS [Member]

Hi-Tech Pharmacal Co. Inc [Member]

Hi-Tech Pharmacal Co. Inc [Member]

Hi-Tech Pharmacal Co. Inc [Member]

Hi-Tech Pharmacal Co. Inc [Member]

Advanced Vision Research, Inc. [Member]

Advanced Vision Research, Inc. [Member]

Advanced Vision Research, Inc. [Member]

Advanced Vision Research, Inc. [Member]

Advanced Vision Research, Inc. [Member]

Merck Products [Member]

Merck Products [Member]

Merck Products [Member]

Merck Products [Member]

Merck Products [Member]

Merck Products [Member]

Minimum [Member]

Maximum [Member]

Initial Fair Valuation [Member]

Change in Estimate [Member]

Adjusted Fair Valuation [Member]

Product

Initial Fair Valuation [Member]

Change in Estimate [Member]

Adjusted Fair Valuation [Member]

Subsequent Event [Member]

JPM Term Loan [Member]

Trademarks and Technology [Member]

Customer Relationships [Member]

Product

Aza Site [Member]

Cosopt [Member]

Cosopt PF [Member]

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition Effective date of acquisition

'

'

'

'

'

'

'

'

'

'

'

'

'

'

28-Feb-12

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3-May-11

'

'

'

'

'

'

'

'

'

Business Acquisition Agreement date of acquisition

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5-Oct-11

'

'

'

'

'

'

22-Dec-11

'

'

'

'

26-Aug-13

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total cash paid at closing

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$60,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business acquisition price per share (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$43.50

'

'

'

'

'

'

'

'

'

'

'

'

'

Merger Agreement termination fee 1,

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

41,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Merger Agreement termination fee 2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

48,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Merger Agreement termination fee 3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Merger Agreement termination fee 4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

32,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected term loan amount to fund acquisition

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

600,000,000

'

'

'

'

'

'

'

'

'

'

'

Maturity period of term loan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'7 years

'

'

'

'

'

'

'

'

'

'

'

Deferred financing fees

'

'

'

'

'

'

'

'

3,032,000

0

5,098,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,400,000

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition, par value of Hi-Tech common stock (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.01

'

'

'

'

'

'

'

'

'

'

'

'

'

Base consideration paid

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

51,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reimbursement for capital expenditure

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent consideration payable

15,000,000

'

'

'

'

'

'

'

15,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

11,600,000

'

'

'

'

'

'

'

181,000

'

'

'

'

'

'

'

'

'

'

Consideration [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash paid

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

8,000,000

'

'

'

'

55,224,000

'

55,224,000

'

45,000,000

49,559,000

'

49,559,000

'

'

'

'

26,011,000

'

'

'

'

52,800,000

52,800,000

'

'

'

'

Less working capital shortfall due back from sellers

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-890,000

-138,000

-1,028,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional consideration paid

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

723,000

'

'

'

'

'

'

'

'

'

'

Present value of contingent consideration

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11,300,000

300,000

11,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition, Purchase Price Allocation, Current Assets, Cash and Cash Equivalents

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

86,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Total consideration

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

54,334,000

-138,000

54,196,000

'

'

60,859,000

300,000

61,159,000

'

640,000,000

'

'

26,734,000

'

'

'

'

'

'

'

'

'

'

Acquisition-related costs [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stamp duties paid for transfer of land and buildings

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,583,000

'

1,583,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquisition-related compensation expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,741,000

511,000

7,252,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Due diligence, legal, travel and other acquisition-related costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

557,000

119,000

676,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquisition-related costs

'

'

'

'

'

'

'

'

2,912,000

9,155,000

743,000

'

'

'

'

'

'

'

8,881,000

630,000

9,511,000

'

'

50,000

'

50,000

1,600,000

'

'

'

246,000

'

'

'

'

'

'

'

'

'

'

Recognized amounts of identifiable assets acquired and liabilities assumed [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Product rights total

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

55,700,000

55,700,000

'

13,800,000

21,600,000

20,300,000

Prepaid expenses

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

730,000

'

'

'

'

48,000

48,000

'

'

'

'

Deferred tax assets, net

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

759,000

759,000

'

'

'

'

Total fair value of acquired assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

56,507,000

56,507,000

'

'

'

'

Consideration paid

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

8,000,000

'

'

'

'

55,224,000

'

55,224,000

'

45,000,000

49,559,000

'

49,559,000

'

'

'

'

26,011,000

'

'

'

'

52,800,000

52,800,000

'

'

'

'

Gain from bargain purchase

'

'

'

'

'

'

'

'

3,707,000

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,707,000

'

'

'

'

Accounts receivable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,130,000

'

2,130,000

'

'

'

'

'

'

'

'

'

611,000

'

'

'

'

'

'

'

'

'

'

Product licensing rights

2,700,000

'

'

'

800,000

'

'

'

2,700,000

800,000

5,700,000

'

'

'

'

'

'

'

'

'

'

'

'

59,525,000

300,000

59,825,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Inventory

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

'

1,799,000

'

1,799,000

'

'

3,825,000

'

3,825,000

'

'

'

'

3,407,000

'

'

'

'

'

'

'

'

'

'

Land

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,714,000

-1,131,000

2,583,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Prepaid expenses and other current assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

730,000

'

'

'

'

48,000

48,000

'

'

'

'

Buildings, plant and equipment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,474,000

'

8,474,000

'

'

'

'

'

'

'

'

'

250,000

'

'

'

'

'

'

'

'

'

'

Construction in progress

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14,231,000

'

14,231,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill, deductible

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

21,609,000

1,004,000

22,613,000

'

'

'

'

'

'

'

'

'

11,863,000

'

'

'

'

'

'

'

'

'

'

Other intangible assets, deductible

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,806,000

102,000

5,908,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Trademarks and technology

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9,500,000

'

'

'

'

'

'

'

'

'

'

Customer relationships

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,900,000

'

'

'

'

'

'

'

'

'

'

Other assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

38,000

'

38,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Assumed liabilities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-2,099,000

-779,000

-2,878,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred tax liabilities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-1,368,000

666,000

-702,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fixed assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Assumed liability - unfavorable contract

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-2,541,000

'

-2,541,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated additional consideration due

-15,000,000

'

'

'

'

'

'

'

-15,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

-11,600,000

'

'

'

'

'

'

'

-181,000

'

'

'

'

'

'

'

'

'

'

Accounts payable & other assumed liabilities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-3,346,000

'

'

'

'

'

'

'

'

'

'

Business combination, recognized amounts of identifiable assets acquired and liabilities assumed, net

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

54,334,000

-138,000

54,196,000

'

'

60,859,000

300,000

61,159,000

'

'

'

'

26,734,000

'

'

'

'

'

'

'

'

'

'

Acquired finite-lived intangible assets useful life

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'4 years

'5 years

'

'

'

'15 years

'

'

'

'

'

'

'

'

'

'15 years

'

'30 years

'15 years

'

'

'

'

'

'

Revenue

84,953,000

81,892,000

77,012,000

73,854,000

71,520,000

69,634,000

63,287,000

51,717,000

317,711,000

256,158,000

136,920,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

600,000

'

'

1,600,000

'

'

'

'

'

Income before taxes

'

'

'

'

'

'

'

'

82,895,000

57,500,000

41,306,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,400,000

'

'

'

'

'

Business acquisition estimated purchase price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

63,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business acquisition cost of acquired entity upfront cash paid

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

45,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash payable for acquired inventory

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

First consecutive performance period subsequent to closing

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Second consecutive performance period subsequent to closing

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Assumed discount rate (in hundredths)

'

'

'

'

'

'

'

'

9.00%

'

'

'

'

'

'

'

'

'

'

'

'

9.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period prior to expiration of inventory for selling, minimum

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'6 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Royalty as percentage of gross profit margin on sales of product (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

55.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period for royalty payment on sale of product

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'6 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Incremental income tax expense of acquiree reimbursed

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

700,000

'

'

'

'

'

'

'

'

'

'

Net cash balance in AVR's bank accounts

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

700,000

'

'

'

'

'

'

'

'

'

'

Gross accounts receivable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,700,000

'

'

'

'

'

'

'

'

'

'

Product returns

'

'

'

'

'

'

'

'

5,000,000

3,800,000

2,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,800,000

'

'

'

'

'

'

'

'

'

'

Allowance for doubtful accounts

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

'

'

'

'

'

'

'

'

Cash discounts

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$100,000

'

'

'

'

'

'

'

'

'

'

Number Of Products To Acquire U.S. Rights Under Asset Sale And Purchase Agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3

'

'

'

Number of products to acquire NDA rights under Asset Sale and Purchase Agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ownership interest amount is below (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

20.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unconsolidated_Joint_Venture_D

Unconsolidated Joint Venture (Details) (USD $)	3 Months Ended		12 Months Ended
	Jun. 30, 2011	Dec. 31, 2010	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Schedule of Equity Method Investments [Line Items]	'	'	'	'	'	'
Joint venture ownership percentage (in hundredths)	'	'	50.00%	'	'	'
Sales and marketing fee from joint venture as percentage of net sales (in hundredths)	'	'	7.50%	'	'	'
Proceeds from joint venture sale of rights	'	'	'	'	'	$63,200,000
Joint venture proceeds from cost of sales of right	'	'	100,000	'	'	'
Joint venture gain on sale of rights	24,200,000	38,900,000	63,100,000	'	'	'
Joint venture gain on sale of rights as percentage of sale proceeds (in hundredths)	38.30%	61.70%	'	'	'	'
Equity in earnings of unconsolidated joint venture	'	'	80,000	0	14,550,000	23,400,000
CONDENSED STATEMENTS OF INCOME [Abstract]	'	'	'	'	'	'
INCOME BEFORE INCOME TAXES	'	'	82,895,000	57,500,000	41,306,000	'
Income tax (benefit) / provision	'	'	30,533,000	22,122,000	-1,707,000	'
Akorn Inc. [Member]	'	'	'	'	'	'
Schedule of Equity Method Investments [Line Items]	'	'	'	'	'	'
Proceeds from joint venture sale of rights	'	'	35,000,000	'	'	'
Joint venture sale of rights (in hundredths)	'	'	55.40%	'	'	'
Akorn Inc. [Member] | Joint Venture Company Product [Member]	'	'	'	'	'	'
Schedule of Equity Method Investments [Line Items]	'	'	'	'	'	'
Revenues from sale of product to the Joint Venture	'	'	'	'	800,000	'
Strides Arcolab Limited [Member]	'	'	'	'	'	'
Schedule of Equity Method Investments [Line Items]	'	'	'	'	'	'
Proceeds from joint venture sale of rights	'	'	28,200,000	'	'	'
Joint venture sale of rights (in hundredths)	'	'	44.60%	'	'	'
Akorn-Strides LLC [Member] | Akorn Inc. [Member]	'	'	'	'	'	'
CONDENSED STATEMENTS OF INCOME [Abstract]	'	'	'	'	'	'
REVENUES	'	'	163,000	0	6,364,000	'
Cost of sales	'	'	-1,000	0	3,562,000	'
GROSS PROFIT	'	'	164,000	0	2,802,000	'
Operating expenses	'	'	3,000	0	499,000	'
OPERATING INCOME	'	'	161,000	0	2,303,000	'
Gain from Pfizer ANDA Sale	'	'	0	0	24,160,000	'
INCOME BEFORE INCOME TAXES	'	'	161,000	0	26,463,000	'
Income tax (benefit) / provision	'	'	0	0	-38,000	'
NET INCOME	'	'	161,000	0	26,501,000	'
ASSETS [Abstract]	'	'	'	'	'	'
Cash	'	'	25,000	794,000	'	'
Other current assets	'	'	1,000	'	'	'
TOTAL ASSETS	'	'	26,000	794,000	'	'
LIABILITIES & MEMBERS' EQUITY (DEFICIT) [Abstract]	'	'	'	'	'	'
Trade accounts payable & other accrued liabilities	'	'	0	431,000	'	'
TOTAL LIABILITIES	'	'	0	431,000	'	'
Members' equity, net of advances	'	'	26,000	363,000	'	'
TOTAL LIABILITIES & MEMBERS' EQUITY (DEFICIT)	'	'	$26,000	$794,000	'	'

Customer_Supplier_and_Product_2

Customer, Supplier and Product Concentration (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	Supplier	Supplier	Supplier
Customer Concentration Risk [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Number of customers considered as concentration risks	3	3	3
Supplier Concentration Risk [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Number of supplier considered as concentration risks	0	0	0
Product Concentration Risk [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration Risk (in hundredths)	11.80%	12.50%	10.40%
Gross Sales [Member] | Customer Concentration Risk [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration Risk (in hundredths)	58.00%	58.00%	66.00%
Gross Sales [Member] | Customer Concentration Risk [Member] | Amerisource [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration Risk (in hundredths)	19.00%	19.00%	23.00%
Gross Sales [Member] | Customer Concentration Risk [Member] | Cardinal [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration Risk (in hundredths)	23.00%	23.00%	27.00%
Gross Sales [Member] | Customer Concentration Risk [Member] | McKesson [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration Risk (in hundredths)	16.00%	16.00%	16.00%
Net Revenue [Member] | Customer Concentration Risk [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration Risk (in hundredths)	41.00%	42.00%	63.00%
Net Revenue [Member] | Customer Concentration Risk [Member] | Amerisource [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration Risk (in hundredths)	14.00%	14.00%	23.00%
Net Revenue [Member] | Customer Concentration Risk [Member] | Cardinal [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration Risk (in hundredths)	16.00%	17.00%	25.00%
Net Revenue [Member] | Customer Concentration Risk [Member] | McKesson [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration Risk (in hundredths)	11.00%	11.00%	15.00%
Gross Accounts Receivable [Member] | Customer Concentration Risk [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration Risk (in hundredths)	63.00%	73.00%	72.00%
Gross Accounts Receivable [Member] | Customer Concentration Risk [Member] | Amerisource [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration Risk (in hundredths)	25.00%	29.00%	29.00%
Gross Accounts Receivable [Member] | Customer Concentration Risk [Member] | Cardinal [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration Risk (in hundredths)	26.00%	30.00%	34.00%
Gross Accounts Receivable [Member] | Customer Concentration Risk [Member] | McKesson [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration Risk (in hundredths)	12.00%	14.00%	9.00%

Related_Party_Transactions_Det

Related Party Transactions (Details) (EJ Financial Enterprises, Inc [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 03, 2010	Aug. 17, 2009	Apr. 13, 2009
EJ Financial Enterprises, Inc [Member]	'	'	'	'
Related Party Transaction [Line Items]	'	'	'	'
Period of sub-lease agreement	'	'8 years	'	'
Sub-lease expenses	$240,000	'	'	'
Borrowing capacity	$25,000,000	'	$10,000,000	$5,650,000

Severance_Charges_Details

Severance Charges (Details) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
	Employee	Employee
Severance Charges [Abstract]	'	'	'
Number of employees severance agreements entered with	'	6	'
Number of employees received severance payment	2	4	'
Accrued severance, amount less than	$25,000	'	$25,000

Selected_Quarterly_Financial_D2

Selected Quarterly Financial Data (Unaudited) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Selected Quarterly Financial Data (Unaudited) [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Revenue	$84,953	$81,892	$77,012	$73,854	$71,520	$69,634	$63,287	$51,717	$317,711	$256,158	$136,920
Gross Profit	46,970	43,697	42,092	39,145	41,971	40,093	35,727	30,901	171,904	148,692	79,689
Operating Income	25,177	22,188	22,251	18,589	19,715	22,603	18,776	7,662	88,204	68,756	33,266
Consolidated Net Income [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Amount	$16,678	$12,205	$12,637	$10,842	$8,811	$13,753	$9,706	$3,108	$52,362	$35,378	$43,013
Per Share Basic (in dollars per share)	$0.17	$0.13	$0.13	$0.11	$0.09	$0.14	$0.10	$0.03	$0.54	$0.37	$0.45
Per Share Diluted (in dollars per share)	$0.14	$0.11	$0.11	$0.10	$0.08	$0.12	$0.09	$0.03	$0.46	$0.32	$0.41

Legal_Proceedings_Details

Legal Proceedings (Details)	Dec. 31, 2013
	Patent
Legal Proceedings [Abstract]	'
Number of U.S. patents licensed, for AzaSite	5